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ABSTRACT OF DISSERTATION

GENETIC REGULATION OF HEMATOPOIETIC STEM CELL NUMBERS
IN MICE
Hematopoietic stem cells (HSCs) transplantations are widely used for the
treatment of hematological and non-hematological disorders in clinic. Successful
transplantation requires sufficient number and efficient homing of HSCs. Many
studies have focused on developing an effective strategy to expand functional
HSC population. Some regulatory molecules have been recently shown great
promise for controlling the amplification of HSCs.
In these dissertation studies, I first aim to identify gene(s) and their allelic
variants contributing to strain-specific difference in HSC numbers between
C57BL/6 (B6, low) and DBA/2 (D2, high) mice by using a classic forward genetic
approach. Firstly, 3 quantitative trait loci (QTL) on chromosome (Chr) 3,5 and 18
were mapped by linkage analyses and confirmed in congenic mice. Secondly,
Chr.3 QTL affected several HSC number-related biological processes. The D2
allele increased cycling and self-renewal whereas it decreased apoptotic rates of
HSCs. Both actions conspired to increase HSC population size. Lastly, a small
number of differentially-expressed genes was identified in Chr.3 congenic HSCs

by a microarray-based candidate gene method, and the differential expression of
one candidate, latexin, was found to relate to HSC number variations. Our
studies report the strong evidence for the potential functions of latexin in HSC
number regulation, and they are important for understanding molecular
mechanisms of stem cell regulation and developing effective stem cell expansion
strategies for clinical applications.
In the second part of my studies, I studied homing and engraftment
capabilities of HSCs. By using functional assays for progenitor and stem cells, I
first reported the absolute homing efficiencies of murine young or old donor cells
into young or old recipient mice. The results indicated that homing of primitive
hematopoietic cells was not efficient and significantly decreased by aging of
donors and recipients. The proliferation and differentiation states of HSCs were
also impaired by homing itself, as well as by donors' and recipients’ age.
Moreover, the hematopoietic reconstitution dynamics following transplantation
were also affected by aging. Together, these findings will provide useful
information for clinical applications especially when older individuals increasing
serve as stem cell donors for elderly patients.
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CHAPTER ONE

Introduction

Hematopoietic Stem Cells and Hematopoietic Hierarchy
Hematopoiesis is the process by which blood cells of multiple and distinct
lineages are produced throughout life. The ultimate burden of the life-long
production of mature blood cells is carried out by a small population of primitive
cells, termed hematopoeitic stem cells (HSCs), which reside predominantly in the
bone marrow in adults. The distinguishing functional capacities of HSCs are selfrenewal to maintain their population throughout life, and multilineage
differentiation to produce all mature blood cell types (Morrison et al. 1995;
Spangrude et al. 1991). The balance between self-generation and differentiation,
at individual cell and population levels, is critical for maintenance of steady-state
hematopoiesis(Lessard, 2004).
The hematopoietic system is organized as a hierarchy of stem and
progenitor cells along a developmental continuum. The HSC population at the
apex of this hierarchy is heterogenous and composed of long-term HSCs (LTHSCs) and short-term HSCs (ST-HSCs). LT-HSCs can self-renew and function
as stem cells throughout the life, whereas ST-HSCs can do this only for limited
periods of time (typically less than 8 weeks in mouse) before they are fully
differentiated (Capel et al. 1990; Rosendaal et al. 1979; Spangrude and Johnson
1990). The hematopoietic progenitor cells (HPCs), which are progeny of HSCs,
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have been traditionally recognized as clonogenic cells that give rise to cells of a
single lineage, or a subset of the hematopoietic lineages (Abramson et al. 1977).
Common lymphoid progenitors (CLP) produce T, B lymphocytes and natural killer
cells (NK); common myeloid progenitors (CMP) generate other lineage blood
cells, including erythrocytes, macrophages, granulocytes and platelets. All these
mature blood cells are circulating in the peripheral blood and responsible for
constant maintenance and immune protection of the body.

Identification of Hematopoietic Stem cells
In vivo long-term reconstitution assay to identify HSCs
The hallmark of the HSCs is their capacity for the lifetime generation of
hematopoietic cells. Therefore, assays designed to identify this rare population
must enable their distinctive properties to be measured. That is, a functional HSC
is one that demonstrates complete and sustained (at least 12 weeks in mouse)
regeneration of the lymphohematopoietic system following transplantation.
“Stem” cells were first functionally defined by Till and Maculloch over 40 years
ago (Till and McCulloch 1961). In this assay, bone marrow-derived cells formed
colonies in the spleen of myelo-ablated recipients after intravenous injection,
termed colony forming unit–spleen (CFU-S). Further experiments revealed that
CFU-S cells were capable of forming additional spleen clonies when serially
transplanted, indicating they could self-renew. Also, this population was
heterogeneous with respect to their latency before forming colonies, the more
primitive cells were, the later they produced colonies (Becker et al. 1963;
2

Siminovitch et al. 1963; Wu et al. 1967). Although further studies showed most
CFU-S were not HSCs, but rather early progenitors (Jones et al. 1990), this
assay underpinned all contemporary methods for the functional identification and
quantitation of HSCs in vivo and in vitro.
The most stringent and reliable method to assay HSCs is one
demonstrating long-term multi-lineage reconstitution capability of HSCs in vivo.
Based on this concept, a competitive repopulation assay (CR assay) was
designed in which the cells being evaluated (“test” cells) are co-injected with
genetically or phenotypically distinguishable “competitor” cells into lethally
irradiated recipient mouse (Harrison 1980). The roles of “competitor” cells are to
exert selective pressure on “test” cells and to ensure the survival rate of
recipients following lethal irradiation. Two different types of competitive
repopulation assays are used in the studies of HSCs. The standard method is to
inject equal numbers of “test” and “competitor” cells into lethally-irradiated
recipients; theoretically 50% of hematopoietic cells will be regenerated by each
population. The skewing of chimerism in favor of either donor indicates its
competitive advantage, which may be due to increased HSC numbers,
proliferation or both (Harrison et al. 1993).
To distinguish these two different mechanisms, the competitive
repopulation assay was modified to incorporate a limiting-dilution design in which
groups of recipient mice are co-injected with graded number of “test” cells
together with a certain number of “competitor” cells. Several months later, the
proportion of recipients injected with each cell dose group that had been
3

engrafted with “test” stem cells is determined, and the absolute frequency
(number) of HSC (operationally defined here competitive repopulating unit, CRU)
can be calculated by applying maximum likelihood and Poisson statistics
(Szilvassy et al. 1990). Moreover, another advantage of the CRU assay is that it
enables the retrospective identification of recipient mice that were repopulated by
a single HSC using two criteria: (i) they were determined by limiting-dilution
analysis to have been transplanted with < 0.3 CRU (“0.3” comes from the p0
value in Poisson equation applied in limiting dilution design: –lnp 0=m when m
equals 1), and (ii), they contained >5% peripheral blood (PB) cells detectable
among B, T and myeloid lineages that had been derived from “test” cells. By
analyzing the percentage of “test” cell-derived PB leukocytes in such recipient
mice, the proliferation and differentiation state of a single HSC may be
determined in terms of clone size and lineage distribution of this single clone
(Szilvassy et al. 2001b; Szilvassy et al. 2003).

In vitro long-term cell culture assay to identify HSCs
As described previously, single HSC can proliferate to generate a colony
containing all stages of hematopoietic cells (Osawa et al. 1996), the late colonyforming cells are more primitive than those generating colony at earlier times.
This temporal hierarchy reflects the developmental hierarchy of the
hematopoietic system (Rosendaal et al. 1979). Therefore, surrogate in vitro
culture assays have been developed to measure HSCs and HPCs. Cobblestone
area forming cell (CAFC) assay is one of such assays which is routinely used in
4

our lab. A stromal cell-derived cell line, such as FBMD-1, is used to mimic the
bone marrow microenvironment to support the growth of bone marrow cells in the
in vitro culture system. Via unknown mechanisms, the primitive cells can migrate
through the stromal layer and start proliferating to form a transient colony
underneath it at characteristic time-points for a period spanning 35 days. The
more primitive a cell, the later it will proliferate to form a cobblestone. Cells
generating cobblestone at day 28 and 35 are considered long-term HSCs and
CAFC day 7 to 21 as HPCs. Combined with a limiting dilution design, this assay
can also be used to determine HSC frequency (Breems et al. 1994; Ploemacher
et al. 1989). The major advantages of this long-term limiting dilution in vitro assay
are that: (i) it measures the entire spectrum of HSCs and HPCs in a single assay
system and avoids separate analysis by using different assays to measure HSC
and HPC activity, and (ii), CAFC frequency correlates very well with stem cell
frequency obtained by in vivo assays, such as the previously mentioned CFU-S
and CRU assays (Ploemacher et al. 1992; Ploemacher et al. 1991). Other in vitro
methods, including the long-term culture-initiating cell (LTC-IC) assay, colonyforming cells (CFC) assay (Hao et al. 1996; Sutherland et al. 1989; Sutherland et
al. 1990), are also commonly used to measure HSC and HPC activity and
operated by similar procedures.

Flow cytometric analysis to identify HSCs
Previously discussed in vitro methods for identification of HSCs rely on
functional detection of stem cell progeny. The stem and progenitor cells
5

themselves are lost in the assay procedure, and their existence is deduced
retrospectively. Fortunately, development of flow cytometry has revolutionized
hematopoietic stem cell study in the last 20 years. In this technique,
fluorescence, which is attached to cells through either antigen-antibody
interactions or direct binding, is excited when single cells pass one at a time
through a laser beam. The subsequent detection and measurement of
fluorescent intensity per cell enables not only identification and quantitation of
HSCs, but also procurement of this rare population prospectively for further
studies.
The more commonly used strategy for HSC separation relies on the
presence or absence of cell surface markers. It is widely accepted that stem cells
are not committed to any lineage of differentiated blood cells, therefore, they do
not express many lineage markers that are characteristic of terminally
differentiating hematopoietic cells. Thus, negative selection removes such
lineage-positive cells and leaves predominantly immature cells. In order to enrich
HSCs to higher purity, positive selection of stem cells is subsequently performed
through stem cell specific markers. At least 2 surface markers are commonly
used for sorting murine bone marrow HSCs. Sca-1 (Ly6a/e) is more or less
restricted to stem cells and has formed the keystone for stem cell purification
ever since its practical use was introduced (Spangrude et al. 1988). C-kit is a
second murine stem cell marker that is widely used and is the tyrosine kinase
receptor for stem cell factor (SCF) or kit ligand (Ikuta et al. 1991). In addition to
these “classical” phenotypes, other markers or strategies to purify murine HSCs
6

have been developed over the past several years. For example, lack of
expression of Flk-2/Flt3 receptor tyrosine kinase and CD34 characterizes a
population of primitive hematopoietic cells with long-term repopulating activity
(Christensen and Weissman 2001). Recent studies have identified a small
population of cells in bone marrow that efficiently efflux a family of fluorescent
dyes, typified by Hoechst 33342, that contains essentially all of the long-term
repopulating cells. Thus cells dimly stained by Hoechst 33342, which is also
named the “side population”, may be analyzed and sorted by flow cytometry as
an enriched source of HSCs (Goodell et al. 1996; Goodell et al. 1997; Wolf et al.
1993). Irrespective of the methods used, an important point in the isolation of
HSCs is the one-to-one correspondence between physically purified cells and
their potential ability to function as stem cells; that is, to have long-term
repopulating activity.

Genetic Approach to Study Stem Cell–Specific Genes
With the development of various of technologies and methods, there have
been significant advances in our understanding of the genes that regulate stem
cells. Both forward and reverse genetics approaches have contributed to the
broadening of our knowledge of this crucial cell population. Figure 1.2 depicts the
similarities and differences between these two approaches. The fundamental
difference is the starting point and, as the name implies, the direction followed by
the experimental pathway. Whereas a forward genetics approach begins with a
natural variation in a stem-cell phenotype and proceeds to the cause of the
7

phenotypic difference at the level of the genome (phenotype to genotype) (Biola
et al. 2003; Glazier et al. 2002), a reverse genetics approach begins with the
discovery of polymorphisms at the genetic level and proceeds to the phenotypic
effects on stem cells (genotype to phenotype).
Until recently, comprehensive studies concerning stem cell specific genes
have been reported using reverse genetics approach. Briefly, two such studies
generated profiles of genes expressed in embryonic stem cells (ESCs), neural
stem cells (NSCs) and hematopoietic stem cells (HSCs) by using microarray
analysis (Ivanova et al. 2002; Ramalho-Santos et al. 2002). Genes common to all
three types of stem cells (200 to 300 genes) were identified and fell into several
functional categories, including those encoding transcription factors, membrane
proteins, nucleic acids binding proteins, and proteins involved in cell-cycle control
and apoptosis. Although these “stemness” genes are theoretically surveyed and
screened using such an approach, the considerable task remains of unraveling
the mechanistic role of the gene in stem cell functioning. This can be especially
difficult because it must be remembered that stem cell genes are always
uncovered in the context of a discrete genetic background that may enlist,
silence, or modify the expression of genes that in another genetic context may go
undetected, be uncovered, or be perceived variously as minor or major
determinants.
Forward genetics does not have the problem of determining phenotype
because a measurable difference in stem cell function is the starting point of
analysis. Because phenotypic variation is usually compared between two genetic
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models, for example, mouse strains, the potential genetic causes are limited to
the genetic polymorphisms that exist between the chosen strains. Because of
extensively documented differences between the hematopoietic systems of
C57BL/6 (B6) and DBA/2(D2) mice, and the powerful genetic tools afforded by
the recombinant inbred strains that have been derived by crossing them, several
genetic studies have begun to shed light on loci in this genetic context that
account for the interstrain variation in stem-cell properties (Liang and Van Zant
2003). Geiger et al. have reported the mapping of quantitative trait loci (QTL) on
chromosomes 1, 3, 5 and 18 regulating natural variation in HSC numbers in bone
marrow. More importantly, their studies have also confirmed the mapping by
phenotypically characterizing congenic strains generated by introgressing the
genomic interval surrounding QTL onto a non-native background (Figure1.2)
(Geiger et al. 2001). In addition, other researchers have identified QTL governing
other phenotypic variations among different inbred mouse strains, including
change in HSC and hematopoietic progenitor cells (HPCs) during aging (Chen et
al. 2000; de Haan and Van Zant 1999), responses of HSCs and HPCs to earlyacting cytokines (Henckaerts et al. 2002), the sensitivity of HSCs and HPCs to
the genotoxic effects of the cell cycle-specific drug hydroxyurea (de Haan et al.
1997) and mobilization of HPCs (Geiger et al. 2004). Furthermore, Bystrykh and
de Haan et.al have recently analyzed gene expression profile in purified HSCs
isolated from BXD recombinant inbred mouse strains and measured the
variations in expression of HSC-specific transcripts among these strains. By
combining QTL mapping, they not only identified genes and loci that are
9

responsible for these variations, but also found that a large number of genes are
regulated through cis-acting QTL, and several key trans-acting QTL are involved
in controlling the expression of HSC-specific genes (Chesler et al. 2005).
Altogether, both forward and reverse genetics approach are designed to
reveal genotypic and phenotypic differences. The two methods can be parallel
and even complementary in the study of complex biological traits. For example,
using a forward genetics approach, Morrison et al. have found that a QTL on
chromosome 17 is responsible for the difference in HSC number between ARK/J
and C57BL/Ka-Thy-1.1 mice (Morrison et al. 2002). Similarly, a reverse genetics
study by Ramalho-Santos et al. have found a relatively large proportion of genes
characterizing “stemness” are distributed on chromosome 17. Therefore, the
possibility exists that the locus identified by Morrison et al. maps to one of the
core stem-cell genes present in embryonic and adult stem cells (Ramalho-Santos
et al. 2002). The complementary results represent the potential genetic power of
integrating the two approaches to search for conceptual and mechanistic
relationships among the limited information that we can get so far.

HSC Frequency (Number) and its Regulation
Murine HSC frequency as measured by different methods.
Different methods of enumeration of HSCs have provided estimate of the
exact numbers of HSCs, although all methods reveal that they are exceedingly
rare cells. In addition there are clear strain and age differences with respect to
stem cell frequencies. Using in vivo limiting dilution competitive repopulation
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assays, murine long-term repopulating cells represent ~1 per 10,000~20,000
adult bone marrow cells (Rebel et al. 1994; Rebel et al. 1996; Szilvassy et al.
1990; Szilvassy et al. 2003). In vitro long-term culture assay, for example CAFC
assay, around 100,000 bone marrow cells in the C57BL/6 mouse contain 1
CAFC day35, a cell considered to be equivalent to HSCs (de Haan et al. 2000;
de Haan and Van Zant 1997; Ploemacher et al. 1989). In addition, using
immunophenotypic staining of HSCs, typical frequencies of Lin- Sca-1+ c-kit+
cells is 0.01% to 0.02% of total bone marrow cells (Morrison and Weissman
1994). Assuming there are 3x108 bone marrow cells in an adult mouse, this
means that there are approximately 3 to 6x104 HSCs are in the bone marrow.
Mounting evidence has shown that HSC frequency changes with age and also
this age effect is strain-dependent. We and others have found that C57BL/6 mice
contain less HSCs than do DBA/2 mice at a young age. However, HSC number
increase steadily as C57BL/6 mice age, whereas in DBA/2 mice HSC numbers
decline with age (Chen et al. 2000; de Haan and Van Zant 1999; Geiger et al.
2001). The strain- and age- specific differences have been experimentally
suggested to be regulated by cell-intrinsic mechanisms (Van Zant, 1990 #480)
and affected by several quantitative trait loci (QTL) in the murine genome.

Factors involved in the regulation of HSCs and their number
What genes and signaling pathways are involved in the regulation of stem
cell? And how are stem cell numbers maintained? As shown in Figure 1.3, HSCs
are regulated by both cell intrinsic (cell autonomous) and cell extrinsic
11

mechanisms. Recent studies have shown that some genes, such as HoxB4
(Antonchuk et al. 2002; Beslu et al. 2004), Runx1 (North et al. 2002), Tel/Etv6
(Hock et al. 2004b) and Gfi-1 (Zeng et al. 2004), encode transcription factors that
activate transcription of specific genes which in turn dictate self-renewal or
differentiation decisions by HSCs. Other genes that are involved in DNA repair,
such as R a d 5 0 and E r c c - 1, have also been reported to affect primitive
hematopoietic cell population (Bender et al. 2002; Prasher et al. 2005). Some
intrinsic factors, such as membrane transporters (Bcrp1/Mdr1a/1b) (Uchida et al.
2002; Zhou et al. 2002; Zhou et al. 2001) and integral membrane receptors (Flk2) (Christensen and Weissman 2001), confer HSC-specific phenotypes and can
be used in stem cell isolation. Because HSCs reside in bone marrow intimately
associated with stroma, signals from this microenvironment also exert their
effects on HSCs. Wnt/ß-Catenin and Notch-Delta signaling pathways have been
recently found to extrinsically regulate HSCs through cell-cell interactions
(Sorrentino 2004). The binding of stroma-derived Wnt proteins to their receptors
Frizzled was found to protect ß-catenin from degradation. The intact ß-catenin
subsequently translocates into the nucleus and activates downstream target
genes. Some members in this signaling pathway are expressed in HSCs . Coculture of Wnt proteins with HSCs and HPCs results in increased proliferation
and expansion of these primitive cells (Austin et al. 1997; Van Den Berg et al.
1996; Willert et al. 2003). Moreover, overexpression of ß-catenin in HSCs
showed a 5-50 fold expansion of HSCs in vivo, suggesting that Wnt signaling is
important in regulating self-renewal of HSCs (Reya et al. 2003). The role of
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Notch-Delta interaction is similar to that of Wnt-Frizzled pathway. Upon stromaderived delta ligand binding, Notch receptors on the surface of HSC are activated
and translocated into the nucleus where it functions as a transcription factor and
regulates self-renewal and differentiation of HSCs (Stier et al. 2002). Most
interestingly, upregulated expression of HoxB4 and Notch-1 was observed in ßcatenin-transduced cells, indicating that different signaling pathways may interact
with each other and form a complex regulatory network to control HSC fate
(Duncan et al. 2005; Reya et al. 2003)). In addition, molecules from the
extracellular matrix, such as MMp-9, have also been shown to be responsible for
the translocation of HSCs between different functional niches, thus affecting their
fate decisions (Heissig et al. 2002).
Under the influences of intrinsic and extrinsic mechanisms, HSC may face
multiple choices. As shown in figure 1.4, some may undergo apoptosis and be
lost from the population. Some may remain viable and progress through the cell
cycle and yet others may remain quiescent or become senescent. If and when
they divide, HSC replication may be symmetric to give rise to two identical
daughter cells—HSC or progeny destined for differentiation—or the division may
be asymmetric to give rise to one daughter HSC and one differentiated progeny.
An asymmetric division preserves the HSC population and at the same time
provides for the replenishment of mature blood cells (Ema and Nakauchi 2003;
Faubert et al. 2004; Muller-Sieburg et al. 2002; Yan et al. 2003). Therefore, cell
cycling, apoptosis and self-renewal are the major processes by which HSC pool
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size is regulated. Intrinsic and extrinsic signals involved in these processes thus
have an effect on HSC number regulation.

Cell cycle, apoptosis and HSC number
Cell cycle is commonly thought to consist of four orderly phases: G1
(gap1), S (DNA synthesis), G2 (gap2) and M (mitosis) phases. Progression
through these phases is controlled by positive and negative regulators. Positive
contributors include the cyclins and the cyclin-dependent kinases (CDK).
Negative regulators include the cyclin-dependent kinase inhibitors (CDKI) and
the retinoblastoma protein (pRb) (Dao and Nolta 1999). It was originally thought
that the majority of HSCs remained quiescent (G0 phase; a sub-state of G1) over
a long period of time (Lajtha 1979), with only one or a few HSC at any one time
actively cycling and contributing to the mature hematopoietic cell populations.
Once a HSC clone is exhausted a new clone would be activated in a process
called clonal succession (Lemischka et al. 1986). More recent BrdU labeling data
have pointed to a more dynamic and active system, in which 75% of HSCs were
in G0 phase, 25% were in S, G2, and M phase of the cell cycle at any given time,
and 8% completed a cell division each day (Cheshier et al. 1999). Whatever
model is correct, the critical point during the cell cycle is the G1-S transitional
checkpoint, where external and internal factors can exert negative or positive
influences on and thus regulate the entry of HSCs into the cell cycle (Dao and
Nolta 1999).
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Apoptosis is caused by the activation of the caspase cascade, which is
initiated by two signaling routes (stress-induced death and death-domain
receptor-induced death) (Domen 2001). This process can be prevented by antiapoptotic molecules, such as Bcl-2 (Domen and Weissman 2000). Direct
evidence for the involvement of apoptosis in HSC number regulation came from
the findings that overexpression of the anti-apoptotic gene bcl-2 led to increased
numbers of Thy-1.1low, Sca-1+, c-kit+, Lin- cells, a population with long-term
multi-lineage repopulation potential (Domen et al. 2000).
Considerable evidence has shown that factors affecting cell cycling and
apoptotic processes can exert great effects on the HSC population. For example,
p21, one type of CDKI, was found to be highly expressed in HSC and to be
required for stem cell quiescence. Absence of p21 increased proliferation and
therefore absolute numbers of HSCs, but resulted in impaired self-renewal and
radioprotection capabilities of HSCs upon serial transplantation (Cheng et al.
2000b). Presumably the p21 checkpoint is overcome by cytokines and
transcription factors such as Hoxb4 (Steinman 2002). In addition, p21
overexpression protects cells from apoptosis (Steinman and Johnson 2000).
Another good example involved in cell cycle progression and apoptosis is the IL6-initiated JAK-STAT intracellular pathways. They stimulate G1 to S transition by
activating cyclin and preventing apoptosis through upregulation of bcl-2, all of
which resulted in expansion of HSCs (Hirano et al. 2000).
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Self-renewal and HSC number
In addition to the above two regulators, enhanced self-renewal capability
also results in HSC expansion. For example, Hoxb4, has been shown to induce
higher in vitro or ex vivo expansions of HSCs by functioning as transcriptional
factor when overexpressed in bone marrow cells. Mice transplanted with these
genetically modulated HSCs showed a greatly enhanced regeneration in the
hematopoietic stem cell compartment, but with normal bone marrow and spleen
cellularity, and normal numbers and distribution of peripheral blood cells
(Antonchuk et al. 2001; Antonchuk et al. 2002). In addition, the recent finding that
Bmi-1-deficient HSCs fail to contribute to hematopoiesis in lethally-irradiated
recipients over the long term suggests that Bmi-1 is another important molecule
regulating self-renewal. In particular, the effects of Bmi-1 are suggested to be
mediated through its repression of the genes encoding p16Ink4a and P19ARF,
which respectively inhibit cell proliferation and enhance cell death, so that in Bmi1 null mice one would predict premature exhaustion of the stem/progenitor cell
pool (Park et al. 2003). Other signaling pathways, such as Notch-Delta
interaction and Wnt pathway, are also revealed to be important to self-renewal of
HSCs (Sorrentino 2004).
Taken together, interactions among the proteins that govern cell cycle
progression and those involved in regulating apoptosis and self-renewal play
critical roles in regulating the HSC pool size. It is a complicated network
controlled by both intrinsic and extrinsic signals. So, a greater understanding of
underlying mechanisms could provide important insights into achieving enhanced
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or even selective HSC expansion, which will be important in clinical
transplantation (Kondo et al. 2003).

Hematopoietic Stem Cell Expansion and Clinical Applications
Since HSCs have tremendous potential for reconstituting the
hematopoietic system by producing all mature blood cells, HSC transplantation
has been developed as a clinical strategy to treat patients undergoing chemoand/or radio-therapy, or patients with hematological malignancies, such as
leukemia, lymphoma and myeloma (Appelbaum et al. 1995; Brown and
Weissman 2004; Verfaillie 2002). However, the limited success to expand HSCs
ex vivo imposes major limitations on the current use of HSC transplantation. This
is especially true in cases where the number of available stem cells is low (e.g.,
cord blood-derived stem cells for transplantation into adults) (Amos and Gordon
1995). Furthermore, most culture conditions employing cytokine combinations
nonetheless result in net HSC losses due to the fact that differentiation is favored
over self-renewal (Bhatia et al. 1997; Glimm and Eaves 1999). Some recent
attention has been focused on cell intrinsic pathways, whose activation has
caused some HSC expansion ex vivo (Bernstein, 2004 #5424; Lessard, 2004
#5404). Therefore, understanding the underlying mechanisms and identifying
gene that regulate self-renewal and differentiation of HSCs has been a longstanding goal in both basic and clinic science (Weissman 2000). The discovery of
these molecules will provide useful information for designing effective HSC
expansion protocols that can be used for stem cell and current gene therapy.
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Aging Effects on Hematopoietic Stem Cells and Bone Marrow Niche
As discussed above, HSC expansion and transplantation is clinically
important to treat patients with hematological and non-hematological disorders. It
is also well known that cancer risk increases in older people (Balducci and
Extermann FEB 2000). Therefore, understanding aging effects on hematopoietic
system, especially on HSCs and their bone marrow microenvironment (“niche”),
may not only help to prevent malignant transformation, but also to determine
efficacy of aging stem cells for transplantation (Pinto et al. 2003; Van Zant and
Liang 2003) .
In experimental animal models, accumulating evidence indicates that both
the number and functional properties of HSCs are altered with age (figure 1.5).
For example, marrow from old C57BL/6 mice contains more HSCs (measured by
cobblestone area formation, primitive phenotype, and competitive repopulating
ability) than bone marrow from young mice (Chen et al. 2000; de Haan et al.
1997; Morrison et al. 1996). In contrast, the stem cell pool from DBA/2 and all
other mouse strains studied contracts in size during aging. This strain-specific
variation in HSC number and other stem/progenitor cell parameters is regulated
by cell-intrinsic mechanisms, and affected by several quantitative trait loci (QTL)
(de Haan and Van Zant 1999; Geiger et al. 2001). In serial transplantation
experiments, marrow from old animals was less able to engraft later passage
recipients than young BM cells (Chen et al. 1999; Harrison 1983). Moreover, old
HSCs exhibit a differentiation pattern skewed toward the myeloid lineage at the
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expense of lymphopoiesis, particularly the production of B cells (Linton and
Dorshkind 2004; Miller and Allman 2003; Offner et al. 1999; Sudo et al. 2000)).
Further evidence of age-related changes in stem cells include the finding that a
higher proportion of Thy-1loSca-1+Lin-Mac-1-CD4-c-kit+ cells from old mice are in
S/G2/M phases of the cell cycle (Morrison, 1996), and the results of Henckaerts
et al., who showed that the proliferative response of Lin-Sca-1+c-kit+ marrow cells
to the early-acting cytokines KL, Flt3L and TPO, decreased dramatically with age
(Henckaerts et al. 2002).
As mentioned previously, the bone marrow niche is the optimal
microenvironment for the growth and functional maintenance of HSCs (Moore
2004; Nilsson et al. 2001). In all experimental and clinical stem cell transplants,
the critical first step leading to successful engraftment is “homing” of stem cells to
the bone marrow, which involves adhesion molecules and cytokines (Ema and
Nakauchi 2004; Spradling et al. 2001; Whetton and Graham 1999). Although
more and more evidence demonstrates that HSCs undergo age-related
quantitative and functional changes, little is known about the effects of aging on
bone marrow niche and HSC homing (Albright and Makinodan 1976; Boggs et al.
1984; Globerson 1999; Liang and Van Zant 2003; Morrison et al. 1996; Van Zant
and Liang 2003). As more and older patients become candidates for
transplantation in the treatment of hematological malignancies and nonhematological diseases, these studies are obviously clinically relevant, yet
remain largely unexplored.
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Experimental Goals and Significance
The first experimental goal described in this dissertation is to study the
genetic control of murine hematopoietic stem cell numbers using a forward
genetic approach. Three specific aims are formulated to address this question: (i)
to confirm the quantitative trait locus (QTL) mapping in congenic mouse model,
(ii) to study stem cell number-related phenotypes, including cell cycle, apoptosis
and self-renewal of HSCs, and (iii) to identify gene(s) responsible for HSC
number regulation. A second goal is to investigate the effects of donor and
recipient age on the bone marrow homing efficiency and engraftment properties
of HSCs and HPCs in mice.
These studies are important because they may lead to the discovery of
novel genetic and molecular pathways that control HSC numbers. Clinically, the
findings can potentially help to develop effective strategies for stem cell
expansion and gene therapy using HSCs as target cells.
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Figure 1.1. The hematopoietic system is hierarchical in nature. A small
number of pluripotent stem cells, especially hematopoietic stem cells (HSCs),
give rise to committed progenitor cells, which can generate all lineages of mature
blood cells. HSCs are a heterogeneous population structured in a hierarchy,
including long-term HSCs (LT-HSCs) and short-term HSCs (ST-HSCs) with
different self-renewal and differentiation capabilities. The progeny of HSCs are
common lymphoid progenitors (CLP) and common myeloid progenitors (CMP),
which generate B, T lymphocytes, nature killer (NK) cells, dendritic cells,
granulocytes, macrophages, erythrocytes and platelets.
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Figure 1.2. Schematic illustration of forward and reverse genetics. Generally
speaking, two strategies are utilized to lead to gene discovery: forward and
reverse genetic approaches. A forward genetic approach starts with strainspecific phenotypes; subsequent linkage analysis maps the location of
quantitative trait loci (QTL) in the genome that contribute to the phenotype.
Generation of congenic mice is the main tool to confirm the existence, function
and location of these QTL. The purpose is to transfer and isolate a specific
interval surrounding the QTL from one strain to another stain to determine
whether phenotype results from introgression of the opposite strain alleles.
Congenic strains can then serve as model systems for gene discovery using a
candidate gene approach and by using positional cloning. Candidate gene in (or
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close to) the QTL may obviously be related to the phenotype; differential
expression between the congenic and recipient (background) strains supports
the candidacy of the gene. Another feasible way to investigate the underlying
genes is fine mapping through backcrossing congenic mice to background strain
animals to narrow down the interval around the QTL. Characterization of
phenotype in subcongenics is carried out to confirm effects of the QTL. Once the
QTL is mapped to a sufficiently small region (<1cM), bacterial artificial
chromosome (BAC) clones spanning the interval may be used to generate
transgenic mice. BACs conferring the expected phenotype contain sufficiently
small fragments of mouse genomic DNA (50-100kb) to be sequenced. Sequence
differences in the open reading frame of the candidate gene, or more likely, in the
promoter region, between two parental alleles will be taken as proof of identity
between the candidate and the QTL.
In summary, the forward genetic approach is based on the strain-specific
phenotype and proceeds toward the underlying genes. Conversely, reverse
genetic approaches adopt an opposite direction, proceeding from polymorphism
in DNA sequence of a gene to its functional analysis usually through gene
overexpression and/or a gene knockout animal model. For example, in recent
studies of stem cell-specific genes, candidates have been selected by differential
expression analysis using microarrays. Gene expression profiles of embryonic
stem cells (ESC), neural stem cells (NSC), and HSC have been compared to
arrive at candidates that specifically confer stem cell attributes. Their functions
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must then be identified through gene overexpression in transgenic mice and/or
loss of function mutations in gene knockout animals.
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Figure 1.3. Intrinsic and extrinsic regulation of hematopoietic stem cells.
Stem cell-autonomous modulators, such as transcription factors (Hoxb4, Runx1)
and cell surface markers (Bcrp1, Flk-2) confer HSC-specific phenotypes and
functions. External signals from stromal cells in bone marrow niche also exert
roles on HSCs through secretion of cytokines (SDF-1), cell-cell interactions
(Notch-delta, Wnt-frizzled), and cell-matrix interactions (MMP-9). Note:
references are cited in the text.
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Figure 1.4. HSCs fate outcomes. Under the influence of intrinsic and extrinsic
regulators, HSCs have three possible fate outcomes: apoptosis, quiescence and
cycling. Apoptosis will cause the loss of HSCs. For a cycling HSC, there are
three potential outcomes: (i) an asymmetrical division leading to the maintenance
of the HSC population by generating one HSC (self-renewal) and one
differentiated daughter cell, (ii) a symmetrical division leading to net expansion of
HSCs by generating two identical HSCs and (iii) a symmetrical division leading to
loss of HSCs by producing two committed progenitor cells.
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Figure 1.5 Diminished functional capacity of hematopoietic stem cells
during aging. (a), a young stem cell population is characterized by few apoptotic
cells, a mix of quiescent and active cells, the latter with robust self-renewal and
differentiation capacity. Young stem cells show balanced differentiation into
lymphoid and myeloid lineages. (b), an aged stem cell population has a higher
rate of apoptosis due to acquired cellular damage. There are fewer quiescent
cells in the stem cell reserve and the active stem cells have restricted lineage
potential. (c), when an old stem cell population comes under hematopoietic
stress, the rate of apoptosis increases as quiescent cells unsuccessfully make
the activation step, further depleting the quiescent reserves. Active stem cells not
only are hampered by lineage restrictions, but the number of differentiated
progeny each produces is diminished, leading to a slow and blunted recovery.
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CHAPTER TWO
Mapping and confirmation of quantitative trait loci linked to
strain-specific difference in hematopoietic stem cell number

Summary

Accumulating evidence has shown that there is a large natural variation
among laboratory mouse strains in the number of bone marrow hematopoietic
stem cells (HSCs). By using in vitro long-term cobblestone-area forming cell
assay (CAFC), we have found that two inbred strains, C57/BL6 (B6) and DBA/2
(D2), demonstrated the strain-specific difference in this parameter, in which B6
mice have fewer marrow HSCs (CAFC day35) than do D2 mice. In order to
understand the genetic basis for this variation, we used a forward genetic
approach and first performed linkage analysis in BxD recombinant inbred strains
and identified three quantitative trait loci (QTL) that linked to this difference. They
were on chromosomes 3, 5 and 18 and correlated most highly with microsatellite
markers D3Mit5, D5Mit352 and D18Mit53, respectively. The QTL mapping was
further confirmed in congenic mouse strains in which a genomic segment
surrounding the QTL was introgressed either from B6 strain mice into D2 genetic
background, or vise versa. In the chromosome 3 “B6 onto D2” (symbolized as
D.B Chr3) congenic strain and its reciprocal “D2 onto B6” strain (B.D Chr3),
CAFC analyses demonstrated that D.B Chr3 mice had more than a 50%
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decrease in CAFC day35 number compared to their D2 background mice,
whereas B.D Chr3 mice had a ~80% increase compared to B6 background strain
(p<0.05). In addition, in vivo repopulation assay showed that 73% more long-term
repopulating HSCs were present in B.D Chr3 mice. However, the numbers of
peripheral blood cells (erythrocytes, leukocytes and platelets) and HPCs (CAFC
day7 and day21) were not different between Chr.3 congenic and their
background strains. Therefore, we conclude that (i) QTL on chromosome 3, 5
and 18 contribute to the strain-specific difference in HSC number between B6
(lower) and D2 (higher) mouse strains, (ii) Chr.3 QTL mapping is confirmed in
congenic mouse strains in which introgression of the B6 allele onto a D2
background confers onto the D2 strain a decreased HSC number, i.e. the B6
strain phenotype, and vice versa, (iii) Chr. 3 QTL specifically regulates HSC
compartment size and has no effects on differentiated hematopoietic cells.

29

Introduction

The number of stem cells in a self-replenishing organ may
significantly impact the maintenance of normal organ function. There is a
large natural variation among laboratory mouse strains in the absolute
number of hematopoietic stem and progenitor cells (HSCs and HPCs) in
bone marrow (de Haan and Van Zant 1997; Liang and Van Zant 2003). Two
such inbred strains, C57BL/6 (B6) and DBA/2 (D2) have been shown to have
significant differences in some characteristics of hematopoietic cells. For
example, young D2 mice have a 2- to 11-fold higher numbers of bone marrow
HSCs than do B6 mice, depending on the assay for stem cell used. However, this
trend is reversed in aged mice, i.e. ~2.5-fold more HSCs are found in old B6 mice
than in D2 mice, indicating HSC compartment size contracts with age in D2 mice
whereas it expands in B6 animals. The same age-related changes were also
observed in the HPC population (de Haan and Van Zant 1999; Geiger et al.
2001). Other evidence showing the strain-specific differences in primitive
heamtopoietic cell includes the higher fraction of cycling HPCs (de Haan et al.
2002) and lower proliferation response of HSCs to exogenous early-acting
cytokines in D2 mice compared to B6 mice (Henckaerts et al. 2002). In addition,
the proportion of mature blood cells, such as peripheral B and T lymphocytes
(Boulton et al. 2003; Chen and Harrison 2002b), were also reported to be
different in the two strains. Therefore, the broad spectrum of phenotypic
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differences in hematopietic cells between B6 and D2 strains, plus the availability
of recombinant inbred stains derived by crossing them, have become the most
powerful genetic models to investigate genetic basis for the natural variations of
HSCs and HPCs.
As discussed previously, the first step in forward genetics approach is to
map quantitative trait loci (QTL) that contribute to the strain-specific phenotypic
differences in B6 and D2 by linkage analysis. BXD recombinant inbred mouse
strains derived from crossing B6 and D2 mice may be used for this purpose (Van
Zant and de Haan 1999; Williams et al. 1998; Williams et al. 2001). As shown in
Figure 2.1, B6 and D2 mice are mated to produce F1 generation, which inherits
one complete set of B6 chromosomes from one parent and one complete set of
D2 chromosome from the other parent. F1 brother and sister mating produces F2
generation, whose genomes are chimeric with alternating stretches of B6 and D2
alleles due to meiotic recombination between aligned B6 and D2 chromatids.
Mating pairs of F2 mice are randomly chosen and become the founders of
individual BXD strains. The brother-sister breeding continues for 20 generations
and creates BXD recombinant inbred (RI) strains that are homozygous at all loci.
Because about 1000 polymorphic microsatellite markers have been identified
throughout the B6 and D2 genome, the genotype at each locus (B6 or D2) can
be identified, and the strain distribution pattern (SDP) in all BXD RI strains can be
obtained for all markers. In order to map loci responsible for phenotypic
variations, specific phenotypes are measured in each BXD strain individually.
This results in a phenotype distribution pattern (PDP) for the entire BXD RI set. A
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sophisticated statistic program compares the PDP with the SDP and identifies
marker SDPs with a high correlation to the PDP. The strength of the correlation is
reflected by LOD (logarithm of the odds ratio) value. These selected markers,
whose genomic location is known, then assign a chromosomal location to a locus
that might be involved in the regulation of specific phenotype.
Moving to the generation of congenic animals is the critical step towards
identifying and studying the function of phenotype-associated gene (Markel et al.
1997; Visscher 1999). The underlying idea is to transfer and isolate a specific
interval surrounding the QTL of interest from the donor strain to a recipient or
background strain (Figure 2.2). For example, in order to transfer a QTL on a
certain chromosome from the genome of B6 onto the D2 strain, B6 and D2 are
crossed to generate F1 hybrids, which are subsequently backcrossed to D2
again to produce a N2 generation. After N2 animals are genotyped at markers on
both sides of the QTL, those that inherit one B6 allele are chosen and then
crossed back to D2 parental strain again. With the process of backcrossing and
genotyping being repeated for 8 generations, the homozygosity for D2 alleles is
increased from 75% at N3 to 87.5% at N4 and eventually to 99.8% at N10. N10
progeny heterozygous for selected markers are then intercrossed to produce
congenic mice that are homozygous for the B6 allele of QTL in the D2 genome
background. By using the same method, we also can transfer D2 QTL allele to
B6 background to generate what is called the reciprocal congenic strain.
Therefore, congenic animals are genomic chimeras: they have donor strain
genes only in the prescribed genomic segment of interest, all other genomic loci
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are homozygous for the recipient strain alleles. Thus, it is possible to determine
the effect of individual, selected genes on a trait in the context of a fixed genetic
background. Our lab has found that young D2 mice have higher HSC numbers
than do B6 mice (de Haan et al. 2000; Geiger et al. 2001). In the current study,
we aimed to investigate the QTL responsible for this strain-specific trait, generate
congenic mice bearing QTL of interest, and confirm QTL mapping in congenic
mouse models.
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Materials and Methods

Animals
Background strains: C57BL/6J (B6) (Ptprcb [Ly-5.2]), DBA/2J (D2) mice
were purchased from the Jackson Laboratories (Bar Harbor, ME).
Congenic stains: Chromosome 3 congenic mice were generated by
Geiger et al. as described previously (Geiger et al. 2001). Genotypes of congenic
mice were checked every 6 months through genetic marker–based polymerase
chain reaction. All primers for simple sequence repeat (SSR) element markers
were bought from Research Genetics, Huntsville, AL. Two strains of
chromosome 3 congenic mice were generated and maintained: B.D Chr3
(14cM~33cM) congenics with D2 QTL being introgressed onto B6 background,
and their reciprocal congenic strains D.B Chr3 (19cM~60cM) with B6 QTL onto
D2 background.
Transplantation recipient mice: B6.SJL (Ptprcb [Ly-5.1]) mice from
Charles River laboratories (Frederick, MD) were used as recipients in
transplantation experiments.
All mice were female and are 6 to 10 weeks old and they were kept in the
animal facilities of the University of Kentucky under pathogen-free conditions
according to NIH-mandated guideline for animal welfare. They were fed with
water and food ad libitum.

Preparation of bone marrow nucleated cells suspension
34

Mice were killed by cervical dislocation after isofluorane anesthesia.
Femora were removed and flushed with Iscove modified Dulbecco media (IMDM)
containing 2% fetal calf serum (FCS), 80 U/mL penicillin, and 80 mg/mL
streptomycin. Cell counts were taken on a Coulter MD8 (Beckman Coulter,
Fullerton, CA). The cells were subsequently used for the cobblestone areaforming cell (CAFC) assay without any further processing.

Cobblestone area-forming cell (CAFC) Assay
CAFC assay were carried out as described previously (Geiger et al. 2001).
In brief, FBMD-1 stromal cells were plated into 96-well tissue culture-treated
plates (Costar, Cambridge, MA) and they subsequently formed a confluent
monolayer after 7 to 10 days. Bone marrow cells were flushed and pooled into
Iscove Modified Dulbecco media (IMDM) with 2% fetal calf serum (FCS) (Life
Technologies). Cells were then seeded into FBMD-1 coated culture plates in
IMDM, 20% horse serum, 80 U/mL penicillin, 80 mg/mL streptomycin (all from
Life Technologies), 10-4 ß-mecaptolethanol, 10-5 M hydrocortisone (both Sigma,
St. Louis, MO) at doses of 81,000, 27,000, 9,000, 3,000, 1,000, or 333 cells per
well. Typically 20 replicate wells per dilution were evaluated. Individual wells
were screened at day 7,14,21,28 and 35 for the presence of a cobblestone area,
defined as a colony of at least 5 small, non-refractile cells growing underneath
the stroma (as shown in Figure 2.3). The longer the latency before cobblestones
appear, the more primitive the nature of cells forming that cobblestone.
Therefore, the most primitive hematopoietic stem cells (HSCs) show
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cobblestones at day 35, whereas colonies that appear earlier are derived from
more committed progenitor cells (HPCs). Frequencies of CAFCs were calculated
by using maximum likelihood analysis. The frequency of CAFCs equals 1 divided
by the number of cells yielding 37% negative wells according to the equation of
lnp0= -m.

Linkage analysis
The frequencies of CAFC day35 in BXD recombinant inbred mouse
strains were measured and published previously (de Haan and Van Zant 1997)
and were used to perform genome-wide searches for linked loci through “Interval
Mapping” and using the “Marker Regression” tool on the WebQTL website
(http://www.webqtl.org/cgi-bin/WebTL.py) (Chesler et al. 2004; Wang et al.
2003). Interval Mapping tool computes linkage maps for the entire genome or
single chromosomes and uses permutation and bootstrap tests to assess
strength and consistency of linkage for the CAFC day 35 trait. This results in
computation of likelihood ratio statistics (LRS) values for genome-wide levels for
at least suggestive linkage. The Marker Regression tool plots permutation
results, lists those markers linked to trait variation, and provides access to
composite mapping functions

In-vivo long-term limiting dilution analysis (competitive repopulation unit
assay, CRU assay)
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Long-term limiting-dilution analysis in competitively repopulated hosts is
an in vivo method to functionally identify HSCs and measure their frequencies
(Szilvassy et al. 1990). The basic idea for the experimental setup is to transplant
graded numbers of “test” cells into myelo-ablated recipients together with a fixed
number of “competitor” cells. In order to distinguish different cell sources, a
hematopoietic cell maker, Ly-5 (or CD45), is commonly used in such kind of
experimental design, in which B6 mice naturally express the Ly-5.2 allelic variant,
whereas competitor cells and recipient mice express the Ly-5.1 allele. The Ly5.1-bearing mice are B6 background animals congenic for the Ly-5.1 allele
introgressed from the SJL strain. Since these allelic variants don’t exist between
D2 and D2-based congenic mice, this assay can’t be performed on these stains.
As shown in Figure 2.3, graded numbers of B.D Chr3 congenic- and B6-derived
Ly-5.2 “test” cells (6,000; 20,000; 60,000) were admixed with a radioprotective
dose (2x105) of competitor cells (Ly-5.1) and injected intravenously into lethally
irradiated (9 Gy) Ly-5.1 recipient mice. Recipients were bled from the retro-orbital
sinus at 5, 10 and 20 weeks after transplantation. Erythrocytes were depleted
from each peripheral blood (PB) sample by hypotonic lysis using NH4Cl, and the
remaining leukocytes then stained in triplicate with a donor (B6)-specific anti-Ly5.2 monoclonal antibody (mAb) conjugated with fluorescein isothiocyanate
(FITC) (clone ALI4A2) and phycoerythrin (PE)-conjugated mAbs (BectonDickinson-PharMingen, San Diego, CA) specific for either B (anti-CD45R/B220;
clone RA3-6B2) or T lymphocytes (anti-Thy-1.2; clone 30H12), or granulocytes
(anti-Ly6G/Gr-1; clone RB6-8C5) and macrophages (anti-CD11b/Mac-1; clone
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M1/70). Samples were analyzed using a FACScan instrument (Becton-Dickinson
Immunocytometry Systems, San Jose, CA). The frequencies of CRU were
calculated from the proportions of negative recipients (in which <5% of the
circulating B, T and myeloid cells were regenerated by Ly-5.2+ stem cells) in
each cell dose group using L-Calc software (StemCell Technologies Inc.,
Vancouver, BC).

Peripheral blood cell counts
Anesthetized mice were bled from the retro-orbital venous plexus.
Circulating leukocyte, erythrocyte and platelet counts were measured by analysis
of 40ul blood using a System 9118+ Hematology Series Cell Counter (Biochem
Immunosystems, Allentown, PA).

Statistical analysis
All experiments were preformed at least in triplicate with a minimum
sample size of 3 mice per group. Data were analyzed by either two-tailed t-test
assuming unequal variances or one-way ANOVA.
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Results

Quantitative trait loci responsible for strain-specific difference in HSC
number were mapped on murine chromosome 3, 5 and 18
By using an in vitro cobblestone-area forming cell assay (CAFC), we have
found that young D2 mice have ~2-fold higher number of marrow hematopoietic
stem cells (HSCs) than do B6 mice (de Haan et al. 2000; Geiger et al. 2001). We
hypothesized that single or multiple genomic regions might contribute this strainspecific quantitative trait. Genome-wide linkage analysis was therefore performed
by comparing phenotype (HSC number per femur) distribution pattern (PDP) with
strain distribution pattern (SDP) in BXD recombinant inbred mice to search for
linked loci (Wang et al. 2003). Three quantitative trait loci (QTL) were mapped on
chromosome 3, 5 and 18 with microsatellite markers D3Mit5 (25cM), D5Mit352
(20cM) and D18Mit53 (27cM) (Figure 2.5), respectively, having the highest
linkage. There are several points to be made from this linkage analysis. First are
the linkage peaks pointing to these 3 chromosomes, whose amplitudes are
above the statistical suggestive threshold (9.2), but below the significant
threshold (16.3). Second, the additive effects, indicated by the arrow in the figure,
are all positive for these 3 makers (D3Mit5, D5Mit352 and D18Mit53), suggesting
that the D2 allele increases, whereas the B6 allele decreases, the trait value
(HSC number). Third, more than one locus affects femoral marrow HSC number,
implying that multiple regulatory pathways either synergistically or independently
are involved in the control of HSC pool size.
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Congenic strains confirm QTL mapping
In order to experimentally validate the mapping, we have generated
congenic mouse strains in which a genomic interval containing the QTL from one
strain is isolated and transferred onto the genomic background of the other
strain, and vice versa. Therefore, the only genotypical difference between
congenic and background animals is the introgressed segment, a configuration
which is helpful to study the independent influences of each QTL. Generation of
congenic strains has been accomplished for each of 3 QTL responsible for D2/B6
variation in HSC numbers. Studies concerning the chromosome 3 (Chr.3) QTL in
congenic mice will be primarily discussed in the following chapters.
In this part of the study, we hypothesized that congenic B.D Chr3 mice, in
which an interval on Chr.3 in B6 background has been replaced by the D2 QTL
segment, would confer the D2 phenotype for HSC number (higher). Conversely,
congenic D.B Chr3 mice, in which the B6 QTL was introgressed into D2
background, would show lower HSC numbers. Therefore, we measured CAFC
day35 frequency in both congenics and their respective background mice. As
predicted from the mapping data, congenic B.D Chr3 mice showed statistically
significant (P<0.005) increases in CAFC day35 numbers compared to B6
background; in fact, more than doubling them. Conversely, reciprocal D.B Chr3
congenic mice had more than a 50% decrease in this parameter (P<0.05) (Figure
2.6). Similar results were also observed in reciprocal congenic strains for the
Chr.5 QTL, demonstrating that each of the QTL have profound effects on stem
cell number. Moreover, mice congenic for both QTL (Chr.3/Chr.5) showed a
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quantitatively similar phenotype as the singly congenic mice and thus the effects
of the QTL are not additive or synergistic.
The differences in CAFC day35 frequency (HSC numbers) shown
between the congenics and their background should also be reflected by an in
vivo analysis. Long-term limiting-dilution analysis in competitively repopulated
hosts is the gold standard method to functionally identify and quantify HSCs in
vivo (Szilvassy et al. 1990). Briefly, graded numbers bone marrow cells from B.D
Chr3 or B6 mice were co-transplanted into myeloablated mice together with a
radioprotective dose of competitor BM cells containing an allelic variant of the
hematopoietic cell-specific marker, Ly-5 (also known as CD45 and Ptprc). The
frequency of HSCs in the test population, measured as competitive repopulating
units or CRUs, was then determined by applying maximum likelihood analysis
and Poisson statistics. As shown in Table 2.2, the long-term repopulating stem
cells were present at a frequency in B6 mice of 1 in 17,424 marrow cells,
whereas this frequency increased to 1 in 10,615 marrow cells in the B.D Chr3
congenics (P<0.05). When these frequencies were calculated into the absolute
number of CRU per femur, B.D Chr3 congenic mice had almost ~80% more longterm repopulating stem cells than did B6 mice, a result consistent with those from
in vitro CAFC assays.
Taken together, both in vitro and in vivo results validate the linkage
analysis, i.e., Chr.3 and Chr.5 QTL are responsible for the strain-specific
difference in HSC number between B6 and D2 strains: D2 alleles increase,
whereas, B6 alleles decrease HSC numbers.
41

Stage-specific regulation of HSCs by Chr.3 QTL
HSCs are the major source of downstream progenitors and all lineages of
mature blood cells. If D2 or B.D Chr3 mice have more HSCs in the bone marrow,
do they give rise to more hematopietic progenitor cells (HPCs), and peripheral
blood cells along their differentiation pathways? Because CAFCs from day 7 to
21 represent different stages of HPCs (Ploemacher et al. 1991; Ploemacher et al.
1989), we therefore compared CAFC frequencies at day 7 and day 21 among
congenic and background strains. Together with cell counts of peripheral
leukocytes, erythrocytes and platelets, we tested the hypothesis whether Chr.3
QTL also affect the numbers of committed and differentiated cells. The results
summarized in Table 2.3 showed that there were no statistically significant
differences in either CAFC day7 or day21 frequencies per femur or peripheral
mature blood cell counts among Chr.3 congenic and their background mice.
These data suggest that HSC population size is regulated in a stage-specific
way, i.e., the gene underlying chromosome 3 QTL specifically control HSC
compartment size, and they have limited or no effects on downstream progenies
along the differentiated pathways. This stage-specific regulation model and
related differentiation gene expression profiles between HSCs and HPCs has
already been suggested by other studies (Geiger et al. 2001; Lawrence et al.
1995; Park et al. 2002; Zhong et al. 2005).
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Discussion

Although increasing numbers of genes have been implicated in the
regulation of HSCs, the signaling pathways and underlying mechanisms that
govern the self-renewal and differentiation of HSCs, and thus determine the
number of bone marrow HSCs, is still poorly understood (Lessard et al. 2004). In
a forward genetic approach, using the BXD recombinant inbred set and
quantitative trait loci (QTL) mapping, we identified multiple loci on chromosome
3, 5 and 18, that were linked to the variations in HSC number of C57BL/6 (B6)
and DBA/2 (D2) mouse strains. We also confirmed Chr.3 QTL mapping in
congenic mouse models.
That the size of the stem cell pool shows natural variation between B6 and
D2 mice has been previously shown. Henckaerts et al. demonstrated that young
B6 mice had more Lin-Sca-1++c-kit+ cells than did D2 mice and suggested that
the stem cell pool in B6 was larger than in D2 mice (Henckaerts et al. 2002).
These results are contradictory to what we and others have found using a variety
of functional assays. Experience and our previous findings have shown that
although Lin-Sca-1++c-kit+ cell population is highly enriched in stem cells, it is not
homogenous (de Haan et al. 2000). Therefore, identification of stem cells solely
on the basis of phenotypic markers is risky, particularly when different strains are
involved. In our study, we used a functional assay, the CAFC assay, to quantify
stem and progenitor cells in B6, D2 and chromosome 3 congenic strains and
found that D2 alleles increased, whereas B6 allele decreased HSC numbers.
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Most importantly, similar results were obtained when we performed more
rigorous in vivo competitive repopulating unit (CRU) assay to measure the
number of long-term repopulating stem cells. Therefore, our findings from both in
vitro CAFC and in vivo CRU assays strongly support the accuracy of our
measurement of stem cell numbers.
The genetic basis for natural variations of HSC number has been
previously reported by Muller-Sieburg and colleagues (Muller-Sieburg and Riblet
1996). They demonstrated similar findings as ours concerning the HSC number
difference between B6 (lower) and D2 (higher) strains. By using the same BXD
recombinant inbred mice, however, they mapped two completely different loci
accounting for the inter-strain variation on chromosomes 1 and 11. This mapping
discrepancy is most likely due to the following reasons. First, the strategies to
define HSCs are different in the two studies. Although they used a similar longterm in vitro culture system with the same stromal cells (FBMD-1) as ours, they
considered cells producing at least 500 non-adherent differentiated cells after 4
weeks of culture as HSCs (called long-term culture initiating cells, LTC-IC).
Therefore, the cells they measured are probably less primitive than those we
identified. This explanation is strongly supported by our previous findings that loci
responsible for the early progenitor cell (CAFC day21) number difference in B6
and D2 mice mapped to chromosome 1 (Geiger et al. 2001). Secondly, the
phenotype used for linkage analysis is different. In their study, they quantified the
frequency of stem cells contained in every 105 bone marrow cells. Since we
already found that B6 mice had more bone marrow cells in the long bone of the
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back legs than do D2 mice (data not shown), in order to exclude the effects of
bone marrow cellularity and provide more accurate and real measurement of
stem cell pool size, we used stem cell frequency per femur as our phenotype to
perform QTL mapping.
In the present study, several loci on chromosome 3, 5 and 18 were
genetically linked to the natural variations in HSC number. Moreover, QTL
mapping were further confirmed in each of our QTL congenic mouse models
(Figure 2.6 and unpublished data for Chr18 congneics). Additional evidence for
the existence of a locus on chromosome 18 regulating HSC number comes from
recently published studies of 5q-deleted myelodysplastic syndromes (Nilsson et
al. 2000). The human 5q chromosomal region is syntenic to the linked locus on
chromosome 18. It was reported that HSCs are dysregulated in this human
disorders, a finding that links this region to the stem cell regulation. Therefore,
multiple, rather than a single QTL, regulate HSC numbers. Whether genes in and
around these QTL regions act independently or synergistically needs to be
further investigated. Our CAFC day35 analyses in Chr.3, Chr.5 and Chr.3/Chr.5
double congenic (Figure 2.6) suggest that the effects of Chr.3 and Chr.5 QTL are
not additive and they may act through a common mechanistic pathway. Taken
together, a forward genetic approach leads to the discovery of multiple genes
involved in the same phenotype, which helps to reveal the interactions of these
genes and the roles of each gene in the regulatory pathway. This can be viewed
as an advantage of forward genetics over reverse genetic approach, which
mainly focuses on the functional effect of an individual gene on stem cells.
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Our QTL mapping, CAFC, CRU analyses and peripheral blood cell counts
in congenic mice further demonstrate that Chr.3 QTL specifically regulates stem
cell pool size, without any observable effects on progenitor and differentiated cell
populations. Stage-specific regulation of stem/progenitor cells is complex in that
several distinct loci have been shown to be involved in this process. Some QTL
specifically determine hematopoietic progenitor cell (HPCs) number, such as loci
on chromosome 1 and 7. Some of them affect both progenitor and stem cells.
Other QTL on chromosome 2 and 18 have been reported to link to the dynamic
changes of stem and progenitor cell number with age (Geiger et al. 2001). In
addition, loci on chromosome 1, 8 and 19 specifically determine the proportions
of peripheral B and T lymphocytes in B6 and D2 strains (Chen and Harrison
2002a). In aggregate, different genomic loci are responsible for the stage- and
strain-specific regulation of hematopoietic cells. Congenic animal models lead to
the further investigation of the roles of individual loci and to the discovery of
underlying gene (de Haan et al. 2002). Furthermore, recent studies about
differential gene expression profile between stem and progenitor cells based on
microarray analyses also help to identify the genes in our QTL that specifically
regulate stem cell population (Park et al. 2002; Zhong et al. 2005).
Even though our analysis revealed significant differences in stem cell
levels, all of the strains tested apparently had normal proportions of mature blood
cells. It is clear that the relatively lower number of HSCs in B6 and congenic D.B
Chr3 mice is entirely sufficient to provide blood cells for the lifespan of the
animal. Therefore, in D2 and B.D Chr3 mice, the excess stem cells might remain
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quiescent and thus would not be evident in the periphery. However, under a
hematopoietic stress condition, such as bone marrow transplantation, the
subpopulation of stem cells might be reactivated and contribute to the
hematopoietic reconstitution. Evidence supporting this explanation comes from
studies of chimeric mice generated by embryo aggregation of B6 and D2 strains
(Van Zant et al. 1983). The hematopoietic contribution of D2 origin gradually
decreased with time and completely stopped after approximately two years.
However, transplantation of the B6/D2 chimeric bone marrow cells into myeloablated recipient mice showed that a higher proportion of D2-derived blood cells
were present in the periphery again, indicating that D2-derived HSCs became
quiescent, rather than extinct. These quiescent D2 HSCs could still be
reactivated and reconstitute the hematopoietic system. Another possible reason
for the existence of “extra” stem cells in D2 and B.D Chr3 mice is that these cells
might be required for a defective hematopoietic compartment. We have found
that a higher proportion of progenitor cells in D2 and B.D Chr3 mice were killed
by hydroxyurea (De Haan and Van Zant 1999 and unpublished data), a chemical
causing DNA damage and consequently interfering with DNA synthesis of cycling
cells. The results suggest that high turnover rate and/or sensitivity to DNA
damage of progenitor cells place increased demand of stem cells in these two
strains and thus require more stem cells to replenish the blood cells and maintain
hematopoietic system.
Stem cell transplantation has become increasingly important in the clinic
for the treatment of a variety of diseases in humans. One obstacle to this
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procedure is the difficulty in procurement of adequate numbers of stem cells
(Kondo et al. 2003). In the present study, we demonstrate that hematopoietic
stem cell numbers are under strict genetic control in mouse and that several
genomic loci are involved. Because of the genomic synteny between human and
mouse (McPeek 2000; Miller et al. 2004), the results may be important to identify
genes regulating stem cell number in humans. If so, these genes may well
provide a desperately needed strategy for stem cell expansion and
transplantation.
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Figure 2.1 Schematic illustration of derivation of BXD recombinant inbred
mouse strains. BXD recombinant inbred (RI) strains are derived from
interbreeding of progeny of C57BL/6 and DBA/2 mice for 20 generations. Every
locus throughout the genome, identified by microsatellite (MIT) marker, is
homozygous for either the C57BL/6 (B) allele or the DBA/2 (D) allele. The
presence of “B” or “D” at each locus in all BXD RI strains forms strain distribution
pattern (SDP) for this marker or locus.
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Figure 2.2 Scheme depicting generation of congenic animals. F1 progeny of
C57BL/6 (B6, gray chromosome) and DBA/2 (D2, black chromosome) are
selected for the presence of the locus of interest (dashed box) and the mice are
backcrossed to either of the parental strains (D2 is the recipient strain and B6 is
the donor strain in this figure). The selection and backcross are performed for 10
generations. In the N10 generation, contaminating donor strain alleles, except for
the locus of interest, have been reduced to a statistically negligible level; that is
(1/2)10 ≤ 0.0005.
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Stromal cells (FBMD1)

Differentiated
cells

Cobblestones

Figure 2.3 Illustration of cobblestone area under microscope. A cobblestone
area derived from primitive hematopoietic cells is defined as a colony of at least 5
small, non-refractile cells growing underneath the stroma (FBMD1 cells). The
differentiated cells are above the stromal layer and are usually bigger and
birefringent.
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Ly5.2
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Competitor cells: Ly5.1
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Test cells: Ly5.2 (B.D Chr.3 or B)B6)
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Ly5.2 / Ly5.1 chimerism is determined in leukocytes
at 20 weeks after transplantation

Figure 2.4 Experimental design for Competitive Repopulation Unit (CRU)
assay. Graded number of B.D Chr3 congenic or C57BL/6 (B6) Ly-5.2 bone
marrow cells are transplanted into lethally-irradiated recipient Ly-5.1 mice,
together with 1x106 Ly-5.1 competitor cells. Test (Ly-5.2)-derived leukocytes in
peripheral blood are measured at 20 weeks after transplantation. CRU frequency
is calculated from the proportion of negative mice in each cell dose group as
described in the Methods.
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Figure 2.5 Genome-wide quantitative trait loci (QTL) mapping. A murine
genome-wide scan of linkage of CAFC day35 number to microsatellite markers,
some of which are listed across the bottom of figure, but illegibly at this scale of
reproduction. Each of the 19 autosomes and the X chromosome is labeled
across the top of the figure. Three peaks above the threshold of suggestive
linkage are labeled on chromosomes 3, 5 and 18, indicating that these 3 loci are
linked to HSC number regulation. The additive effects demonstrate the effects of
B6 or D2 allele on the phenotype: positive additive value represents D2 allele
increase the phenotype whereas negative value indicates B6 allele increase the
phenotype.
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background mice. Relative numbers of HSCs (CAFC day35) per femur are
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measured in 6 congenic strains compared with their background strains (either
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B6 or D2). Congenic mice include single reciprocal congenics (B.D Chr3
150

(14cM~33cM), B.D Chr5 (8cM~29cM), D.B Chr3 (19cM~60cM), D.B Chr5
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(5cM~38cM)) and double congenics (B.D Chr3 (14cM~33cM)/B.D Chr5
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0 Chr3 (19cM~60cM), D.B Chr5 (5cM~38cM)). The values
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derived from at least 9 samples are shown as mean ± 1SEM. The dashed line
linked chromosome

(100%) indicates the same value between congenic and background mice. **
represents P <0.005, and * represents P<0.05.
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Table 2.1 Determination of long-term competitive repopulating units (CRUs)
frequency in B6 and B.D Chr3 mice.
Number of negative mice#

No. cells
transplanted
per recipient mouse

B6

B.D Chr3

6,000

13/21&

11/21

20,000

7/22

4/22

60,000

1/12

0/12

1/CRU frequency‡
(±SEM)

17424
(14221~21349)

10615 *
(8661~13009)

No. CRU per femur¶
(±SEM)

1326
(1082~1624)

2289 *
(1806~2713)

# Negative mice are defined as animals in which < 5% of the peripheral blood B
and/or T lymphocytes and/or myeloid cells were derived from donor (Ly5.2+)
stem cells.
& Values are shown as the number of negative mice out of total number of
recipient mice at the 20-week-timepoint. The data were pooled from 3
independent experiments in which serial dilutions of Ly5.2+ donor cells were
transplanted into lethally irradiated Ly5.1+ recipient mice along with 2X105
Ly5.1+ competitors, and peripheral blood of recipients was analyzed for
lymphomyeloid engraftment 20 weeks after transplantation.
‡ CRU frequency is calculated by applying Poisson statistics to the proportion of
negative recipients at different dilutions using L-Calc software, and represented
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by the number of bone marrow cells containing 1 CRU. Numbers in parentheses
give the range of CRU frequency defined by ± 1 SEM.
¶ Values shown are calculated by multiplying CRU frequency with femoral
cellularity. The cellularity per B6 mouse femur averaged 23.1 (± 1.1) X106, and
that of B.D Chr3 was 23.5 (± 1.7) X106 . Numbers in parentheses give the range
of CUR frequency defined by ± 1 SEM.
* Statistical analysis was performed using L-Calc software. P<0.05 is considered
significant difference.
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Table 2.2 Comparison of hematopoetic progenitor cells (HPCs) and
peripheral blood cell numbers among congenic and background mouse
strains.
Compared to
background strains
Mouse
strains

Peripheral blood cell accounts

CAFC
day7 per
femur (%)

CAFC
day21 per
femur (%)

Leukocytes
(x103/ul±
1 SEM)
5.1±0.3

Erythrocytes
(x106/ul±
1 SEM)
9.9±0.2

Platelets
(x105/ul±
1 SEM)
11.1±0.3

B.D
Chr3
D2

89.9±7.4

89.0±7.3

6.2±0.7

9.4±0.3

10.5±0.5

7.8±0.3

10.3±0.1

11.1±0.2

D.B
Chr3

95.0±11.5

7.6±0.3

10.3±0.2

11.1±0.2

B6

87.3±6.8

HPC numbers are represented by CAFC day7 and day 21 frequencies. A
differentiated cell count of peripheral blood samples from congenic and
background mice (n≥9) was performed for leukocytes, erythrocytes and platelets.
Data shown are the average values ± 1 SEM. The normal ranges of the
leukocytes, erythrocytes and platelets are 5~8x103/µl, 9~11 x106/µl and 11~14
x105/µl respectively. No significant differences were shown in these parameters
between Chr. 3 congenic and their respective background mouse strains by a
student t-test using two samples comparison analysis.
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CHAPTER THREE
Changes in cycling, apoptotic and self-renewal capabilities of
HSCs in congenic mouse models

Summary

The strain-specific difference in hematopoietic stem cell (HSC) number
between C57BL/6 and DBA/2 has been shown to link to several genetic
quantitative trait loci (QTL), which have been further confirmed in congenic
mouse models. However, the underlying biological processes that are involved in
the regulation of stem cell number are not yet clear. Therefore, in this study we
aimed to investigate the cell cycling, apoptotic and self-renewal status of HSCs in
chromosome 3 congenic mouse strains by using immunostaining, flow cytometry
and serial bone marrow cell transplantation strategies. HSCs in the S/G2/M
phases of the cell cycle detected by DAPI staining comprised 5-7% of the
population and didn’t show any differences among Chr3 congenic and control
mice. However, measurement of cell cycle kinetics by in vivo BrdU incorporation
showed that B.D Chr3 congenic HSCs replicated at a faster pace than did B6
cells. Our studies also demonstrated that under steady-state conditions B6 HSCs
underwent apoptosis at a 3-fold higher frequency (2.67%) than D2 stem cells
(0.86%). The introgression of D2 alleles around chromosome 3 QTL onto a B6
genetic background (B.D Chr3) resulted in a D2-like apoptotic phenotype,
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whereas reciprocal D.B Chr3 HSCs had a further reduced apoptotic rate (0.29%).
In addition, competitive repopulation advantages of B.D Chr3-derived HSCs over
B6 cells in recipient mice were significantly higher and were retained in
successive transplants, indicating that the D2 chromosome 3 QTL conferred
higher self-renewal capability to stem cells. Taken together, these findings
indicate that the chromosome 3 QTL also plays roles in regulating the cell cycle,
apoptosis and self-renewal of HSCs, which may in turn account for the natural
variation of stem cell number between B6 and D2 mouse strains.
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Introduction

Hematopoietic stem cells (HSCs) are rare cells, comprising only a very
small proportion of bone marrow cells. Different methods of enumeration give
somewhat different estimates of the exact numbers (Coulombel 2004). Moreover,
there are clear strain variations with respect to stem cell frequency (Liang and
Van Zant 2003). Using in vivo and in vitro functional assays, a typical HSC
frequency is 1 per 10,000-15,000 marrow cells (Conneally et al. 1997; Szilvassy
et al. 1990). Similarly, immunostaining-defined HSCs comprise 0.01% to 0.02%
of the whole marrow population (Christensen and Weissman 2001; Morrison et
al. 2002; Morrison and Weissman 1994; Zhou et al. 2002)). Assuming 3x108
bone marrow cells in an adult mouse, about 3-6x104 HSCs should be present in
all marrow spaces.
How do such a small number of HSCs maintain themselves as well as
produce all lineages of blood cells in the life history of an animal? Initial retroviral
marking studies pointed toward a largely quiescent stem cell pool with only one
or a few HSC clones actively cycling and giving rise to mature blood cells at any
time. Once one HSC clone was exhausted a new clone appeared to be activated,
thus following a clonal succession pattern (Becker et al. 1963; Lemischka et al.
1986). However, this view has been challenged by recent 5-bromodeoxyuridine
(BrdU) labeling experiments in defined stem cell populations. Bradford et al.
analyzed the proliferation kinetics of highly enriched HSCs that were defined by
Hoechst (Ho) and Rhodamine 123 (Rho) exclusion (Bradford et al. 1997). They
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demonstrated that around 90% of Rh/Holow primitive hematopoietic stem cells
had incorporated BrdU and thus underwent at least one round of DNA replication
over a period of 12 weeks, with an average turnover rate time of 30 days. Similar
studies by Cheshier et al. extended the previous observations and found more
than 99% of long-term HSC-enriched population, c-kitbright, Thy1.1lo, Sca-1+,
Lineage- (KTSL-), had incorporated BrdU by 6 months, and approximately 8% of
them entered the cell cycle each day in an asynchronous manner (Cheshier et al.
1999). Therefore, around 2400~4800 murine HSCs (3~6x104 x 8%) begin
dividing and generate hematopoietic cells each day. All studies are consistent
with the idea that a majority of HSCs are not dormant but divide slowly and
regularly to maintain themselves as well as produce differentiated cells.
Specific components of the cell cycle machinery that determine whether
cells continue proliferating or cease dividing have been reported to regulate stem
cell pool size. For example, in knockout model for cyclin-dependent inhibitors
(CKIs), the absence of p21 increased the proliferation of HSCs and led to
expanded stem cell numbers. However the self-renewal of these stem cells was
impaired (Cheng et al. 2000a; Cheng et al. 2000b). Interestingly, defective p18
had similar effects on the proliferation and number of stem cells, but enhanced
their renewal capability (Cheng et al. 2000a; Yuan et al. 2004). Another important
cell cycle regulator, cyclin D, has also been studied for effects on hematopoietic
systems. Cyclin D1/D2/D3-deficient mice demonstrated a dramatic decrease in
numbers and functions of HSCs and HPCs in fetal liver. Moreover, the ability of
these cells to proliferate was profoundly impaired (Kozar et al. 2004). Other
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regulators, which are not included in cell cycle machinery, may also affect stem
cell numbers by indirect mechanisms. A recent report indicated that Bmi-1, an
upstream inhibitor of p16 and p19ARF, was critical for HSC self-renewal and
population size (Iwama et al. 2004). Taken together, data indicate that HSCs are
always cycling and that cell cycle control is one of the critical regulators of stem
cell number and function. However, as discussed previously, more HSCs are
generated each day than are apparently necessary to replenish mature blood
cells lost through “wear and tear”. In order to keep the normal level of stem cell
number, other mechanisms, such as apoptosis, self-renewal and/or the rate of
differentiation, must be involved to physiologically balance with cell cycle control
(Sommer and Rao 2002).
Several lines of evidence have indicated that apoptosis acts as an
important regulator of stem cells. First of all, expression of some apoptosisrelated genes were detected in human and/or murine HSCs (Domen 2001).
Secondly, targeted disruption of some of these genes in null and dominant
negative mutant mice interfered with normal apoptotic processes in HSCs. For
example, overexpression of Bcl-2, a negative regulator of apoptosis, increased
not only the numbers and competitive repopulation capabilities of HSCs, but also
the resistance of HSCs to apoptosis induced by ionizing radiation (Domen and
Weissman 2003). Inactivation of another anti-apoptotic gene, Bcl-XL, displayed
massive cell death in immature hematopoietic cells at embryonic day 13
(Motoyama et al. JUN 7 1999). Furthermore, of the caspase null mutants studies,
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clear abnormalities during fetal hematopoiesis at the progenitor level have also
been reported for the caspase 8 null mutant (Varfolomeev et al. 1998).
As described above, there are three potential outcomes for a dividing
HSC: (1) a symmetric division produces two HSCs, resulting in net expansion of
stem cell population, or (2) produces two differentiated cells, leading to the loss
of HSCs; (3) an asymmetric division produces a stem cell and a differentiated
cell, leading to maintenance of HSCs (Faubert et al. 2004; Liang and Van Zant
2003). Therefore, the choices between symmetric and asymmetric division,
resulting in self-renewal versus differentiation, are important in the regulation the
number of HSCs. Although the molecular mechanisms determining symmetric or
asymmetric division in mammalian HSCs are not yet clear, a growing list of
genes have been found recently to be involved in the regulation of stem cell
renewal and their numbers. Overexpression of some positive regulators in HSCs,
such as HoxB4, Bmi-1, ß-catenin, resulted in net expansion of HSC population
as well as an enhancement of their repopulating/self-renewal capabilities
(Antonchuk et al. 2001; Antonchuk et al. 2002; Beslu et al. 2004; Karanu et al.
2000; Krosl et al. 2003; Reya et al. 2003; Sauvageau et al. 1995; Stier et al.
2002; Thorsteinsdottir et al. 1999; Vercauteren and Sutherland 2004). Similarly,
knockout or inactivation of such genes impaired both numbers and functions of
HSCs (Brun et al. 2004; Duncan et al. 2005). Recent studies concerning the
roles of the Gfi1 transcription factor in murine HSCs demonstrated that deletion
of this gene led to both a dramatic decrease in stem cell frequency and in
repopulating ability in serial transplantation assays. These defects were
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counterbalanced by an increase in proportion of cycling HSCs, indicating that
Gfi1 restrains proliferation of HSCs and thereby preserves their functional
integrity in terms of self-renewal and engraftment abilities (Hock et al. 2004a;
Zeng et al. 2004).
Altogether, most studies investigating the functions of genes in HSCs are
performed by a reverse genetic approach; that is, through enforced
overexpression or knockout of a specific gene in transgenic mouse models. In
contrast, in forward genetics, genetic manipulations in congenic mice are through
natural breeding processes and gene expression is usually not outside of
physiological range (Wakeland et al. 1997). Therefore, congenic mouse models
are very useful for investigations of stem cell-related genes and their functions
under physiological conditions. In spite of this, very little work has been done to
characterize HSC population using these models. In our chromosome 3 congenic
mice, we have shown that a QTL on this chromosome specifically regulates HSC
numbers. Although most of the genes discussed previously that regulate cycling,
apoptosis and renewal of HSCs are not located within this QTL congenic interval,
it is highly probable that these processes might be directly or indirectly altered
such that they affect stem cell pool size. Therefore, this study was aimed at the
analysis of these stem cell number-related phenotypes and to determine whether
the chromosome 3 QTL also has an effect on these parameters.
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Materials and Methods

Animals
Background strains: C57BL/6J (B6) (Ptprcb [Ly-5.2]), DBA/2J (D2) mice
were purchased from the Jackson Laboratories (Bar Harbor, ME).
Congenic stains: Chromosome 3 congenic mice were generated by
Geiger et al. as described previously (Wakeland et al. 1997). Genotypes of
congenic mice were checked every 6 months through genetic marker–based
polymerase chain reaction. All primers for simple sequence repeat (SSR)
element markers were bought from Research Genetics, Huntsville, AL. Two
strains of chromosome 3 congenic mice were generated and maintained: B.D
Chr3 (14cM~33cM) congenics with D2 QTL being introgressed onto B6
background, and their reciprocal congenic strains D.B Chr3 (19cM~60cM) with
B6 QTL onto D2 background.

Immunofluorescent staining of hematopoietic stem cells (HSCs)
Bone marrow cells were flushed and pooled into Hank’s balanced salt
solution (HBSS, Gibco, Grand Island, NY) containing 2% fetal calf serum (FCS)
(Life Technologies). They were then blocked with anti-CD16/32 (clone 2.4G2, Fc
Block), and stained with biotin-conjugated rat monoclonal antibodies specific to
lineage antigens on the surface of murine mature blood cells, including CD5
(clone 53-7.3), CD8a (clone 53-6.7), CD45R/B220 (clone RA3-6B2),
CD11b/Mac-1 (clone M1/70), Ly-6G/Gr-1 (clone RB6-8C5), and TER119/Ly-76
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(clone TER-119). In addition, cells were also incubated with fluorescent-labeled
stem cell-specific markers, phycoerythrin (PE)-conjugated anti-Ly-6A/E (Sca-1;
clone E13-161.7) and allophycocyanin (APC)-conjugated anti-CD117 (c-kit;
clone2B8) monoclonal antibodies. Following washing, they were resuspended in
medium containing streptavidin-APC-Cy7, which specifically bound to biotinconjugated lineage antibodies. After 30 minutes incubation, the cells were finally
resuspended into 5ug/mL propidium (PI) solution to distinguish viable and dead
cells. All monoclonal antibodies were purchased from Pharmingen, San Diego,
CA. Flow cytometric analysis was performed on a dual-laser FACSVantage
(Becton Dickinson Immunocytometry Systems, San Jose, CA) to select PI
negative, lineage negative, Sca-1 and c-kit positive cells (Pi-, Lin-, Sca-1+, c-kit+
(LSK) cells), which highly enriched viable hematopoietic stem cell (HSC)
population (Figure 3.1).

Cell cycle analysis of HSCs
Flow cytometry was used to quantify the cell cycle status in HSC
compartment. Bone marrow cells were isolated and immunofluorescetly stained
as described previously except that different fluorochromes were conjugated to
lineage (CD5, CD8a, CD45R/B220, CD11b/Mac-1, Ly-6G/Gr-1 and TER119/Ly76) and stem cell-specific (Sca-1 and c-kit) monoclonal antibodies. Phycoerythrin
(PE)-conjugated antibodies were used here to stain all lineage-positive mature
blood cells, and phycoerytherin Texas Red (PETR)-conjugated anti-Sca-1 and
fluorescein isothiocyanate (FITC)-conjugated anti-c-kit antibodies detected the
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existence of stem cells. Following the immunofluorescent staining, cells were
fixed using 1% formaldehyde (Polysciences, Inc. Warrington, PA) and
permeabilized by 0.2% Triton X-100 (Bio-Rad Laboratories, Richmond, CA).
10µl/ml 4’, 6-diamidino-2-phenylindole, dilactate (DAPI, Sigma, St. Louis, MO)
was used to determine the DNA content and the percentage of cycling stem
cells. DNA content, and thus stoichiosmetric DAPI signal, in cells in G2/M phase
of the cell cycle is 2 times higher than that of cells in G0/G1 phase, with S phase
cells possessing an intermediate amount. Flow cytometric analysis was
performed on a dual-laser FACSVantage (Becton Dickinson Immunocytometry
Systems, San Jose, CA).

In-vivo bromodeoxyuridine (BrdU) incorporation
Cell cycle analysis using DAPI staining only revealed the percentage of
HSCs in S/G2/M phase at a specific timepoint in vitro, but couldn’t determine cell
cycle kinetics in vivo. The long-term administration of BrdU was used to
investigate in a dynamic way, the cycling history and turnover rate of HSC
population.
BrdU stock solution was made up at a concentration of 10mg/mL in PBS
(Sigma, St. Louis, MO), and frozen at -80ºC. Age-matched chromosome 3
congenic and background mice were given BrdU-containing drinking water at a
concentration of 0.5mg/mL for 1, 2, 3, 4, 5 days (4 mice in each group at each
timepoint). Containers of BrdU water were wrapped in aluminum foil to prevent
light exposure and water bottle were changed every 5 days. For the zero time
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point, mice were injected intraperitoneally with 100ul (0.5mg) BrdU and sacrificed
90 minutes later.
Harvesting of bone marrow cells and immunofluorescent staining of
lineage and stem cell markers were as described previously. The cell cycle
analysis was performed using the BrdU Flow Kit (Pharmingen, San Diego, CA).
Briefly, labeled cells were fixed and permeabilized with Cytofix/Cytoperm Buffer
for 40 minutes. After washing with Perm/Wash Buffer, cells were treated with
DNase at 37ºC for 1 hour to expose BrdU epitopes. Cells were subsequently
resuspended in FITC-anti-BrdU solution for 30 minutes at room temperature.
Flow cytometric analysis was carried out to determine the proportion of BrdU
positive Lin-Sca-1+c-kit+ (LSK) cells.

Apoptotic analysis of HSCs
Bone marrow cells were prepared and immunofluorescently stained as
described previously. In brief, LSK cells were selected by HSC-specific
antibodies that were tagged with APC-Cy7, phycoerythrin (PE) and
allophycocyanin (APC) respectively. FITC-conjugated Annexin V and 7-AAD
were utilized to identify early apoptotic cells. Thymocytes were used as the
control to distinguish Annexin V positive and negative cells (all from Pharmingen,
San Diego, CA). 3 independent experiments were performed in each strain, and
at least 2 mice were analyzed in each experiment. All experiments were carried
out on ice and completed within 1.5 hours. Flow cytometric analysis was
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performed on a dual-laser FACSVantage (Becton Dickinson Immunocytometry
Systems, San Jose, CA).

Competitive repopulation and serial transplantation assay
Recipient mice, B6.SJL (Ptprcb [Ly-5.1]), were given drinking water ad
libitum containing 0.16mg/ml sulfamethoxazole and 0.004mg/ml trimethoprim for
at least 5 days before irradiation. They were then exposed to 9 Gy total-body γ
irradiation from a

137

Cs source administered as a single dose at least 6 hours

before transplantation. Unfractionated bone marrow cell suspensions were
prepared as described before. 1x106 B.D Chr3 congenic- and B6-derived Ptprcb
[Ly-5.2] donor cells were injected retro-orbitally into recipients, together with
equal number of competitor Ly5.1 cells. There were 8 recipient mice in each
group and 3 independent experiments were performed. At 16 weeks after
transplantation, recipient mice were bled from the retro-orbital venous plexus.
Peripheral blood was analyzed to determine the hematopoietic reconstitution
capability of donor cells. Erythrocytes were eliminated by hypotonic lysis. The
remaining leukocytes were stained with FITC-anti-Ly5.2 (CD45.2, clone 104) and
PE -anti-Ly5.1 (CD45.1, clone A20) to detect the presence of Ly5.1- or Ly5.2positive cells. In addition, the percentage of donor-derived myeloid and lymphoid
cells was determined by labeling cells with FITC-anti-Ly5.2 and PE-conjugated
lineage antibodies, which are specific to macrophages (anti-CD11b/ Mac-1, clone
M1/70), granulocytes (anti-Ly6G/Gr-1, clone RB6-8C5), B lymphocytes (antiCD45R/B220, clone RA3-6B2) and T lymphocytes (anti-Thy-1.2; clone 30H12)
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respectively (all from Pharmingen, San Diego, CA). Samples were then analyzed
by a FACScan instrument (Becton-Dickinson immunocytometry System, San
Jose, CA, USA). At the last timepoint (16th week), recipients’ bone marrow cells
were also analyzed to determine the Ly5.1/ Ly5.2 chimerism in whole bone
marrow and in the Lin-, Sca-1+ and c-kit+ (LSK) cell population. FITC-anti-Ly5.2
labeling was used to identify the chimerism, and immunofluorescent staining of
LSK cells was performed as described before.
In serial transplantation experiments, as shown in Figure 3.2, primary
recipient mice were sacrificed at 16 weeks after transplantation. Bone marrow
cells were pooled from 16 mice, and 1x107 cells were retroorbitally injected into
16 (8 for each group x 2 groups) lethally irradiated secondary Ly5.1 recipients
(9Gy). Peripheral blood and bone marrow were assayed for Ly5.1/Ly5.2
chimerism 16 weeks post-transplant. The same procedure was reiterated for the
tertiary and quaternary recipients.
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Results

Cell cycling status of HSCs
A small proportion of HSCs in the bone marrow is always cycling to
maintain a steady-state level of stem cells and mature blood cells (Bradford et al.
1997; Cheshier et al. 1999; Pietrzyk et al. 1985). The cycling status of HSCs is
one of the important determinants to control their population size and the number
of differentiated progeny they produce (Steinman 2002). An increased proportion
of actively dividing stem cells and/ or a shortening of their cycling time will lead to
HSC expansion. Since D2 and B.D Chr3 congenic mice have more bone marrow
HSCs, I therefore hypothesized that a higher proportion of cycling HSCs may
exist in these strains. Flow cytometric analysis was performed to measure the
cell cycle status of the stem cell-enriched Lin-Sca-1+c-kit+ (LSK) population. A
DNA dye, DAPI, which binds strongly and stoichiometrically to AT-rich regions in
the minor groove of DNA, was used to determine the DNA content of the cells at
different cell cycle stages. As shown in figure 3.3 A and B, cells in G2/M phase
have a 2 times higher DNA content than those in G0/G1, with S phase cells
possessing an intermediate amount. Differential DNA content enables the
measurement of percentage of cycling stem cells by simply comparing the profile
of DAPI signals in a cell population. The results summarized in table 3.1
demonstrate that in all studied strains, around 5-7% of LSK cells were in S/G2/M
phase of the cell cycle, a number similar to previous reports by other groups,
indicating that a small number of HSCs are always dividing in order to maintain
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the steady-state hematopoiesis. However, no significant differences were
observed in the fraction of cycling LSK cells among chromosome 3 congenic and
their respective background mouse strains, suggesting that the effects of
chromosome 3 QTL on HSC number may not be through regulation of HSC
cycling.

In vivo cell cycle kinetics of HSCs
Cell cycle analysis by using DAPI staining could only tell us the
percentage of HSCs in S/G2/M phase at a specific timepoint in vitro, but couldn’t
determine cell cycle kinetics of HSCs in vivo. The BrdU incorporation experiment
is an alternative way to achieve this goal. BrdU is a thymidine analog that can be
incorporated into newly synthesized DNA of replicating cells (Pietrzyk et al. 1985;
Willis et al. 1993). When BrdU was added to the drinking water of the
chromosome 3 congenic mice and their controls for 5 days, the continuous BrdU
incorporation into LSK bone marrow populations allowed me to measure
accumulations of replicating cells, and thus stem cell turnover rates over the
long-term (Forster and Rajewsky 1990; Hagan and MacVittie 1981; Kriss and
Revesz 1962; Tice et al. 1976). Two populations of LSK cells were analyzed
according to the brightness of Sca-1 staining: the entire LSK population which
contains all long-term HSCs as well as some short-term HSCs and multipotent
progenitor cells not as brightly stained with Sca-1 (LSK), and a population of only
the brightest Sca-1 staining LSK cells (LSK++) which are most highly purified
long-term HSC subset (Okada et al. 1991; van de Rijn et al. 1989).
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Figure 3.4 shows different BrdU labeling patterns of the two population
LSK cells in different mouse strains. In both B.D Chr3 congenic and B6 LSK cells
(upper curve), the rate of BrdU incorporation increased dramatically in the first 2
days, and by day 2 ~70% of LSK population was labeled. Subsequently, the
BrdU uptake slowly increased, and only around 20% more LSK cells were
labeled in the following 3 days. 90% of LSK cells were BrdU positive at 5 days.
Even though the overall pattern of labeling was similar in all mouse strains, the
more striking difference was observed in LSK populations between the congenic
and background strains. An average of 15% of B.D Chr3 congenic LSK cells
were labeled 1 hour after a single pulse of BrdU, and 46% were BrdU positive by
day 1. In contrast, labeling of the analogous population of B6 cells proceeded at
a slower pace, showing a 3-fold lower labeling in 1 hour (~5%), and 50% less
labeling at day1. In the more primitive LSK++ cell population (lower curve), the
overall BrdU labeling rate was significantly slower compared to LSK population,
which is consistent with the turnover dynamics of the hematopoietic hierarchy
(Cheshier et al. 1999; Pietrzyk et al. 1985). During the pulse-labeling period (T0),
1.6±1.2% of LSK++ cells in B.D Chr3 mice and 3.1±1.5% in B6 cells were
undergoing DNA synthesis and incorporating BrdU, but the difference was not
statistically significant. B.D Chr3 LSK++ cells showed a 2-fold higher labeling
than analogous B6 cells (10.8±4.9% vs 5.4±1.1%) by day1 but also without
statistical significance. During the 5 days period of BrdU exposure, nearly one
third of LSK++ cells were labeled in 3 days and more than half were labeled by
day 5. All BrdU labeling data derived from B6 mouse strain are very similar to the
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published results obtained by other labs (Bradford et al. 1997; Cheshier et al.
1999). Although extended periods of time need to be further investigated, these
results underscore that (1) HSCs divide regularly during steady-state
hematopoiesis. (2) Within heterogeneous HSC populations, different subsets of
cells possess different proliferative rates. In general, the more primitive cells are,
the slower they proliferate. And (3) B.D Chr3 congenic LSK stem cells replicate
faster than do B6 cells, a finding that is mainly attributed to the presence of less
primitive cells in this population.

Apoptosis status of chromosome 3 congenic HSCs
Studies have previously shown that apoptosis is an important pathway in
regulating HSC numbers. Apoptosis can be identified by a series of morphologic
changes, including cell shrinkage, membrane blebbing, chromatin condensation,
caspase activation, and enzymatic internucleosomal DNA destruction (Brown
and Attardi 2005). Early in this process, cells lose their phospholipid membrane
asymmetry and expose phosphatidylserine (PS) to the outer leaflet of the cell
membrane (Martin et al. 1995). This change can be monitored by Annexin V, a
Ca2+ -dependent, phospholipid-binding protein with high affinity for PS (Vermes et
al. 1995). The DNA stain 7-AAD is used to identify viable cells able to actively
exclude the dye (Schmid et al. 1994). Therefore, early apoptotic cells are
Annexin V positive and 7-AAD negative, whereas necrotic cells are double
positive for both Annexin V and 7-AAD. By using a flow cytometry protocol that
simultaneously identifies LSK cells, apoptosis can thus be measured in this
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primitive population (Anthony et al. 1998). Figure 3.5 depicts the Annexin V and
7-AAD staining profile of B6 (panel A) and B.D Chr3 (panel B) LSK cells. Panels
C to E are a control series using freshly isolated thymocytes, which contains
significant numbers of apoptotic and necrotic cells, to determine quadrant
positions. In all profiles, the apoptotic cells are in the lower right quadrant and
necrotic cells are in the upper right quadrant. Table 3.2 summarizes the apoptotic
analysis of stem cells in chromosome 3 congenic and control strains. Under
steady-state conditions B6 and D2 apoptotic LSK cells comprised 2.67±0.42%
and 0.86±0.2%, respectively, of the population (P<0.001). The replacement of D2
chromosome 3 QTL alleles in a B6 genetic background (B.D Chr3) reduced the
apoptotic LSK fraction to 0.55±0.1% (P<0.001), resulting in a D2-like phenotype.
However, introgression B6 alleles around QTL onto the D2 background (D.B
Chr3), which might be expected to increase apoptosis, further reduced the
already low D2 apoptotic rate to 0.29±0.03 (P<0.001). These data suggest that
strain-specific apoptotic rates exist in hematopoietic stem and progenitor
populations and that they can be altered by genetic manipulation. The dramatic
range (9-fold) of this important parameter among these strains underscore the
critical role it may play in the determination of stem cell population size.

Measurements of self-renewal capabilities of congenic HSCs
In order to examine the self-renewal capability of HSCs, serial
transplantation experiments were performed to partially mimic the replicative
demands on HSCs during a lifetime of hematopoiesis (Becker et al. 1963;
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Hellman et al. 1978; Krause et al. 2001; Siminovitch et al. 1964). As illustrated in
Figure 3.2, B6 control and B.D Chr3 congenic bone marrow cells (Ly-5.2 donor
cells) were injected into 2 separate groups of irradiated Ly-5.1 recipients along
with Ly-5.1 competitor cells. Sixteen weeks post-transplant, Ly5.1/Ly5.2 chimeric
bone marrow cells from primary recipients were transplanted into secondary
recipients without the addition of competitor cells, and such serial transplantation
was continued until the 4th generation of recipients. At each transplant, the
peripheral blood and bone marrow of recipient mice were analyzed and
quantified for initially injected B6 or B.D Chr3 (Ly-5.2) cells, which are the sole
source of stem cells to reconstitute hematopoietic system in serial myelo-ablated
recipients. The competitive repopulation advantage of HSCs of one strain relative
to the other is reflected by the percentage of donor-derived cells. The more
donor-derived hematopoietic cells, the higher repopulation or self-renewal
capability HSCs have (Harrison et al. 1993; Harrison and Zhong 1992; Szilvassy
2003)). As shown in Figure 3.6, higher numbers of B.D Chr3 congenic-derived
cells were found in peripheral blood leukocytes (panel A), unfractionated bone
marrow (panel B), and LSK stem cells (panel C) than those derived from
transplanted B6 cells. All of the differences are highly significant (P<0.001) and
sustained with each successive transplant. Therefore, the B.D Chr3 stem cells
clearly have a numerical competitive repopulation advantage relative to B6.
Moreover, only 8 of initial 16 (50%) survived in the group of quaternary recipients
that were transplanted with B6 cells, whereas all 16 mice survived in B.D Chr3
group. All data suggest that B.D Chr3 congenic HSCs replicate with a
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competitive advantage that permits serial transplantation well beyond that of B6derived stem cells, and importantly, that the D2 chromosome 3 QTL confers this
higher self-renewal capability to HSCs.
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Discussion

Stem cell population size could be affected by as least 3 fundamental
factors: the rate of proliferation, apoptosis, and the capability for self-renewal
(Morrison et al. 1997). Studies were therefore performed to characterize these
parameters in chromosome 3 congenic strains in order to understand which
factor involves in chromosome 3 QTL-mediated HSC number regulation.
Two strategies were used to measure the proportions of HSCs entering
the cell cycle: DAPI staining of LSK cells and BrdU labeling of LSK and LSK++
cells. The results from the first method showed that, consistent with previously
published data (Cheshier et al. 1999; Morrison and Weissman 1994), ~5% of
LSK cells were in S/G2/M phase of the cell cycle, and no significant differences
were observed among all 4 strains (Table3.1). In contrast, BrdU incorporation
experiments demonstrated that ~15% of B.D Chr3 congenic LSK cells were
labeled in 1 hour after BrdU administration, a value 3-fold higher than that of B6
LSK cells (Figure 3.4). This discrepancy between DAPI results and the BrdU
labeling might be due to the following considerations: (1) The experimental
techniques are different between two methods: DAPI staining is done on fixed
cells in vitro whereas the BrdU labeling is in vivo; (2) the DAPI method measures
the fraction of cells in S/G2/M phase only at the precise time that the bone
marrow is harvested, whereas BrdU cumulatively labels the cells that undergo at
least one division during the period of exposure to BrdU (Dolbeare et al. 1983);
and (3) the LSK population identified by both methods are not precisely the same
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because different combination of antibodies and fluorochromes had to be used
as described in Methods.
The time-course results from 5 days of BrdU administration are
comparable with those of Cheshier et. al (Cheshier et al. 1999). The overall
experimental strategy in their study was similar to ours, except that they used
one additional marker, Thy1.1, to identify B6 HSCs. LSKThy1.1negative and
LSKThy1.1negative/low cell populations, whose contents are comparable to our
LSK++ (highly purified long-term HSCs) and LSK (heterogeneous HSCs) cells
respectively, were studied for their BrdU incorporation rates. Within the
overlapping periods of labeling, both studies showed similar patterns and extents
of BrdU labeling in long-term and heterogeneous HSC populations. When the
labeling period was extended in Cheshier’s study, the time for virtually all
LSKThy1.1negative/low and LSKThy1.1negative cells to incorporate BrdU were 30 and
180 days respectively, times very similar to what we observed in B6 background
HSCs (data not shown). The fact that the more primitive HSC subset possesses
a longer turnover time is further supported by previous studies of Pietrzyk et.al
(Pietrzyk et al. 1985). Although all HSCs theoretically enter the cell cycle by a
certain timepoint, the slow replicating feature of more primitive HSCs supports
the idea that the HSC population is hierarchically organized on the basis of their
cycling or quiescence state (Spangrude and Johnson 1990). In another point of
view, the specific stage in a cell cycle might in turn determine whether primitive
cells function as a stem cell or a progenitor cell (Habibian et al. 1998; Lambert et
al. 2003; Quesenberry et al. 2002). Nevertheless, the low cycling rate is a typical
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feature of long-term HSCs and is necessary for the preservation of stem cell
function as well as potentiality in the hematopoietic system.
The effects of the chromosome 3 QTL on HSC proliferation are only
present in LSK cells in the 24-hour BrdU pulse-labeling. The fact that D2 alleles
enhanced the cycling rate and this effect was restricted to a subset of HSCs
suggest that the chromosome 3 QTL interval must contain specific gene that
regulate stem cell proliferation. An increasing numbers of regulatory molecules
have been implicated in the control of cell cycle progression in different HSC
compartment. One of them is cyclin D2, which was found to be highly expressed
in most of LSKThy1.1negative cells in Cheshier’s study (Cheshier et al. 1999).
Furthermore, absence of cyclin D1/D2/D3 profoundly impaired the proliferation of
both HSCs and multi-lineage hematopoietic progenitor cells, suggesting that
cyclin D might act as one of the controllers (Kozar et al. 2004). Other cell cyclerelated genes, such as p21, p18 and p27, were also reported to be involved in
regulating different types of hematopoietic cells (Cheng 2004; Steinman 2002).
For example, p21 and p18 specifically control HSC proliferation, whereas p27
only affects hematopoietic progenitor cells. Further study of the chromosome 3
QTL interval in the congenic mouse model may provide a platform leading to the
discovery of novel cycle-active gene and/or functions of already known genes.
The apoptotic analyses shown in Table 3.2 are novel. It is the first report
that natural variations in steady-state apoptosis exist in the HSC compartment,
and apoptosis is a more important natural regulator of stem cell population size
than expected. The proportion of apoptotic HSCs in B6 mice was 3-fold higher
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than that of D2 mice, and the difference was confirmed in 3 replicate and
independent experiments. This observation is consistent with the idea that a high
rate of apoptosis leads to a decrease in cell numbers in a given population and
indicate that apoptosis might be one of mechanisms causing a lower HSC
frequency in young B6 mice (Domen 2001). Another interesting finding in this
analysis is that D2 alleles in the chromosome 3 congenic interval completely
conferred the D2 phenotype to B6 stem cells, resulting in a similar fold decrease
in apoptotic rate in B.D Chr3 HSCs. In contrast, introgression of B6 alleles onto a
D2 background further decreased the already low apoptosis in D2 mice, which
was opposite to what was expected. This discrepancy might be due to the fact
that the B6 chromosome 3 congenic interval (19cM~60cM) introgressed onto D2
background is not identical to the D2 interval (14cM~33cM) on the B6 genome,
although both contain the QTL at 25cM. It is highly possible that another locus or
loci located in this congenic interval and/or in the genetic background might also
have profound effects on apoptosis of HSCs in vivo perhaps in conjunction with
the QT gene (Bystrykh et al. 2005). Nevertheless, there is clearly a locus or loci
in the chromosome 3 congenic intervals that regulate apoptosis of HSCs and this
locus/loci might be responsible for natural variations in this parameter.
Furthermore, the interactions between this locus/loci and the genetic background
also exert their effects in vivo. However, whether the variations in both apoptosis
and stem cell number are attributed to the same locus on chromosome 3, and
whether there is a cause-effect relationship between these two parameters is still
not clear yet. To answer these questions, further studies, such as fine mapping,
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positional cloning and/or microarray analysis, may be necessary to discover
underlying mechanisms (Biola et al. 2003; Mackay 2001).
In order to study the effects of chromosome 3 QTL on stem cell renewal,
serial transplantation experiments, the “gold-standard” method to measure this
parameter, were performed in B.D Chr3 congneic and their B6 background mice.
Although the same numbers of bone marrow cells from both strains were injected
into primary recipient mice, the peripheral blood leukocytes and bone marrow
nucleated cells derived from congenic mice were significantly higher than those
of B6 cells at 16 weeks post-transplant, a time at which long-term HSCs are
considered to be the only source of hematopoietic reconstitution (Harrison et al.
1993). Two mechanisms might be responsible for these competitive repopulating
advantages: high proliferation rate of HSCs and/or high stem cell numbers
(Szilvassy 2003). Since we have previously shown that a higher proliferation rate
exists in B.D Chr3 congenic HSCs, we next determined whether the stem cell
number difference also contributes to the differential engraftment levels. The
results from analyses of chimeric bone marrow LSK stem cells showed that
around 75% more LSK cells were derived from B.D Chr3 congenic HSCs
compared to B6 stem cells, suggesting that a competitive advantage of congenic
cells also results from the higher HSC frequency.
Several interesting results were observed in the serial transplant
experiments. First of all, initially injected B.D Chr3 and B6 Ly-5.2 cells could be
detected in both peripheral blood and bone marrow of all secondary, tertiary and
quaternary recipient mice over a period of 64 weeks, indicating that these donor82

derived cells contain an adequate number of HSCs to be able to self-replicate
and repeatedly reconstitute the hematopoiesis over the long-term. Secondly, the
competitive advantage of B.D Chr3 congenic cells over B6 cells existed in both
differentiated and in stem cells of all serial passages, suggesting the B.D Chr3
LSK stem cells have a higher self-renewal ability than do B6 HSCs. This
conclusion is further supported by the survival rate of quaternary recipients, in
which only half of B6 recipients survived compared to B.D Chr3 recipients. It is
well known that the demands on HSCs for regeneration of both stem cells (selfrenewal) and mature cells (differentiation) are increased under conditions of
hematopoietic reconstitution after transplantation. This replicative stress is
amplified with serial transplants and results in stem cell exhaustion (Hellman et
al. 1978; Krause et al. 2001). Stem cells with higher renewal abilities usually
endure more serial transplants. Consistent with these theories, our results
indicated D2 alleles around the chromosome 3 QTL increase HSC renewal at
least 2-fold, which might consequently lead to an approximate 2-fold increase in
HSC numbers. In other words, stem cell renewal might be one of the
mechanisms by which chromosome 3 QTL regulated HSC numbers. Since Ly5
congenic mice don’t exist on a D2 genetic background, such competitive
repopulation and serial transplantation assays can’t be performed with D2 and
D.B Chr3 congenic cells. Whether B6 alleles would decrease the stem cell
renewal is still a question that needs to be addressed. Finally, analysis of Ly5.1/Ly-5.2 chimerism in bone marrow LSK stem cells has showed that both the
B.D Chr3 congenic and B6 stem cells have a very strong competitive advantage
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over Ly5.1 competitor cells, and that by the 4th serial transplant almost all bone
marrow LSK stem cells were derived from B.D Chr3 and B6 LSK cells (90%).
The complete dominance of B.D Chr3 and B6 LSK cells over Ly5.1 competitor
cells might come from the effects of Ly5 alleles and/or a passenger locus in the
Ly5 congenic interval. The evidence supporting the first possibility comes from
studies by van Os (van Os et al. 2001). They found that the engraftment level of
Ly5.1 cells in Ly5.2 hosts was lower than that of Gpi-1a cells in Gpi-1b hosts
under the conditions of low-dose irradiation (≤ 4Gy) and/or transplantation of
small numbers of cells (2x106). Although both Ly5 and Gpi-1 act as cellular
markers to distinguish donor from host cells, Ly5 has an extracellular protein
domain that may induce an immune response whereas Gpi-1 is an intracellular
protein (glucose phosphate isomerase) without immune activity. Further studies
demonstrated that the disparity between Ly5.1 and Ly5.2 antigen could slightly
induce a T cell-mediated immunological response directed against Ly5.1-derived
cells, probably HSCs, and consequently impaired the engraftment capability of
Ly5.1 cells. Therefore, the gradual loss of Ly5.1 cells, especially bone marrow
LSK stem cells, during the serial transplants shown in our studies might be due
to T cell-mediated immunity under certain conditions, such as a low number
(1x106) of Ly5.1 cells were injected. This explanation is also supported by the
findings from other researches (Chen et al. 2004; Xu et al. 2004).
In aggregate, all results demonstrate that B.D Chr3 HSCs have a high
competitive self-renewal potential coupled with increased cycling and decreased
cell death during steady-state hematopoiesis. Although some of these analyses
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were not performed in the reciprocal congenic HSCs (D.B Chr3), these data at
least suggest that the regulation of HSC number by chromosome 3 QTL is
complicated, probably involving several biological processes and multiple
molecular mechanisms. The results in this chapter have provided a direction to
screen the genes in the congenic interval based on these phenotypical analyses.
Moreover, it also helps to understand the coordination of cell cycle regulation
with cell differentiation and survival in HSCs.
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Figure 3.1 Identification of Lin-, Sca-1+, c-Kit+ (LSK) HSCs by flow
cytometry. Bone marrow cells (A) were stained with antibodies against lineage
and stem cell markers as described in Methods. The viability of HSCs was
determined by PI staining (B), in which PI negative cells are viable (R1 region,
PI- cells). The negative selection (C) of viable cells eliminated all lineages of
differentiated cells and retained immature cells (R2 region, Lin- cells), whereas
the positive selection (D) defined Sca-1+, c-kit+ stem cells (R3 region).
Therefore, HSCs identified by flow cytometric analysis are PI-, Lin-, Sca-1+ and
c-kit+ (LSK) cells.
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Donor cells: Ly5.2 1x106 BM cells
Group1: B6; Group2: B.D Chr3
Ly5.2

9 Gy
Ly5.1

Ly5.1

1st

1x107 cells
16 weeks

Ly5.1

Ly5.1

Ly5.1

2nd

3rd

4th

Competitor cells:Ly5.1
1x106 BM cells
Ly5.1/ Ly5.2 chimerism analysis
16 weeks after transplantation
• PB
• BM nucleated cell
• BM LSK cells

Figure 3.2 Schematic illustration of serial transplantation of bone marrow
cells to measure self-renewal of HSCs. Bone marrow (BM) cells harvested
from C57BL/6 (B6) and B.D Chr3 congenic (Ly5.2) mice were transplanted into
two separate groups of lethally-irradiated Ly5.1 mice (primary recipients), along
with equal numbers (1x106) of Ly5.1 competitor cells. 16 weeks after
transplantation, 1x107 BM cells pooled from 1º recipients were injected into 2º
recipients. The procedures were reiterated in tertiary and quaternary
transplantations. In each generation of recipients, peripheral blood (PB), BM and
BM Lin-, Sca-1+, c-kit+ (LSK) stem cells were analyzed for Ly5.1/Ly5.2
chimerisms 16 weeks post-transplant. Two separate and independent
experiments were performed for each strain and in each experiment, 8 recipient
mice were included for each transplantation.
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Figure 3.3 Cell cycle analysis of unseparated bone marrow cells and LSK
stem cells by DAPI staining. Bone marrow cells and bone marrow LSK cells
were identified as shown in figure 3.1. DNA content, and the percentage of
cycling cells (S/G2/M phase of the cell cycle) was determined from the DAPI
histogram of gated bone marrow (A) and LSK cells (B). Cells with greater than a
diploid DNA content (M2 region) represent cycling cells, whereas other diploid
cells (M1 region) are in G0/G1 phase.
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Figure 3.4 Cell cycle kinetics of HSCs measured by BrdU incorporation.
BrdU was added to the drinking water of the B.D Chr3 congenic and C57BL/6
(B6) background mice for 5 days. The BrdU incorporation rate was measured
daily in cohorts (4 mice at each timepoint) of mice and the time zero point was
obtained 1 hour following an intraperitoneal injection of BrdU. Two populations of
LSK cells were assayed for BrdU uptake: the entire LSK population and the
LSK++ cells that were most strongly stained with Sca-1 antibody. The
percentages of BrdU positive cells at each timepoint are the average of 4 mice
and error bars represent ±1 standard deviation. *p<0.05 relative to background.
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Figure 3.5 Measurement of apoptotic LSK cells by Annexin V and 7-AAD.
LSK cells were identified as shown in figure 3.1. The Annexin V and 7 AAD
staining profile of LSK cells from B6 background mice (A) and B.D Chr3 congenic
mice (B) are shown. Apoptotic cells, which are annexin V positive and 7-AAD
negative, are in the lower right quadrants, whereas necrotic cells fall in upper
right quadrants (both Annexin V and 7-AAD are positive). The lower row of
panels (C, D, E) is a control series run with each experiment using mouse
thymocytes, which contains significant numbers of apoptotic and necrotic cells.
Panels C and D show single staining of thymocytes for Annexin V and 7-AAD,
respectively, whereas Panel E shows the double staining.
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Figure 3.6 Serial transplants of B6 and B.D Chr3 congenic bone marrow
cells to measure HSC self-renewal capability. Serial transplantation
procedures were performed as described in figure 3.2. 16 weeks following each
of the serial transplants, the percentages of Ly5.2-derived cells in recipients’
peripheral blood (A), bone marrow (B) and bone marrow LSK (C) populations
were determined and compared between B6 (solid line) and B.D Chr3 congenic
groups (dashed line). The survival rate was also measured in quaternary
recipients in both groups. The values at each timepoint are the averages of 16
recipient mice from two independent experiments. The percentages of B.D Chr3-
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derived cells are higher than those of B6-derived cells with a statistical
significance (p<0.05) in every comparison.
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Table 3.1 Cell cycle analysis of LSK HSCs by DAPI staining in chromosome
3 congenic and their background mouse strains.
Mouse strains
B6

Percentage of LSK cells in S/G2/M
(% ± 1 SEM)
5.20 ± 0.98 %

B.D Chr3

7.29 ± 1.88 %

D2

5.59 ± 0.79 %

D.B Chr3

5.62 ± 0.75 %

Bone marrow LSK stem cells were identified as shown in figure 3.1. Cells in the
G2/M phases (tetraploid) of the cell cycle have twice the DNA content of those in
G0/G1 (diploid), with S phase having the intermediate content. DNA contents
were determined by DAPI staining, as per the profile in figure 3.3. The
percentages of LSK cells in S/G2/M phases of the cell cycle were measured and
compared among all chromosome 3 congenic lines and their respective
background strains. Data shown in above table are the mean ± SEM that were
pooled from at least 3 independent experiments, with at least 2 mice per
experiment.
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Table 3.2 Apoptotic analysis of LSK HSCs by Annexin-V and 7-AAD
staining in chromosome 3 congenic and their background mouse strains.
Mouse strains
B6

Percentage of apoptotic LSK cells
(% ± 1 SEM)
2.67 ± 0.42 %

B.D Chr3

0.55 ± 0.1 % *

D2

0.86 ± 0.2 % *

D.B Chr3

0.29 ± 0.03 % *

Bone marrow LSK stem cells were identified as shown in figure 3.1. Apoptotic
cells were identified by Annexin V and 7AAD staining and the staining profiles
were shown in figure 3.4. The percentages of apoptotic LSK cells were measured
and compared among all chromosome 3 congenic and their respective
background strains. Data shown are the mean ± SEM that were pooled from at
least 3 independent experiments, with at least 2 mice per experiments. * denotes
a statistical significance (p<0.001) in any pair comparison of all 4 strains.
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CHAPTER FOUR
Identification of quantitative trait gene
responsible for HSC number regulation

Summary

In order to identify the gene within chromosome 3 QTL region that are
responsible for HSC number variations between B6 and D2 mouse strains, a
microarray-based candidate gene approach was performed. By measuring
mRNA expression profiles in purified HSCs (LSK cells) using Affymetrix gene
chips (MGU74Av2), I found that 17 genes were differentially expressed among
chromosome 3 congenic and their respective background mice. However, only
one gene, which encodes latexin, was located within the chromosome 3 QTL
interval that was overlapping in both congenic strains. Latexin mRNA was found
to be highly expressed in D.B Chr3 and B6 LSK cells compared to B.D Chr3 and
D2 LSK cells, and these differential expressions were validated by quantitative
real-time PCR. Surprisingly, I also found the identical differential latexin mRNA
expressions in all downstream progeny of LSK cells, including bone marrow Linand nucleated cells, and mature peripheral blood cells. Moreover, Western blot
using polyclonal anti-latexin Ig-G antibody demonstrated that the differential
expression pattern of latexin protein was consistent with that of its mRNA in bone
marrow Lin- and nucleated cells. Altogether, our results suggest that B6 alleles
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in chromosome 3 QTL up-regulated, whereas D2 alleles down-regulated the
expression of latexin mRNA and proteins. In order to identify the relationship
between latexin expression level and HSC number changes, I constructed
recombinant retroviral vector containing latexin cDNA and overexpressed this
gene in D2 and D.B Chr3 congenic bone marrow cells. CAFC and CRU
functional analyses of latexin-transduced cells were performed to investigate the
regulatory role of latexin on HSC numbers. However, the results were not
available at the time when the dissertation was under preparation. Our data is the
first to report that latexin is expressed in HSCs; it also provides strong evidence
concerning the reverse relationship between latexin expression level and the
changes of murine HSC numbers. These findings may be useful for developing
effective stem cell expansion strategies in the clinic. Moreover, understanding the
underlying mechanisms and signaling pathways involving latexin will probably
reveal further not appreciated as regulators of stem cell function.
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Introduction

Genetic complex traits (also called quantitative traits) are usually
controlled by multiple genes, which pose special challenges that make gene
discovery more difficult (Biola et al. 2003; Darvasi and Pisante-Shalom 2002).
Current strategies aimed at the identification of quantitative genes typically
employ a combination of positional gene mapping, candidate gene testing, and
bioinformatics, as depicted in Figure 1.1. Most importantly, having congenic
strains that display the phenotype of interest is a critical jumping off point for both
a candidate gene approach and a positional cloning approach leading to gene
discovery (Glazier et al. 2002).
With the development of an extensive array of genomic resources and
technologies, the success for identifying “stemness” genes have improved
markedly. Four comprehensive studies have recently been published describing
stem cell-specific genes. Three of them used similar approaches by generating
profiles of genes expressed in embryonic stem cells, neural stem cells, and
hematopoietic stem cells. After reductionist comparisons of the profiles, all
studies showed around 200 to 300 genes were commonly expressed in all three
categories of stem cells, although the genes that overlapped among these
studies were very few (Fortunel et al. 2003; Ivanova et al. 2002; Ramalho-Santos
et al. 2002). Nevertheless, the commonly expressed genes fell into several
functional categories, including those encoding transcription factors, membrane
proteins, protein binding nucleic acids, and proteins involved in cell-cycle control
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and apoptosis. In a fourth study, Park et al. used substractive hybridization and
gene array analyses to screen and identify the genes specifically regulating HSC
functions (Park et al. 2002). The four studies collectively turned to so many stem
cell-specific genes that the task of unraveling the mechanistic role of the genes in
stem cell functions is demanding. In contrast, gene discovery in forward genetics
does not have the problem of determining phenotype because a measurable
difference in stem-cell function is the starting point of analysis. In my study,
although I also performed microarray-based candidate gene approach to identify
genes that regulate an already-known phenotype (HSC numbers) (Tabor et al.
2002), congenic strains displaying the phenotype was a great advantage to
reduce the number of candidate genes to a level feasible enough that functional
study of individual genes could be undertaken.
Because of extensively documented differences between the
hematopoietic systems of C57BL/6 and DBA/2 mice and the powerful genetic
tools afforded by the recombinant inbred strains by crossing them, several
genetic studies using forward genetic approach have begun to shed light on loci
in this genetic context that account for the strain-specific variations in
hematopoietic stem cell (HSC) properties. The natural variations of HSC
numbers, the changes of its number with age and self-renewal capabilities of
HSCs have been reported to link to several QTL (Chen et al. 2000; de Haan and
Van Zant 1997; Geiger et al. 2001; Kamminga et al. 2000; Muller-Sieburg et al.
2000; Muller-Sieburg and Riblet 1996; Phillips et al. 1992). Moreover, other QTL
responsible for HPC mobilization and their sensitivity to the genotoxic effects of
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the cell cycle-specific drug hydroxyurea have been also mapped (de Haan and
Van Zant 1999; Geiger et al. 2004). In addition to these cell-intrinsic properties,
the responses of HSCs to extracellular cueswere reported to link to specific QTL
(Henckaerts et al. 2002; Langer et al. 2004). Furthermore, de Haan et al. used a
combination of linkage analysis, a congenic mouse model, substractive
hybridization, and gene array technologies to reveal gene clusters on
chromosome 11 associated with QTL that were linked with the sensitivity of
HPCs to hydroxyurea (de Haan et al. 2002). Although some QTL have been
confirmed in congenic mouse models and some even provide evidence for the
underlying molecular basis of the QTL, none of them have successfully identified
the specific gene (also called quantitative trait genes) that are directly associated
with the corresponding quantitative traits. However, in our present study, I have
for the first time identified latexin, a gene near the chromsome 3 QTL, and have
shown that it is potentially responsible for strain-specific variation in HSC
numbers. By performing gene array hybridization, quantitative real-time PCR,
and Western blotting, I found that latexin, which encodes a carboxypeptidase A
inhibitor (Normant et al. 1995), was differentially expressed in hematopoietic cells
at both the mRNA and protein levels among chromosome 3 congenic lines and
their respective background strains. Upregulated latexin expression was
associated with the decreased HSC numbers, and vice versa. These promising
results not only show the potential role of latexin in regulating HSC number, but
also demonstrate the feasibility of a forward genetic approach for gene discovery.
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Materials and Methods

Animals
Background strains: C57BL/6J (B6) (Ptprcb [Ly-5.2]), DBA/2J (D2) mice
were purchased from the Jackson Laboratories (Bar Harbor, ME).
Congenic stains: Chromosome 3 congenic mice were generated by
Geiger et al. as described previously (Geiger et al. 2001). Genotypes of congenic
mice were validated every 6 months by screening genetic markers flanking the
congenic interval and located throughout the genome. All primers for simple
sequence repeat (SSR) genetic markers were bought from Research Genetics,
Huntsville, AL and genotyping was carried out by PCR. Two strains of
chromosome 3 congenic mice were generated and maintained: B.D Chr3
(14cM~33cM) congenics with D2 QTL being introgressed onto B6 background,
and their reciprocal congenic strains D.B Chr3 (19cM~60cM) with B6 QTL onto
D2 background. The overlapping congenic interval in the two strains spanned
14cM that is from 19~33cM.

Cell preparations
All cell populations were prepared from the above 4 strains and at least 3
independent biological samples were used in each analysis.
1. Enrichment of hematopoietic stem cells
Bone marrow cells from the femora and tibiae were flushed into Hank’s
balanced salt solution (HBSS, Gibco, Grand Island, NY) containing 2% heat
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inactivated fetal calf serum (FCS, Life Technologies). The pooled marrow was
layered over a Ficoll-Paque PLUS (Amersham Biosciences, Uppsala sweden)
gradient and after centrifugation the mononuclear cell layer was removed.
Mononuclear cells were subsequently stained with a panel of biotinylated
antibodies specific to lineage mature blood cells, including CD5 (clone 53-7.3),
CD8a (clone 53-6.7), CD45R/B220 (clone RA3-6B2), CD11b/Mac-1 (clone
M1/70), Ly-6G/Gr-1 (clone RB6-8C5), and TER119/Ly-76 (clone TER-119)]. The
labeled cells were then incubated with goat antirat IgG paramagnetic beads
(Dynal, Lake Shearer, NY) at a bead:cell ratio of 4:1, and cells bound to lineagespecific antibodies were removed in a strong magnetic field. The lineagedepleted cells were blocked with anti-CD16/32 (clone 2.4G2), and stained with
streptavidin-FITC, phycoerythrin (PE)-anti-Ly-6A/E (Sca-1; clone E13-161.7) and
allophycocyanin (APC)-anti-CD117 (c-kit; clone2B8). The labeled cells were
resuspended into PBS containing 5ug/mL propidium (PI) solution to distinguish
viable and dead cells. PI-, Lin-, Sca-1+ and c-kit+ (LSK) cells were sorted on a
Becton Dickinson FACS Vantage flow cytometer.

2. Purification of hematopoietic progenitor-enriched cell population
The entire procedure was similar to LSK cell sorting except that at the final
step the blocked lineage-depleted cells were stained only with streptavidin-FITC
and PI. The cell suspensions were subsequently sorted for the Lin- population, in
which almost all mature blood cells were eliminated and progenitor cells were
enriched.
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3. Preparation of peripheral blood and bone marrow nucleated cells
Mice were bled from the retro-orbital venous plexus and bone marrow
cells from 1 femur per mouse were flushed into medium containing Hank’s
balanced salt solution (HBSS, Gibco, Grand Island, NY) with 2% heat inactivated
fetal calf serum (FCS, Life Technologies). Erythrocytes in peripheral blood and
bone marrow cell suspensions were eliminated by hypototic lysis. The remaining
cells were washed with medium twice and cells were counted by cell coulter. A
precised number of cells were used for analyses.

Total RNA isolation
Total RNA was extracted from a prescribed number of cells by using
RNeasy® Kit (QIAGEN, Valencia, CA). Briefly, cells were centrifuged to obtain a
cell pellet, which was disrupted with guanidine isothiocyanate - containing buffer
(Buffer RLT) with β-mercapitoethanol and homogenized by vortexing for 1 minute
(homogenized cell lysate could be frozen in -80°C and used later). An equal
volume of 70% ethanol was added to adjust conditions suitable for the binding of
RNA to the membrane. Samples were applied to an RNase spin column for
adsorption of RNA to membrane. The contaminants were removed with wash
spins (Buffer RW1 and RPE provided by kit). The total RNA was then eluted into
RNase-free water and quantified by spectrophotometric analysis. The extracted
total RNA was used for either microarray analysis on the Mouse Genome
U74Av2 chip or quantitative real-time PCR analysis.
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Microarray analysis of LSK cells
Oligonucleotide arrays of LSK cells were performed by the Microarray
Facility Center at the University of Kentucky. Briefly, for each of 4 mouse strains,
total RNA were extracted from at least 550,000 LSK cells from a minimum of 30
mice in order to obtain sufficient RNA for probing Affychips. The extracted RNA
was then reverse transcribed into cDNA, which was subsequently used to
generate biotin-labeled cRNA. Fragmentation and hybridization of labeled cRNA
to the Mouse Genome U74Av2 chips (MGUAv2, Affymetrix, Santa Clara, CA)
were then performed. The genechips were then washed and stained and
subsequently scanned for quantification of gene expression. Three independent
biological samples were obtained for each strain and each was run on an
individual chip. The gene expression levels were compared among all 4 strains
by using one way-ANOVA with a statistical cutoff of p<0.05. The genes that were
differentially expressed were screened for genomic location and function of the
gene products.

Quantitative real-time PCR
Identical numbers (200,000) of cells were used for total RNA extraction in
each type of cell population (peripheral blood, bone marrow, Lin- and LSK cells)
isolated from each mouse strain. Isolated total RNA was reverse transcribed into
cDNA using random hexamers in a TaqMan® reverse transcription solution (PN
N8080234) and stored at -20ºC. Quantitative real-time PCR analyses of selected
genes were performed in single reporter assays with an ABI PRISM 7700
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sequence detection system (PE Biosystems, Foster city, CA, USA). PCR
reactions were set up according to manufacturer’s instructions using TaqMan®
universal PCR master mix (PN 4304437), and the primer and probe mixes for
each tested gene were purchased from Applied Biosystems (Foster city, CA,
USA). TaqMan® rodent glyceraldehyde-3-phosphate dehydrogenase (GAPDH
(PN 4308313) served as an endogenous control to normalize gene expression.
The analysis of gene expression was performed by the relative standard curve
method. In brief, standard curves were prepared for the GAPDH control and for
each of tested genes, and the amount of GAPDH control and test gene were
determined from the standard curve. A normalized test gene value was
determined relative to GAPDH expression. Each biological sample was obtained
from at least 5 mice, and each sample was run with at least 5 replicates within an
experiment. Three replicate biological experiments were performed in each
strain.

Immunoblots
Cell samples were lysed at a concentration of 2x107 cells/ml in protein
lysis buffer containing: 10mM tris pH7.5, 50mM NaCl, 30mM sodium
pyrophosphate, 50mM NaF, 5µM ZnCl2 and 1 % Triton X-100, 2.8ug/ml aprotinin
(Sigma), 1mM phenylmethylsulfonyl fluoride (Sigma), 1mM sodium vanadate
(Na3VO4) 1ug/ml pepstatin, and 1µg/ml leupeptin (Oncogene Research, MA,
USA). Lysate was incubated on ice for 30min, and then centrifuged at 15,000 x g
for 10 minutes to remove debris. The resulting supernatant was then aliquoted
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and stored at -80°C. For immunoblot analysis, protein lysates were thawed and
mixed with running buffer and a reducing agent (Novex, San Diego, CA, USA,
per manufacturer’s instruction) and heated at 95°C for 5 minutes. Samples were
then analyzed by denaturing PAGE (Novex, 10% Bis-Tris gel) using the
equivalent of 4x105 cells per lane. Following electrophoresis, samples were
electro-transferred onto immunobilon-P membranes (Millipore, Bedford, MA,
USA), which were subsequently blocked and probed with polyclonal rabbit antilatexin Ig-G antibody at a 1:3000 dilution. This polyclonal rabbit anti-latexin Ig-G
antibody was generated against an amino acid sequence of mouse latexin
protein that I selected, CKHNSRLPKEGQAE, and was produced by Bethyl
Laboratories, Inc (Montgomery, TX). Primary antibodies were detected using
alkaline phosphatase-conjugated secondary antibodies (Santa Cruz
Biotechnology) and electro-chemifluorescent (ECF) reagent (Pharmacia Biotech)
according to the manufacturer’s instructions. Blots were visualized using a
Molecular Dynamics STORM 860 system and Imagequant Software. Following
the detection and quantification of anti-latexin antibody, immunobilon-P
membrane was sequentially stripped in 40% methanol and buffer containing
100mm ß-mercaptoethanol, 2% sodium dodecyl sulpahate and 62.4mM Tris-HCL
to remove ECF reaction product and antibodies, respectively. The stripped
membrane was reprobed with anti-actin antibody (Sigma) at 1:500,000 dilution
and detected as previously described.

Retroviral vectors
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Retroviral vector, Sfbeta 91 (a gift from Dr. Hartmut Geiger, Cincinnatti
Children’s Hospital), served as both control and the backbone for cloning of
latexin (Lxn) cDNA. It contained the 5’-long terminal repeat (LTR) derived from
myeloproliferative sarcoma virus (MPSV) and a 3’-LTR that is derived from
spleen focus forming virus (SFFV). The internal ribosomal entry site (IRES)
sequence derived from the encephalomyocarditis virus was used for
simultaneous translation of gene insert and the gene for enhanced green
fluorescent protein (GFP). The latexin cDNA sequence was cloned upstream of
the IRES of the Sfbeta91 vector (MPSV-IRES-GFP-SFFV) to create a
recombinant latexin-carrying vector (MPSV-Lxn-IRES-GFP-SFFV). Production of
high-titer helper-free retrovirus was carried out by standard procedure in
ectotropic Phoenix packaging cells.

Infection of primary murine bone marrow cells
Primary mouse bone marrow cells were transduced as previously described
with modifications specified below (Sauvageau et al. 1995). Briefly, bone marrow
cells were extracted from mice treated 4 days previously with 150 mg/kg body
weight 5-fluorouracil (5-FU) (Sigma, St. Louis, MO) and cultured for 24 hours in
Dulbecco's modified eagle's medium (DMEM) supplemented with 10% fetal
bovine serum (FBS), 1% penicillin/streptomycin, 50 ng/mL recombinant mouse
stem cell factor (mSCF), 10ng/mL mouse interleukin 6 (mIL-6), and 10ng/mL
mouse interleukin 3 (mIL-3) (R&D Systems, Minneapolis, MN). Media and serum
were purchased from Gibco Technologies (Carlsbad, CA). The cells were then
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harvested and slowly spread on the top surface of the membrane of a Transwell
insert (Corning Incorporated Life Sciences, Acton, MA) at a density of 2x106 cells
per well. The viral supernatants were added to the Transwell inserts along with 4
µg/ml of polybrene to enhance adherence of viral particle to cells. The membrane
provided a platform to enhance infection of cells by viral particles (Liu et al.
2000a). The cells were co-cultured with viral supernatants for a further 48 hours
and the viral supernatant was changed 3 times during this period of time. The
recovered cells were then transplanted into sub-lethally irradiated (600 Rad)
recipient mice at a dose of at least 1x106 cells per mouse. Around 12 weeks after
transplantation, retrovirally-transduced, i.e. GFP positive, bone marrow cells of
the recipients were flow cytometrically sorted using a FACSVantage (BectonDickinson) and subject to functional analysis of HSCs (CAFC and CRU assays).
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Results

Identification of differentially-expressed gene in chromosome 3 congenic
HSCs by microarray analysis
We have found that a quantitative trait locus (QTL) on mouse
chromosome 3 affects the number of bone marrow HSCs as well as their cycling,
apoptotic and self-renewal states. In order to identify the quantitative trait gene
responsible for these effects, a candidate gene approach was pursued as
indicated in the upper path of the schema in Figure 1.2. To this end, gene
expression levels of LSK stem cells from all 4 mice strains (B.D Chr3 and D.B
Chr3 reciprocal congenics and their respective background B6 and D2 strains)
were measured by microarray analysis using Affymetrix chips (Mouse Genome
U74Av2 set). The genes that were differentially expressed were screened
according to a statistical cutoff of p<0.05 when one-way ANOVA analysis was
performed. Ninety six of the ~12,000 genes on the Affychip were differentially
expressed, either up- or down-regulated, in the congenic B.D Chr3 LSK cells
relative to B6 background cells. Comparable comparison of D.B Chr3 reciprocal
congenic and its D2 background strains showed 84 differentially expressed
genes. However, only 17 genes overlapped in these two comparison groups and
3 of them were located on chromosome 3 (Table 4.1), with the rest scattered
throughout the genome. These 3 genes were latexin, S100a6 and S100a11,
whose genomic locations, relative to the congenic interval and QTL marker, are
shown in Figure 4.1. The overlapped congenic interval in B.D Chr3 and D.B Chr3
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mice ranges from 19cM to 33cM, and the marker of highest linkage to the trait
(HSC number) is D3Mit5 at 25cM. As indicated in the figure, the only gene
located in the overlapping region is latexin at the genomic position of 31.6cM,
whereas the other two are 20cM telomeric to D3Mit5. Although latexin apparently
lies almost 6.6cM downstream from D3mit5 and outside the 95% confidence
limits of the mapping statistics, the results suggested that latexin was the cisregulated quantitative gene responsible for the stem cell frequency trait under
study (Bystrykh et al. 2005). The lack of gene and genetic markers (single
nucleotide polymorphisms, SNPs) between D3Mit5 and the start codon for latexin
suggests that the distance may be considerably less in operational terms,
although it is also possible that an important latexin regulatory site may exist
such a long distance upstream (Cowles et al. 2002). Both scenarios are possible
and have precedents. Moreover, the RNA expression levels of latexin in LSK
cells from all 4 mouse strains showed that latexin was highly expressed in D.B
Chr3 and B6 LSK cells compared to B.D Chr3 and D2 cells, indicating that B6
alleles may up-regulate whereas D2 alleles down-regulate latexin expression.
Considering the phenotypic differences in chromosome 3 congenic and
background mice, it is therefore hypothesized that B6 alleles might be
responsible for the higher expression of latexin which subsequently results in
decreased HSC number, whereas D2 alleles decrease latexin expression and
thereby increase HSC number.
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Latexin expression in hematopoietic cells at different differentiation stages
Latexin, a candidate gene for regulating HSC numbers, was first identified
in neurons of the lateral neocortex of rat with immunohistochemistry employing a
monoclonal antibody PC3.1 in 1992 (Arimatsu et al. 1992). It is also detected in
non-neural tissues in rat and human, including lung, spleen, kidney, heart,
digestive tracts, ovary and prostate. (Hatanaka et al. 1994; Liu et al. 2000b)
Further studies have shown that its protein product, a 29kD molecule with 222amino-acid residues, contains two potential Ca2+ /calmodulin-dependent protein
kinase sites and one cGMP-dependent protein kinase phosphorylation site
(Callahan 1999; Takiguchi-Hayashi and Arimatsu 1995). Although the functions
of latexin haven’t been well studied, Normant et al. showed that it functioned as a
carboxypeptidase A inhibitor and was involved in protein degradation (Normant
et al. 1995). Studies from Takiguchi-Hayashi et al. also suggested that it might
play a role in cortical regional specification of the brain (Takiguchi-Hayashi and
Arimatsu 1995). All of the above results suggest that latexin is mainly expressed
in differentiated cells at least in the nervous system.
Since my microarray data for the first time showed that HSCs express
latexin, I further investigated whether hematopoietic cells at other differentiation
stages also expressed the gene. To this end, quantitative real-time PCR was
performed on populations of peripheral blood nucleated cells (PB), bone marrow
nucleated cells (BM), progenitor-enriched Lin- cells, and LSK HSCs. As shown in
Figure 4.2, a very low level of latexin was expressed in mature blood cells and its
expression gradually increased with the enrichment of HSCs, reaching the
110

highest level in primitive progenitor and stem cell populations. Moreover, the data
for LSK cells also confirm, both qualitatively and quantitatively, the results
obtained with microarrays. Most interestingly, cells that had B6 alleles had
significantly higher levels of latexin transcripts than cells containing D2 alleles in
each cell type. Therefore, these results indicate that latexin is specifically
expressed in bone marrow primitive hematopoietic cells, and high expression is
associated with B6 alleles that have been shown to contribute to a smaller HSC
population size. If latexin functions as a carboxypeptidase inhibitor in HSC
population size regulation, it may imply that protein target of carboxypeptidase
may be associated with increasing HSC cycling, decreasing HSC apoptosis, or
both.

Latexin is differentially expressed at the protein level in congenic cells
Differential mRNA expression patterns of latexin have been demonstrated
by both microarray and real-time PCR. These differences are also associated
with the strain-specific genotypes (B6 vs D2 alleles) and phenotypes (low vs high
number of HSCs). We next measured latexin protein expression by Western
blotting. Mouse anti-latexin antibody is not commercially available, polyclonal
rabbit anti-latexin Ig-G antibody was therefore specifically produced against an
amino acid sequence of mouse latexin protein that I specified:
CKHNSRLPKEGQAE. To test the validity and specificity of this antibody, we
performed Western blot using this antibody on B6 BM nucleated cells as well as
on human cord blood, peripheral blood cells and adult BM cells from subject of
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different ages. The results (Figure 4.3) showed that a 29 kD protein, which is
consistent with the size of latexin protein reported previously (Arimatsu et al.
1992; Hatanaka et al. 1994), was detected in mouse BM cells by this antibody.
However, this antibody failed to demonstrate the presence of latexin protein in
human-derived biological samples. These results suggest that the antibody
specifically bound to mouse latexin protein without cross-reacting with the human
species.
In order to test the hypothesis whether or not the differential expression
pattern of latexin transcripts is reflected at the protein level, Western blots of two
populations of cells were performed: bone marrow (BM) and Lin- cells. Because
LSK stem cells are so rare, insufficient numbers could be obtained to perform
this analysis on this population.

As shown in figure 4.4, latexin protein

expression is much higher in Lin- cells than in BM cells. Moreover, consistent
with the microarray and real-time PCR results, both D.B Chr3 and B6 cells in
each population have a higher content of latexin protein compared to the
reciprocal B.D Chr3 and D2 cells. Therefore, the differential expression patterns
of latexin among all 4 stains are identical at both mRNA and protein level. It is
reasonable to speculate that this expression pattern for latexin protein might also
exist in LSK stem cell populations, albeit at even higher expression level.

Model of latexin overexpression in bone marrow cells
Since I have shown that D2 alleles on chromosome 3 QTL are associated
with downregulated expression of latexin as well as increased HSC number
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(CAFC day35), I next investigated the effects of overexpressing this gene on
HSC functions. To this end, recombinant retroviral vectors containing latexin
cDNA were constructed and transduced into D2 and B.D Chr3 congenic bone
marrow cells. Isolated cells were subsequently transplanted into sublethally
irradiated recipient mice of the same genetic background, and the GFP+ cells will
be selected at least 12 weeks post-transplant. At the time of dissertation writing,
these data haven’t been available yet. It is hypothesized that overexpression of
latexin will lead to the decreased HSC numbers in D2 and B.D Chr3 congenic
mice. In other words, overexpression of latexin may confer a B6-like phenotype
to D2 HSCs.

113

Discussion

It has been very difficult to identify quantitative trait (QT) genes underlying
QTL that are linked to quantitative traits, especially those related to steady-state
hematopoiesis (Biola et al. 2003; Darvasi and Pisante-Shalom 2002; Korstanje
and Paigen 2002). The prospects for successful gene discovery have improved
markedly, however, with the recent development of gene array technology and
the sequencing of mouse strain genomes (Glazier et al. 2002). In my studies, I
took advantage of the former technology and have been the first demonstrate
that the latexin gene, located in the chromosome 3 QTL region, was differentially
expressed in C57BL/6 (B6), DBA/2 (D2) and Chr3 congenic HSCs. The
differential expression pattern was further confirmed by quantitative real-time
PCR and by Western blot analyses. Moreover, down-regulated latexin
expression is associated increased HSC numbers, and vice versa. Retroviral
gene transfer and bone marrow transplantation results will provide further
evidence for the potential roles of this gene in the hematopoietic system.
Compared to previous forward genetic studies of hematopoietic cells,
several novel features have been added in my studies. First, we used unique
congenic mice, whose genome differs only in the genomic region of the
chromosome 3 QTL from background strain mice. Since the mutually inclusive
interval in the reciprocal congenics is 14cM (19~33cM, figure 4.1), this represents
only around 1% of the entire mouse genome assuming the total length of mouse
genome is 1300cM. This 1% genomic difference greatly reduces the number of
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polymorphic loci between congenic and background mice. The microarray results
underscored this. Only 90 genes were differentially expressed (p<0.05) between
congenic and background LSK HSCs whereas 940 genes were differentially
expressed between D2 and B6 cells. A second feature of the microarray
approach was that I used two reciprocal congenic strains. A comparison of
differential gene expression between strains with overlapping congenic intervals
provided not only corroborating evidence for a particular candidate, for example if
it were up-regulated in one congenic and down-regulated in the reciprocal, but it
provided evidence and identities of modifying genes in the respective genetic
backgrounds (Nadeau 2001; Nadeau 2003). Thirdly, unlike most studies, cDNA
amplification was not used. Due to the limited numbers of HSCs in BM, most, if
not all, other stem cell studies using gene arrays were performed by hybridizing
amplified RNA samples onto gene chips (Bystrykh et al. 2005; Ivanova et al.
2002; Ramalho-Santos et al. 2002). Amplification may cause representational
skewing of low abundance RNA species. In order to avoid this problem, we made
great efforts to obtain sufficient LSK cells and RNA for probing Affychips without
amplification. Usually more than 550,000 LSK from a minimum of 30 mice of
each strain were needed for a single chip. Moreover, three independent
biological samples were obtained for each strain and each was run on an
individual chip. Thus, our gene expression profiles of LSK cells are more reliable
and the results of differentially expressed genes are more convincing. Most
importantly, the microarray results reveal the relationship of differential
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expression of a single candidate gene, latexin, to the HSC number changes
(Wayne and McIntyre 2002).
Validation of the candidate gene, latexin, identified by microarray was
accomplished by quantitative real-time PCR. This method is substantially more
quantitative than microarrays and reliably detects small expression differences
(Bustin 2000; Chuaqui et al. 2002). Consistent with the microarray data, the
quantification of latexin in LSK stem cells demonstrated that B6 alleles on
chromosome 3 QTL increased whereas D2 alleles decreased latexin expression
by around 2-fold. These results are in quantitative agreement with my microarray
results. Differential expression patterns were also reproduced at the protein level,
indicating that latexin is mechanistically involved in our quantitative trait loci and
trait. However, its location 6.6cM telomeric to the markers of highest linkage to
our trait, presents problems in interpreting these results. Perhaps the simplest
explanation is that too few BXD strains, or a lack of microsatellite markers used
for linkage analysis, led to discrepant mapping. However, two recent studies
identifying the regulatory QTL that affect gene expression in HSCs and brain
cells demonstrated that most of genes were regulated through cis-acting QTL
that mapped within 10cM of the gene itself. A regulatory site may therefore exist
a long distance upstream of latexin start codon that is involved in the latexin
expression (Bystrykh et al. 2005; Chesler et al. 2005).
In order to add to the veracity of latexin as a candidate, we used
recombinant retrovirus containing latexin cDNA and overexpressed latexin in D2
and B.D Chr3 congenic bone marrow cells. Although data in these studies
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haven’t been available at the time of dissertation writing, and further studies,
such as knockdown latexin in B6-derived cells using small interfering RNAs and
in vivo functional assay of latexin-trasnduced cells, are needed, our current
findings demonstrate the reverse relationship between latexin expression and
hematopoietic cell population size. These findings also suggest the potential role
of latexin in the regulation of HSC numbers.
I next asked what mechanisms may contribute to the differential
expression of latexin in different mouse strains. The level of a given mRNA
transcript is controlled both by cis-acting factors (such as DNA polymorphisms
and methylation) in the regulatory DNA sequence of the gene and trans-acting
modulators (such as transcription factors) that are themselves regulated by other
genetic and environment factors (Cheung and Spielman 2002; Hubner et al.
2005; Pastinen and Hudson 2004)). Cis-regulatory polymorphisms are DNA
elements and are distributed over long distances upstream and downstream of a
gene, but on the same linkage group. Introns as well as the 5’ and 3’
untranslated regions have also been shown to harbor regulatory elements.
Therefore, I hypothesized that the cis-acting variations might explain the different
expression level of latexin transcript in B6 and D2 HSCs. Celera Discovery
System (CDS) (http: www.celeradiscoverysystem.com) is a commercially
available database in which single nucleotide polymorphisms (SNPs) of a given
gene have been detected among different mouse strains and species. I thus
searched for SNPs in and around the latexin open reading frame in B6 and D2
mouse stains. Only 4 SNPs were shown in both strains and all of them were
117

located in intronic regions. It is possible that some of these SNPs may modify
latexin expression, but more experimental evidence is needed to test their
effects, such as site-directed mutagenesis (Mackay 2001). Moreover, more SNPs
may also be discovered with additional repeated coverage and scrutiny of longer
distance of upstream flanking regions (Brent 2000).
As for the regulatory roles of trans-acting factors in the differential
expression of latexin, another useful database (www.WebQTL.org) was used
(Chesler et al. 2004; Wang et al. 2003). WebQTL is a database of quantitative
gene expression in LSK stem cells of all of the BXD strains currently available,
and an important feature is that it is linked to a mapping program. Thus one can
map the location of genes or QTL that modify the expression of other LSK genes
(Bystrykh et al. 2005; Chesler et al. 2005). When modifiers of latexin expression
were queried using such an approach, highly suggestive linkage (LRS=11) was
obtained to two markers at 29.5cM and 33cM, which are very close to genomic
locations of D3Mit5 (25cM) and latexin (31.6cM) (Figure 4.6). Moreover, the
negative additive effects for both markers suggest that the B6 allele increases
the trait values, i.e., latexin expression, which is precisely consistent with our
results from microarray, real-time PCR, and Western blot analyses. Therefore,
these results not only suggest existence of regulatory factor in the upstream and
downstream region of the latexin sequence, but also corroborate D3Mit5 as a
marker, presumably the primary one, for a QTL directly or indirectly responsible
for the phenotypes conferred by the chromosome 3 QTL.
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Latexin is expressed in specific neurons in both the central and peripheral
nervous system in the rat. It is mainly used as a molecular marker for the
regional specification of the neocortex (Arimatsu et al. 1999a; Arimatsu et al.
1999b). Contrary to the expression pattern in the nervous system, we found that
latexin was highly expressed in more primitive hematopoietic cells (Linprogenitor and LSK stem cells) rather than differentiated blood cells.
Nevertheless, the fact that latexin is expressed in both hematopoietic and
neuropoietic cells is in line with the recent demonstration of the overlapping gene
expression profiles between these two systems (Goolsby et al. 2003; Li et al.
2004; Steidl et al. 2004; Terskikh et al. 2001). More and more genes that are
primarily assigned to the nervous system have been found in primitive
hematopoietic cells (HSCs and HPCs) in both mice and humans. Recently, two
comprehensive studies from the Melton and Lemischka laboratories detected
gene expression profiles in embryonic stem cells (ESCs), neural stem cells
(NSCs) and HSCs by using microarray techniques (Ivanova et al. 2002;
Ramalho-Santos et al. 2002). 432 genes were found to be commonly expressed
in NSCs and HSCs in the former study and 644 genes in the latter. Latexin,
however, is not included in both gene lists. To our knowledge, the only evidence
for the existence of latexin in NSCs comes from the supplementary database
published online in the Melton study (Ramalho-Santos et al. 2002). According to
the concept of adult stem cell plasticity and the fact of genetic overlapping
between NSCs and HSCs (Terskikh et al. 2001; Wagers and Weissman 2004),
our results showing expression of latexin as well as its potential regulatory roles
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in HSCs may also apply to NSCs. Studies aimed at addressing these questions
are currently being performed in collaboration with the lab of Dr. James Geddes
and the results could provide potential implications in areas of transplantation
and tissue regeneration.
Although we provide strong evidence that the potential association of
latexin with the regulation of HSC numbers, very little information is available to
help us to understand the underlying molecular mechanisms. Latexin has been
used to elucidate the mechanism of cortical regional specification and modulation
of sensory perception in the nervous system (Arimatsu et al. 1999a). Studies by
Normant et al. demonstrated that latexin had carboxypepsidase A inhibitor
activity (Normant et al. 1995). Recent findings concerning latexin expression in
rat mast cells and mouse macrophages indicated it might also be involved in
inflammation. Moreover, studies of the latexin protein structure showed that
latexin protein had a similar fold architecture as cystatin (cysteine proteases
inhibitor) and had a motif similar to TIG1 (human putative tumor suppressor
protein), indicating other potential roles of latexin (Aagaard et al. 2005). Studies
by Callahan et al. revealed that the absence of a candidate gene, whose protein
product had 85% identity of the mouse latexin protein, was associated with
increased incidence of ovarian cancer. In addition, induced expression of this
gene by 5-aza-2’-deoxycytidine implicated methylation as one of the mechanisms
for its inactivation. Latexin was also found to contain two potential
Ca2+/calmodulin-dependent protein kinase site, one c-GMP-dependent protein
kinase phosphorylation site, and three glycosylation sites (Callahan 1999).
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Therefore, G protein-coupled receptor and/or calcium/calmodulin singnaling
pathways might also be involved in the latexin-mediated regulation of HSCs. This
hypothesis is supported to a certain extent by our observations of differential
expression of S100a6 and S100a11 (Table 4.1), a cluster of calcium binding
protein genes, between both sets of congenics and their respective background
strains. Therefore, we propose that genes, or gene clusters, at these several
locations in and around the chromosome 3 congenic interval may have
interrelated roles in stem cell function.
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Figure 4.1 Schematic illustration of chromosome 3 congenic map and
genomic location of candidate quantitative genes. D.B Chr3 congenic mice
contain a B6-derived genomic interval from 19cM to 60cM, while the reciprocal
B.D Chr3 mice have a D2-derived interval between 14cM and 33cM. The
consensus congenic region between both strains is from 19cM to 33cM on
chromosome 3 (80cM of total length), which contains the marker of tightest
linkage to the trait, D3Mit5, at 25cM. 3 out of the 17 genes, which are
differentially expressed among Chr 3 congenic and their respective background
strains, are located in chromosome 3. One of them is latexin, which is in the
consensus congenic interval at 31.6cM. The other two are members of S100a
family, S100a6 and S100a11, which are in D.B Chr3 congenic region, but not in
B.D Chr3 interval. Latexin is the only one of the genes to be up-regulated in one
congenic strain (D.B Chr3) and down-regulated in the reciprocal congenic strain
(B.D Chr3)
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Figure 4.2 Development-dependent differential expression of latexin mRNA
in chromosome 3 congenic mice. Identical numbers (200,000) of peripheral
blood (PB), bone marrow (BM), lineage-depleted, progenitor-enriched bone
marrow cells (Lin-), and LSK stem cells were obtained from chromosome 3
congenic (B.D Chr3 and D.B Chr3) and their respective background mice (B6
designated as B and D2 as D). Quantitative real-time PCR was performed to
measure latexin mRNA expression in these cell populations. The latexin
expression level represented in Y axis is the mean value (±SEM) of 3 separate
experiments performed on 3 independent biological samples. With one exception
(B and D Lin- population as signed *), all B-derived alleles significantly (p<0.05)
up-regulate latexin expression whereas D alleles down-regulate latexin
expression.
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Figure 4.3 Latexin protein expression in mouse and human cells. Western
blot was performed using mouse bone marrow (BM) cells and human peripheral
blood (PB), cord blood (CB) and BM (young and old adults, 30 and 83 years old
respectively) cells as described in Methods. Blots were probed with polyclonal
rabbit anti-mouse latexin Ig-G antibody. Latexin protein was detected as a 29kD
molecule in mouse BM cells.
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Figure 4.4 Development-dependent differential expression of latexin protein
in chromosome 3 congenic mice. Western blot was performed to quantify
latexin protein level in bone marrow (BM) nucleated cells, lineage-depleted and
progenitor-enriched bone marrow cells (Lin-) from chromosome 3 congenic (B.D
Chr3 and D.B Chr3) and their respective background mice (B6 designated as B
and D2 as D). Panel A is a representative Western blot profile of latexin protein;
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actin was used as the control. In each cell population and each strain, cell lysate
derived from equal numbers of cells were probed with polyclonal rabbit antimouse latexin antibody and detected as described in Methods. Panel B shows
corresponding quantification of latexin protein level normalized to control actin
level. Two separate experiments were performed with 2 independent biological
samples.
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Figure 4.5 Experimental design for latexin overexpression model. The
Sfbeta 91 recombinant retroviral vector was used as control and backbone to
construct latexin (Lxn) cDNA-containing vector. High-titer viral supernatant was
generated in the ectotropic Phoenix (Eco-Phoenix) packaging cell line as
described in Methods. Bone marrow cells were obtained from D2 mice that had 4
days previously received an intravenous injection of 150mg/kg body weight of 5fluorouracil (5-FU) and co-cultured with viral supernatant in a Transwell insert for
2 days. The transduced cells were recovered and transplanted into sub-lethally
irradiated (600Rad) D2 recipient mice. Around 12 weeks after transplantation,
transduced cells (GFP+) were selected for functional analyses of HSCs (CAFC
and CRU assays)
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Additive effects

Figure 4.6 Identification of QTL regulating latexin expression. WebQTL was
used to identify loci that regulate latexin expression in LSK stem cells. This
database is based on the gene expression profile of LSK cells in all BXD
recombinant strains and linked to mapping program. Two QTL on chromosome 3
were linked to latexin expression with a suggestive significance, D3Mit185
(29.5cM) and D3Mit241 (33cM). The additive values, as indicated in the figure,
for both markers are negative, indicating that the B allele increases the trait
whereas the D allele decreases the trait.
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Table 4.1 Differentially expressed genes in both chromosome 3 congenic
and their respective background mice.
Gene

Gene title

Location

Functional annotation

symbol
Fcer1a

Fc receptor, IgE, high Chr1,
affinity I, alpha

Signal transduction

94.2cM

polypeptide
Gfi1b

Lxn

Growth factor

Chr2,

independent 1B

28.9Mb

Latexin

Chr3,

ATP binding

31.6cM
S100a6

S100 calcium binding Chr3,

Calcium ion binding

protein A6 (calcyclin)

Growth factor activity

43.6cM

Regulation of cell cycle and cell
proliferation
S100a11 S100 calcium binding Chr3,
protein

Cytokine activity

93.7Mb

Calcium ion binding

Not available

A11(calizzarin)
C73003

RIKEN cDNA

Chr3,

6B01Rik

C730036B01 gene

121Mb

Gtf3a

General transcription

Chr5,

factor IIIA

144Mb
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DNA binding

2610507

RIKEN cDNA

Chr7

L03Rik

2610507L03 gene

23.8Mb

9130011

RIKEN cDNA

Chr8,

J15Rik

9130011J15 gene

71.9Mb

Aplp2

Amyloid beta (A4)

Chr9,

Endopeptidase inhibitor activity

precursor-like protein

13.0cM

Serine protease inhibitor activity

2
Pttg1

Not available

Not available

DNA binding

Pituitary tumor-

Chr11,

Cell growth and/or maintenance

transforming 1

29.4Mb

DNA repair
Chromosome segregation
Mitosis

Mybbp1

MYB binding protein

Chr11,

a

(P160) 1a

40.0cM

Nptx1

Neuronal pentraxin

Chr11,
75cM

Mapk8

Tuba1

Rasgrp2

Mitogen activated

Chr14,

Signal transduction

protein kinase 8

29.4Mb

Tubulin,

Chr15,

Microtubule-based movement and

alpha1

60.4cM

process

RAS,guanyl

Chr19,

Calcium ion binding kinase activity

releasing protein 2

6.1Mb

Guanyl-nucleotide exchange facor
activity
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Small GTPase mediated signal
transduction
0710001

RIKEN cDNA

Chr19,

O03Rik

0710001O03 gene

9.5Mb

Not available

The genes are listed in the sequence of chromosome location. Some locations
are represented as centimorgan (cM), others are megabases (Mb). 1cM is
theoretically equal to 2Mb.
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CHAPTER FIVE
Effects of aging on the homing and engraftment of murine
hematopoietic stem and progenitor cells

Summary

To test the hypothesis that aging has negative effects on stem cell homing
and engraftment, young or old C57BL/6 BM cells were injected, using a limitingdilution, competitive transplant method, into old or young Ly5 congenic mice.
Numbers of hematopoietic stem cells (HSCs) and progenitor cells (HPCs)
recovered from BM or spleen were measured and compared to the numbers
initially transplanted. Although the frequency of marrow competitive repopulation
units (CRU) increased ~2-fold from 2 months to 2 years of age, the BM homing
efficiency of old CRU was ~3-fold lower than that of young CRU. Surprisingly, the
overall size of individual stem cell clones generated in recipients transplanted
with a single CRU was not affected by donor age. However, increased age of
both HSC donors and transplant recipients caused a marked skewing of the
pattern of engraftment toward the myeloid lineage, indicating that both HSCintrinsic and HSC-extrinsic (microenvironmental) age-related changes favor
myelopoiesis. This correlated with changes post-transplant in the rate of recovery
of circulating leukocytes, erythrocytes, and platelets. Recovery of the latter was
especially blunted in aged recipients. Collectively, these findings have important
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implications for clinical HSC transplantation where older individuals increasingly
serve as donors for elderly patients.
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Introduction

Hematopoiesis is maintained throughout life by self-renewing stem cells
with a high potential for proliferation and multilineage differentiation (Szilvassy
2003). Accumulating evidence indicates that as animals age, both the number
and functional properties of HSCs are altered (Geiger and Van Zant 2002; Van
Zant and Liang 2003). However, these effects of aging on stem cells and their
BM microenvironment are not clearly defined. For example, marrow from old
C57BL/6 mice contains more HSCs (measured by cobblestone area formation,
primitive phenotype, and competitive repopulating ability) than BM from young
mice (de Haan and Van Zant 1999; Geiger et al. 2001; Henckaerts et al. 2004;
Morrison et al. 1996; Sudo et al. 2000). In contrast, the stem cell pool from
DBA/2 and all other mouse strains studied contracts in size during aging (de
Haan and Van Zant 1999; Harrison et al. 1989). There is compelling evidence
that strain-specific variation in this and other stem/progenitor cell parameters is
regulated by cell-intrinsic mechanisms, and is affected by several quantitative
trait loci (QTL) (Chen et al. 2000; Henckaerts et al. 2002; Henckaerts et al. 2004;
Kamminga et al. 2000; Muller-Sieburg and Riblet 1996; Van Zant et al. 1990). In
serial transplantation experiments, marrow from old animals was less able to
engraft later passage recipients than young BM cells (Ogden and Micklem 1976).
Moreover, old HSCs exhibit a differentiation pattern skewed toward the myeloid
lineage at the expense of lymphopoiesis (Kim et al. 2003; Sudo et al. 2000).
Further evidence of age-related changes in stem cells include the finding that a
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higher proportion of Thy-1loSca-1+Lin-Mac-1-CD4-c-kit+ cells from old mice are in
S/G2/M phases of the cell cycle (Morrison et al. 1996), and the results of
Henckaerts et al. who showed that the proliferative response of Lin-Sca-1+c-kit+
marrow cells to the early-acting cytokines KL, Flt3L and TPO, decreased
dramatically with age (Henckaerts et al. 2004).
In addition to such quantitative and functional changes of HSCs with aging,
the density or activity of several cell surface antigens and membrane transporters
that facilitate their identification and isolation fluctuates during ontogeny and
throughout adulthood (Ito et al. 2000; Matsuoka et al. 2001; Ogawa 2002).
Therefore, functional measurements of HSC properties may actually reflect the
effects of aging on this important population. The competitive repopulation assay
is currently the most rigorous test for defining HSCs by their capacity for longterm reconstitution of the lympho-hematopoietic system (Harrison 1980;
Szilvassy et al. 1990). When combined with a limiting-dilution design, this assay
enables measurement of HSC numbers in vivo (Szilvassy et al. 1990). In the
present study, graded numbers of “test” BM cells were co-transplanted into
myeloablated mice together with competitor BM cells containing an allelic variant
of the hematopoietic cell-specific marker, Ly-5 (also known as CD45 and Ptprc).
The frequency of HSCs in the test population, measured as competitive
repopulating units or CRU, was then determined by applying maximum likelihood
analysis and Poisson statistics. (Szilvassy et al. 1990). Because this method also
identifies animals engrafted by a single HSC, it has the further advantage of
determining the proliferation and differentiation status of HSCs at the individual
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cell level by permitting measurements of clone size and composition. Competitive
repopulating advantages of young or old HSCs can then be ascribed to
qualitative properties such as higher proliferative state, or to quantitative variation
in population size (Szilvassy et al. 2003).
In all experimental and clinical stem cell transplants, the critical first step
leading to successful engraftment is homing of stem cells to the BM. Szilvassy et
al. previously showed that CRU from fetal liver (FL) and young adult BM had
roughly the same seeding efficiency to the marrow of lethally irradiated young
recipients when measured 24 hours after intravenous transplantation (Szilvassy
et al. 2003). However, Morrison et al. found that old stem cells have only about
one-fourth the competitive repopulating activity of young stem cells (Morrison et
al. 1996). As more and older patients become candidates for transplantation in
the treatment of hematological malignancies and non-hematological diseases,
the effects of aging on homing of stem/progenitor cells are clinically relevant, yet
remain largely unexplored.
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Materials and Methods
Animals
Female C57BL/6J (B6) mice (Ptprcb [Ly-5.2]) were used as BM donors,
and congenic female B6.SJL(BoyJ) mice (Ptprca [Ly-5.1]) were used as
recipients. Young mice (6 to 8 weeks) were purchased from Charles River
Laboratories (Frederick, MD) via the National Cancer Institute Animal Program.
Old mice (22-25 months) were either purchased from Harlan (Indianapolis, IN)
via the National Institute on Aging Animal Program, or aged at our own facilities.
Mice were maintained under specific pathogen-free conditions in the animal
facility of the University of Kentucky Chandler Medical Center.

Homing assay for competitive repopulating units (CRU)
Young or old B6.SJL mice were exposed to 9.0 Gy total body irradiation
administered in two doses of 4.5 Gy, ~3 hours apart. Later the same day, 6
irradiated mice (primary recipients) were injected intravenously with 3 x 106 B6
BM cells and, 24 hours later, cells from pooled femora and tibiae were harvested
into 1.5 ml of medium. Assuming that the 4 long bones represent 25% of the total
marrow mass of the mouse, this cell suspension thus contained 1.5 primary BM
equivalents (3.0 equivalents analyzed in total for the 2 replicates of this
experiment that were performed in Tables 5.1 and 5.2) at a concentration of 1
“homed” BM equivalent/ml. To measure the B6 HSC content of this homed
suspension, 4 groups of secondary, irradiated B6.SJL mice (6-8 weeks of age)
were injected with graded numbers of primary BM cells (0.5%-12.5% homed BM
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equivalents/mouse), together with 2 x 105 B6.SJL competitor BM cells (6-8 weeks
of age). The number of CRU in the original B6 cell suspensions (fresh BM cells)
was determined by limiting-dilution assays in separate sets of irradiated B6.SJL
animals (6-8 weeks of age). Four groups of mice were each injected with 2 x 103
to 6 x 104 BM cells admixed with 2 x 105 B6.SJL competitor BM cells as
previously described (Szilvassy et al. 2001a; Szilvassy et al. 2003). Recipients of
fresh or homed BM cells were bled from the retro-orbital sinus at 5, 10, 17 and 26
weeks after transplantation. Erythrocytes were depleted from each peripheral
blood (PB) sample by hypotonic lysis, and the remaining leukocytes then stained
in triplicate with a donor (B6)-specific anti-Ly-5.2 monoclonal antibody (mAb)
conjugated with fluorescein isothiocyanate (FITC) (clone ALI4A2; purified from
hybridoma supernatant and conjugated in our laboratory) and phycoerythrin
(PE)-conjugated mAbs (Becton-Dickinson-PharMingen, San Diego, CA) specific
for either B (anti-CD45R/B220; clone RA3-6B2) or T lymphocytes (anti-Thy-1.2;
clone 30H12), or granulocytes (anti-Ly6G/Gr-1; clone RB6-8C5) and
macrophages (anti-CD11b/Mac-1; clone M1/70). Samples were analyzed using a
FACScan instrument (Becton-Dickinson Immunocytometry Systems, San Jose,
CA). The frequencies of CRU in the initial B6 BM suspensions, and in the BM of
primary mice 24 hours after homing, were calculated from the proportions of
negative recipients (in which <5% of the circulating B, T and myeloid cells were
regenerated by Ly-5.2+ stem cells) in each cell dose group using L-Calc software
(StemCell Technologies Inc., Vancouver, BC). The seeding efficiency of CRU
was then calculated by dividing the number of stem cells recovered in the BM of
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primary recipients by the number initially transplanted (x100%). Mice engrafted
by single HSCs were retrospectively identified by two criteria: (i) they were
determined by limiting-dilution analysis to be transplanted with < 0.3 CRU, and
(ii), they contained >5% donor (B6)-derived PB cells detectable among B, T, and
myeloid lineages (Szilvassy et al. 2003). Although experiments to measure the
homing of young CRU to young BM were reported previously in part these were
performed contemporaneously with the present studies using animals of varying
ages.

Homing assay for HPC
Young or old B6 BM cells were injected into lethally irradiated old or young
B6.SJL recipients (1 x 107 cells/mouse). The number of clonogenic progenitors in
these BM suspensions and in the BM and spleen of transplanted mice 3 hours
after homing was determined by plating cells in duplicate 35-mm culture dishes
(3 x 104 to 1x105 cells/dish) containing Methocult medium (StemCell
Technologies) as previously described (Szilvassy et al. 2001a). BM and spleen
cells from irradiated but untransplanted mice served as negative controls and did
not generate any colonies in this assay. The total number of HPCs that had
homed to the BM and spleen was calculated by multiplying progenitor cell
frequencies by total organ cellularities (in the case of the marrow assuming that 2
femurs and 2 tibiae represent 25% of the total marrow mass of the mouse)
(Boggs 1984). The seeding efficiency of HPC was then calculated by dividing
progenitor cells that were recovered in the BM or spleen of primary recipients by
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the total number initially transplanted (x100%).
Analysis of lineage-specific engraftment kinetics
Young or old B6.SJL(BoyJ) mice were irradiated as described above and
injected intravenously with 2 x 106 old, or 3 x 106 young nucleated BM cells,
respectively. PB was collected from the retro-orbital sinus 6, 9,12, 15, 18, 25, 32,
42, 56, and 120 days after transplantation. Until day 25, only half of the mice in
each cohort were analyzed alternately at each time-point so that no individual
animal was bled more frequently than every 7 days. Circulating leukocyte,
erythrocyte, and platelet counts were measured by analysis of 40 µL blood using
a System 9118+ Hematology Series Cell Counter (Biochem Immunosystems,
Allentown, PA).

Statistical analysis
All values represent the mean ± SEM. Statistical differences between
means were assessed using the two-tailed t-test assuming unequal variances
and ANOVA with two factors.
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Results

The homing efficiency of HPCs declines with donor and recipient age
Compared to young adult BM progenitors, ~10-fold fewer fetal liver HPCs
homed to the BM in 3 hours after intravenous injection and a similar trend toward
reduced BM homing of FL HSCs has been reported (Szilvassy et al. 2001a;
Szilvassy et al. 2003). To determine whether aging of the BM also influenced
homing, lethally irradiated young (6 to 8 weeks) or old (22 to 25 months) Ly-5.1
mice were transplanted with young or old Ly-5.2 BM cells, and 3 hours later
recipient BM and spleen cells were assayed for HPCs. As shown in Figure 5.1,
advanced donor or recipient age reduced the homing of HPCs to the BM by
about one-third (from ~9% to ~6%, P<0.01). The age-related intrinsic (i.e.
progenitor-dependent) and extrinsic (i.e. microenvironment-dependent)
mechanisms contributing to decreased BM seeding efficiency were similar in
magnitude. The effects of age on splenic homing of HPCs were even more
dramatic. HPC recovery declined from ~6% for the young into young donor/host
combination to ~1% for the young into old, or old into young combinations
(P<0.001).

The homing efficiency of HSCs declines with donor and recipient age
We hypothesized that aging had similar effects on the homing of more
primitive HSCs that regenerate and maintain lymphohematopoiesis for up to 6
months after transplantation. To address this question, we used a limiting141

dilution competitive repopulation assay to measure the 24-hour BM homing
efficiencies of young adult BM cells transplanted into old recipients and old BM
cells transplanted into young recipients. The design of this assay is depicted in
Figure 5.2. BM cells isolated from young or old Ly-5.2 mice were injected into
lethally irradiated, old or young Ly-5 congenic mice (3 x 106 c/mouse). Twentyfour hours later, BM from these primary recipients was harvested and
competitively transplanted into Ly-5.1 secondary recipients to measure the
number of Ly-5.2+ CRU that had “homed” to this organ. Simultaneously, the
number of CRU that were present in the original young or old B6 BM cell
suspensions was measured by limiting-dilution competitive repopulation assays
in a separate set of irradiated Ly-5.1 mice.
The results from the experiments performed with young BM cells
transplanted into old recipients are given in Table 1 and the results of old BM
cells transplanted into young recipients are in Table 2. Comparison of the upper
half of the two tables shows that the frequency of both early (5 and 10-week time
points) and long-term (17 and 26-week time-points) CRU increased by ~2-fold
from early adulthood to old age. For example, CRUs that contribute to
hematopoiesis for at least 10 weeks post-transplant represent 1 per 20,000
young BM cells and 1 per 10,000 old BM cells. As shown previously, CRU
contributing to early engraftment were somewhat more prevalent (one 5-week
CRU per ~15,000 young BM cells) than those detectable at later times (one 26week CRU per 7,000 old BM cells), consistent with the hierarchical organization
of the stem cell compartment (Morrison et al. 1995; Rosendaal et al. 1979).
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Furthermore, the HSC frequencies obtained in this study using a rigorous
functional assay are similar to those determined previously using phenotypic or
surrogate in vitro measures (such as cobblestone area-formation) of stem cells
and confirm that HSC in B6 mice increase significantly with age (Chen et al.
2000; de Haan and Van Zant 1999; Morrison et al. 1996; Szilvassy et al. 2003).
The seeding efficiency of young or old CRU in old or young recipients,
respectively, was determined by dividing the total number of CRU recovered in
the BM of primary recipients 24 hours after homing (as shown in the lower halves
of each Table) by the absolute number of CRU originally injected (calculated
from the CRU frequencies in freshly isolated BM in the upper halves of Tables
5.1 and 5.2). These data are summarized in Figure 5.3 and compared to
previous studies begun contemporaneously with the present studies in which
young BM CRU were transplanted into young recipients (Szilvassy et al. 2003).
Twice as many young (6% to7%) than old (2% to 3%) HSCs homed to the BM of
young recipients in the first day after transplantation. Moreover, CRU that
generated lymphoid and myeloid progeny at 5 weeks exhibited a greater decline
in homing as they aged than CRU that are detectable at later times. Of equal
importance, advanced recipient age also resulted in significantly reduced homing
of HSCs (from 6% to 7% to 2% to 3%) compared to young CRU transplanted into
young hosts. Thus, the effects of donor or recipient aging are similar, each
leading individually to a 50% to 60% decline in HSC homing compared to their
young counterparts.
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Effects of aging and prior transplantation on the proliferation potential of
HSCs
One advantage of the CRU assay is that it enables the retrospective
identification of recipient mice that were repopulated by a single HSC. Circulating
blood cells in such mice, identified using criteria described previously (Szilvassy
et al. 2003) and in the Methods, were then analyzed in more detail to
characterize the proliferation and differentiation potentials of individual CRU in
vivo. To assess the impact of aging on proliferation potential, we compared the
size of clones generated by single young or old CRU (expressed as the
percentage of donor-derived PB leukocytes) in recipients of varying age. The
average clone sizes of freshly isolated young CRU in young recipients differed
for stem cells whose progeny were detected at early or late times after
transplantation (Figure 5.4A); ~9% for 5- and 10-week CRU vs. 25% to 28% for
17- and 26-week CRU, P<0.05). This finding is consistent with the empirical use
of longer assay times in repopulation assays to identify more primitive HSCs with
a higher proliferation potential. Perhaps surprisingly, no difference was observed
in the size of clones generated by young and old CRU (Figure 5.4A and 5.4C).
However, both young and old long-term CRU (17- and 26-week) that were
selected by prior homing to either young or old BM generally produced smaller
clones than those generated by freshly isolated HSCs. The sole exception was
the larger clone generated by “homed” old CRU at the 26-week time point, but
because this value was derived from a single clone in a single animal, we view it
with caution. Interestingly, young CRU that previously “homed” to either young
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or old BM did not differ in their subsequent proliferation in young secondary
recipients (compare panels A and B for homed HSCs). In aggregate, these data
indicate that the proliferation potential of long-term repopulating HSCs is reduced
significantly by prior transplantation.

Effects of aging and prior transplantation on the differentiation potential of
HSCs
We next compared the proportion of B and T lymphocytes, and myeloid
cells, in the PB of young or old animals engrafted with single, freshly isolated or
“homed” CRU that were isolated initially from young or old donor mice. As shown
in Figure 5.5, clones generated by fresh old CRU contained ~5-fold more myeloid
cells (40% to 60% of donor-derived cells), and ~2.5-fold fewer T cells (15% to
20% of donor-derived cells) than those produced by young CRU (compare
panels A and C). This skewing of the differentiation potential of old HSCs toward
myelopoiesis, at the expense of T lymphocyte production, was also evident
among old CRU that had been subjected to prior homing (Figure 5.4C). Myeloid
skewing of older HSCs has been reported previously (Offner et al. 1999; Sudo et
al. 2000) and suggests an age-related alteration of their proportional production
of various blood cell lineages relative to that normally observed in early
adulthood.
Aging of the recipient BM microenvironment had similar effects on HSC
differentiation. Young CRU “homed” in old recipients also produced ~3.5-fold
more myeloid cells and ~2-fold fewer T cells than young CRU homed to young
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BM, or than freshly isolated CRU (compare Figures 5.5A and 5.5B; P<0.05).
There were no significant changes in the average proportional representation of
B-lineage cells in the clones produced by freshly isolated vs. “homed” HSCs in
young or old recipients. These data suggest that HSC differentiation potential
changes not only as a function of cell-autonomous, age-related mechanisms, but
also in response to extrinsic signals from the marrow microenvironment that are
altered by aging.
Finally, we compared the contributions that individual CRU made to all PB
cells of the myeloid, B or T lineages (Figure 5.6). In general, “homed” CRU
recovered from the BM of primary recipients 24 hours after transplantation made
significantly smaller contributions to all three lineages in secondary mice than did
fresh CRU that were allowed to engraft primary hosts long-term. Once again,
donor aging resulted in increased myeloid contribution, and the total number of
myeloid and B cells produced by young CRU that had homed to old BM were 2 to
3-fold higher than those generated from young CRU homed to young BM
(compare panels A and B).

Differential engraftment kinetics of young and old BM cells in recipients of
variable ages
We hypothesized that age-related variation in the homing efficiency of
HSCs and HPCs would translate into differences in the subsequent rate of
hematopoietic reconstitution. To address this question, young or old BM cells
were injected into old or young Ly-5 congenic recipients, and the recovery of
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circulating blood cells was measured over 4 months after transplantation. Until
day 12, the rate of leukocyte recovery was indistinguishable among the 3 groups
(young into young, young into old, and old into young) (Figure 5.7A). Thereafter,
the rate of leukocyte recovery in old mice that were transplanted with young BM
cells began to surpass the other two groups. In young recipients that were
engrafted with old BM, leukocyte production accelerated sharply after ~1 month
and reached normal levels shortly after the young into old pairing. White cell
recovery in young mice injected with young BM cells lagged behind the other two
groups and failed to reach normal levels even after 4 months. This finding was
consistent with the myeloid skewing of old CRU, or as a result of recipient aging,
that was observed in Figure 5.5. Young and old BM cells were similarly effective
in preventing anemia following transplantation into young recipients (Figure
5.7B). In contrast, old mice that were transplanted with young BM cells became
severely anemic early after transplant, and erythrocytes recovered at a slow rate
until reaching normal levels after 6 weeks.
Figure 5.7C depicts the dramatic age-related differences observed in
platelet recovery kinetics. Young BM cells required nearly a month to regenerate
near normal levels of platelets following transplantation into young recipients. In
contrast, transplantation of old marrow into young mice led to normal platelet
counts in ~15 days. Profound thrombocytopenia was still not resolved by 4
months after the transplant of young marrow into old mice. These data illustrate
both the strong intrinsic bias of old BM cells toward platelet production and the
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failure of the old marrow microenvironment to foster platelet recovery when
seeded with young marrow.
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Discussion

Homing of primitive stem/progenitor cells to the BM represents the crucial
first step to successful engraftment after transplantation. However, the use of the
term ‘homing’ in the literature has been confusing and duplicitous, referring both
to (a) the initial events following hematopoietic cell infusion in which primitive
cells lodge in supportive niches, and (b) extending erroneously to the subsequent
engraftment process, which is characterized by differentiated blood cell formation
over many weeks and months. Experiments conducted in the 1960’s to measure
the 24-hour seeding efficiency of spleen colony-forming units (CFU-S), termed ‘f’
for factor (Siminovitch et al. 1963), yielded estimates of 10% to 20% (Fred and
Smith 1968; Lord 1971; Siminovitch et al. 1963). Subsequent studies to
determine the ‘f’ factor of HSCs for BM seeding yielded estimates of ~1% per
femur, or ~12% for the entire marrow mass of the mouse (Lord 1997; Lord et al.
1975). As rigorous functional assays for HSCs have been refined, a similar value
of ~10% was obtained for CRU derived from murine BM and FL and for human
CB and FL (Szilvassy et al. 2003) repopulating cells assessed in a
xenotransplant model (Cashman and Eaves 2000).
These findings, and those from clinical experience that demonstrate graft
failure if too few stem cells are transplanted (Bender et al. 1992; Bensinger et al.
1995), beg reconciliation with experiments demonstrating engraftment with only a
few, or even one, purified HSCs (Benveniste et al. 2003; Matsuzaki et al. 2004;
Osawa et al. 1996). In many such studies claiming highly efficient seeding, it was
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long-term engraftment that was assessed, not homing of HSCs or HPCs within
the first day after infusion. Small numbers of (or even single) HSCs will engraft if
they fortuitously lodge in a receptive niche in either the BM or spleen. Cao et al.
used bioluminescent imaging to monitor engraftment derived from single
luciferase-labeled HSCs. They showed that foci of hematopoiesis are detectable
within the first few weeks post-transplant in the spleen and in widely dispersed
BM sites throughout the skeleton, with no apparent preference for one site or
another (Cao et al. 2004). Primitive hematopoietic cells emanating from the
primary focus then initiated additional foci that nearly completely engrafted all
hematopoietic sites over the following several weeks. These results are
consistent with a dynamic series of events initiating widespread hematopoiesis
involving multiple progeny of transplanted HSCs.
Despite increasing evidence that aging causes quantitative and qualitative
changes in HSCs directly, or indirectly through BM stromal cells (Geiger and Van
Zant 2002), the effects of age on homing of primitive hematopoietic cells remain
poorly understood. In the present study, we provide the first measurement of the
absolute homing efficiency of old HSCs to BM 24 hours after intravenous
injection. Only 2% to 3 % of transplanted CRUs were recovered at this time from
the BM of young recipients. This value is 2 to 3-fold lower than that for young
HSCs infused into young recipients (7% to 10%), as shown here and in previous
studies measuring homing of hematopoietic cells labeled with a vital fluorescent
dye (Hendrikx et al. 1996; Szilvassy et al. 1999). This reduced seeding efficiency
for old CRU is consistent with a report by Morrison et al. who found that a smaller
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proportion of young recipients were engrafted long-term when transplanted with
limiting numbers of phenotypically identical old vs. young HSCs (Morrison et al.
1996).
Several mechanisms may be involved in the intrinsic, age-associated
decline of HSC homing. First, impaired homing may reflect changes in the levels
or binding activity of receptors, extracellular matrix or adhesion molecules during
aging. Indirect evidence indicates that CXCR4 expression on HSCs may change
with age (Martin et al. 2003) and result in their altered ability to enter BM
“niches”. Possible modulation of CD26, a peptidase expressed on engrafting
hematopoietic cells and which negatively regulates homing and engraftment
potential (Christopherson et al. 2004), during aging also deserves study. Second,
changes in the cycling status of HSCs during aging may alter their homing. HSCs
that are in G0 phase of the cell cycle at the time of transplantation promote higher
levels of engraftment than HSCs in G1 (Gothot et al. 1998; Habibian et al. 1998)
and specifically in S-phase (Monette and DeMello 1979; Orschell-Traycoff et al.
2000). A greater proportion of HSCs in old mice are cycling (Morrison et al. 1996)
so this difference may underlie their diminished capability for homing. Third, it is
possible that there is an age-related change in radiosensitivity of HSCs
manifested in the present experiments by differential ablation of host HSCs, and
thus a differential probability with which transplanted HSCs may find unoccupied
niches. In addition, there may be an age-related change in the radiosensitivity of
the BM microenvironment such that hematopoietic support for stem cels that do
home to old BM is impaired. To our knowledge, neither the effect of age on the
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radiosensitivity of HSC nor the microenvironment has been tested
experimentally, but this important issue deserves further study.
In the present study, we have for the first time quantitatively determined
that recipient age has a dramatic influence on HSCs homing; the seeding
efficiency of young HSCs in the BM of old mice is only one-third to half (2% to
3%) that measured in young mice. This striking difference points to a decline in
the capacity of the marrow stroma to capture or retain, or both, stem cells in old
age. Stromal cells regulate HSCs by secreting various growth factors and
providing appropriate cell contacts that define the BM “niche”. Aged stromal cells
produce lower amounts of interleukin (IL)-7 and are less capable of supporting
the proliferation of B lymphocytes in vitro (Stephan et al. 1998). Although no
studies have demonstrated unequivocally that IL-7 is involved in homing of
HSCs, it and other stromal cell-derived chemokines, such as SDF-1, may be
down-regulated during the aging process, leading to defects in the ability of
HSCs to maintain associations with the stroma (Petit et al. 2002).
In assays to measure the homing of HPCs, we also observed a dramatic
(~80%) decline in homing to the spleen with donor and recipient age. Reduced
splenic seeding was not due to a decrease in organ size or cellularity with age
(data not shown). In these studies, homing of progenitors was determined after 3
hours rather than the 24-hour period used for HSCs to preclude unpredictable
population size changes (either losses or gains) in HPCs that resulted from
proliferation or differentiation initiated 1 day after transplantation. Because HPCs
mediate short-term engraftment and ameliorate myelosuppression immediately
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following ablative conditioning, the present findings bear consideration when
transplanting older patients and indicate that both donor and recipient age might
affect outcome.
Analysis of mice that were transplanted at limiting-dilution with <0.3 CRU,
which when engrafted were ascertained with 95% statistical confidence to be
repopulated by a single HSC, revealed important age-related differences in stem
cell developmental potential. No difference was observed in the sizes of clones
generated by young and old CRU, indicating that HSC proliferation potential is
not affected by donor age. In contrast, young CRU that were recovered from the
BM of primary mice 24 hours after homing exhibited diminished proliferation in
secondary recipients, regardless of the age of primary host. Donor and recipient
aging was associated with enhanced myelopoiesis at the expense of
lymphopoiesis and further amplified in HSCs selected by prior homing. Our
findings corroborate and extend several previous reports of the link between
aging, transplantation, and this characteristic pattern of lineage skewing (Kim et
al. 2003; Spangrude et al. 1995; Sudo et al. 2000). Interestingly, in contrast with
these findings of diminished differentiation potential of previously homed BM,
Lanzkron et al. and Krause et al. found lineage-negative and quiescent BM cells
that were re-isolated from the BM 48 hours following transplantation not only
contained long-term repopulating HSCs (Lanzkron et al. 1998) but were also
capable of differentiation into non-hematopoietic lineages (Krause et al. 2001).
There are clear methodological differences between their findings and our study
that likely account for this discrepancy: (i) we did not enrich stem cells from
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either the initial marrow source or the BM that was re-isolated for secondary
transplantation, and (ii) we recovered homed CRU after 24 hours rather than 48
hours. Nevertheless, our finding that age-related HSC changes were
exacerbated by prior homing is consistent with Harrison’s early finding that
transplantation itself induced decrements in HSC function (Harrison et al. 1978).
However, unlike Harrison et al. who attributed the erosion of HSC function to
engraftment history rather than aging, we found that both donor and recipient age
as well as prior homing are important.
Differences in the recovery rates of PB cells following BM transplant
(Figure 5.7) underscored the theme that old HSCs and an old marrow
microenvironment both predispose HSC differentiation to myelopoiesis. Young
HSC engrafting in old recipients dramatically enhanced leukocyte recovery at the
expense especially of platelet recovery. Interestingly, anemia resulted in old
recipients transplanted with young marrow but not in young recipients
transplanted with old marrow. This suggests that the old microenvironment plays
a more dominant role in determining the numbers of various lineages of
terminally differentiated cells in the circulation early after transplantation than the
age of the HSC. This is not surprising given the important role the
microenvironment plays in supporting hematopoiesis through cell:cell interactions
and especially cytokine production, the profile of which changes during aging
(e.g. IL-7 and B cell production). Interestingly, the age of the transplanted HSC
has meaningful effects on platelet formation during the first two weeks following
transplant and on leukocyte generation after the first month of engraftment. Old
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HSCs, in both cases, have enhanced generative capacity compared to young
HSC when engrafted into young recipients. Thus, the diminished homing ability
of old stem cells may be more than offset by the increase with age in CRU
numbers in C57BL6 mice as shown here and/or by the increased numbers of
progenitors we showed previously. The enhancement of platelet recovery by old
HSC is noteworthy because in clinical transplantation prolonged
thrombocytopenia is a consequential issue. Unfortunately, in the clinical setting
the recipient, not the donor, is more likely to be older, and as can be seen in
Figure 5.6, this age combination gives, by far, the poorest platelet recovery.
A final important result of this study is that decrements in the seeding
efficiency of HSCs caused by (a) procurement from old donors and (b) the
marrow microenvironment of old recipients, individually and in concert, will affect
calculations of stem frequency in experimental transplantation assays. For
example, the measured frequency of BM CRU from young C57BL/6 donors (1 in
~20,000) is about half that of HSCs taken from old mice (1 in ~10,000. However,
because the marrow seeding efficiency (in young recipients) of young HSCs is
7% and that of old HSCs is 2% to 3%, the actual difference in stem cell numbers
may be twice again as large, or 4-fold overall between young and old C57BL/6
mice. It might be argued that a distinguishing characteristic of stem cells is their
ability to home to hematopoietic sites, and the decline in seeding efficiency with
HSC age may represent an age-related decline in function. If this argument is
accepted, an adjustment in stem cell frequency on the basis of a lower seeding
efficiency would be unwarranted. However, Table 5.2 shows that the seeding
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efficiency in old recipients of young HSCs is 2-fold less than the same cells
assayed in young recipients. In this case because the alteration in seeding
efficiency is extrinsic to the HSC, an adjustment in measured stem cell frequency
would be justified.
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Figure 5.1 Reduced homing capacity of HPCs with donor and recipient age.
Lethally irradiated, young or old Ly-5.1 mice were injected with 1 x 107 old or
young Ly-5.2 donor cells. Three hours later, HPCs that had homed to the BM
(white bars) or spleen (black bars) were measured by hematopoietic colonyformation in vitro. Shown are the mean (± SEM) percent of donor-derived HPCs
recovered per organ, relative to numbers injected. Data are pooled from 3
independent experiments with 3-5 mice per group. Differences between young
cells injected into young recipients, and either young cells transplanted into old
recipients, or old cells transplanted into young recipients are significant (*
represents P<0.05).
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Figure 5.2 Experimental design for competitive repopulation studies.
Lethally irradiated, young or old Ly-5.1 mice were intravenously injected with 3 x
106 old or young Ly-5.2 BM cells. Twenty-four hours later, marrow from the
primary recipients was harvested to assay the number of Ly-5.2+ stem cells that
had homed there following transplant. The frequencies of CRU in the initial BM
suspensions and in the BM of primary mice after homing were determined by
competitive repopulation of two sets of Ly-5.1 mice that were transplanted with
graded numbers of fresh or “homed” BM cells admixed with 2x105 Ly-5.1
competitor BM cells. Donor (Ly-5.2)-derived lymphoid and myeloid cells in PB
were then measured at 5, 10, 17 and 26 weeks after transplantation. CRU
frequencies were calculated from the proportions of negative mice in each cell
dose group as described in the Methods.
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Figure 5.3 Age-related decline in the homing efficiency of murine HSCs.
Lethally irradiated, young or old Ly-5.1 mice were intravenously injected with 2-3
x 106 old or young Ly-5.2 donor cells as depicted in Figure 2. The number of
CRU recovered from the BM 24 hours later was determined by limiting-dilution
competitive repopulation assays conducted in young secondary recipients that
were assessed for donor engraftment at 5, 10, 17 and 26 weeks after
transplantation (see Tables 1 and 2). The homing efficiency of HSCs was
calculated by dividing the number of CRU recovered in the primary BM 24 hours
after transplantation, by the number of CRU initially injected, and multiplying by
100%. Three different transplantation groups, young cells into young (white
bars), young cells into old (gray bars), and old cells into young recipients (black
bars), are depicted. Data for young to old, and old to young groups are derived
from the experiments described in Tables 1 and 2. Data for the young to young
group, although collected contemporaneously with the other transplant groups
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were reported previously by Szilvassy et al., and are shown for comparison. All
values are mean ± SEM, and statistically significant differences are designated
with an * (P<0.05).
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Figure 5.4 Effect of aging and prior transplantation on the proliferation
potential of CRU
Following determination of the CRU frequency in fresh and “homed” BM (Tables
1 and 2), it was possible to retrospectively identify mice that had been injected
with <0.3 CRU, and in which both the lymphoid and myeloid compartments were
subsequently repopulated with donor stem cells. On the basis of Poisson
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statistics, it is 95% probable that such mice were engrafted with a single HSC.
Clone sizes generated by single, fresh (open bars) or “homed” (hatched bars)
CRU as a function of donor and recipient age are represented as the mean ±
SEM percentage of donor (Ly-5.2+)-derived PB leukocytes assessed 5 to 26
weeks after transplantation (4 to 8 mice per group from 2 pooled experiments).
Note that data for the young to young group was collected contemporaneously to
other groups but in part reported previously in reference.
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Figure 5.5 Effect of aging and transplantation on the differentiation
potential of CRU
Mice that had been repopulated with a single, fresh (open bars) or homed
(hatched bars) CRU were identified as described in the Figure 5.4 legend and
Methods. The lineage composition of clones generated by single, young or old
HSCs in old or young hosts was defined as the proportion of donor (Ly-5.2+)derived leukocytes expressing markers for B (CD45R/B220+) or T (CD90/Thy163

1.2+) lymphocytes, or myeloid (Gr-1/Ly6G+ and Mac-1/CD11b+) cells. Values
shown for the 3 combinations of variably aged donors and recipients represent
the mean ± SEM of 2 pooled experiments with 3 to 6 mice per group. Note that
data for the young to young group was collected contemporaneously to other
groups but in part reported previously in reference.
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Figure 5.6 Differential contribution of single BM CRU to hematopoietic
engraftment
Recipient mice that were repopulated with a single, fresh (open bars) or homed
(hatched bars) CRU were identified as described in the Figure 5.4 legend and
Methods. The differential contribution of individual CRU to engraftment was
defined as the proportion of all circulating B (CD45R/B220+) or T (CD90/Thy1.2+) lymphocytes, or myeloid (Gr-1/Ly6G+ and Mac-1/CD11b+) cells that were
Ly-5.2+. Values shown for the 3 combinations of variably aged donors and
recipients represent the mean ± SEM of 2 pooled experiments with 3-6 mice per
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group. Note that data for the young to young group was collected
contemporaneously to other groups but in part reported previously in reference.
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Figure 5.7 Differential engraftment kinetics of young or old BM cells in old
or young recipients
2 x 106 young (◊) or old () Ly-5.2 BM cells were injected into lethally irradiated
young mice, or 3 x 106 young Ly-5.2 BM cells were injected into lethally irradiated
old Ly-5.1 mice (Ο). Shown are the mean ± SEM number of PB leukocytes (A),
erythrocytes (B), and platelets (C) counted on the indicated days after
transplantation (pooled data from 2 experiments with 10 mice per group). The
absence of error bars for specific data points indicates that fewer than three
animals were available for analysis. Note that the time after transplantation is not
depicted on a linear scale. Shaded areas indicate normal ranges of blood cell
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counts in age-matched B6.SJL control mice. Data for the young to young group
was collected contemporaneously to other groups but in part reported previously
in reference.
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Table 5.1 Determination of the number of intravenously transplanted young
CRU that home to the BM of old irradiated mice

No. cells (fresh) or fraction
of
1° BM (homed) injected per
mouse

Cell type injected

Fresh Young BM

Proportion of negative mice

#

5 weeks

10 weeks

17 weeks

26 weeks

3

15/16

15/16

16/16

16/16

3

12/16

12/16

12/16

12/16

4

3/15

4/15

7/15

7/14

4

0/8

0/8

0/8

0/8

15,242

16,814

23608

24,578

2X10
6X10
2X10
6X10

1/CRU frequency∗
(±SEM)

(12,124~19,163) (13,350~21,178) (18,571~30,012) (19,232~31,409)

No. CRU injected

¶

(±SEM)

Homed Young BM

197

178

127

122

(157~247)

(142~225)

(100~162)

(96~156)

0.005

8/8

8/8

7/7

7/7

0.014

13/14

13/13

13/13

13/13

0.042

11/14

10/14

11/14

9/11

0.125

7/14

6/14

8/14

8/14

£

CRU frequency:
1 per 1° BM Fraction

0.182

0.159

0.231

0.247

(±SEM)

(0.134~0.247)

(0.119~0.213)

(0.166~0.323)

(0.174~0.352)

‡

1/CRU frequency:
No. CRU Recovered per
1° BM

5.5

6.3

4.3

4.0

(±SEM)

(4~7.5)

(4.7~8.4)

(3.1~6.0)

(2.8~5.7)

Lethally irradiated old (20 to 22 months) Ly-5.1 mice were injected with 3X106
young (6 to 8 weeks) Ly-5.2 BM cells and their marrow was harvested 24 hours
later. The frequency of CRU in this primary BM, and in the B6 suspension
injected initially, were determined by transplanting graded numbers of fresh or
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“homed” BM cells into separate sets of lethally irradiated Ly-5.1 recipients that
were analyzed for donor (Ly-5.2+)-derived engraftment at the indicated times.
Pooled data from 2 independent experiments.

# Negative mice are defined as animals in which <5% of the circulating B and/or
T lymphocytes and/or myeloid cells were derived from donor (Ly-5.2+) stem cells
at the time of analysis.
∗ Shown are the number of BM cells containing one CRU. The range in CRU
frequencies defined by ± 1 SEM is shown in parentheses.
¶ Absolute values were determined by multiplying 1/CRU frequency (∗) by 3X106
cells, the number of fresh cells injected into primary recipients.
£ Frequencies of homed CRU are expressed as the proportion of primary (1°)
BM cells that contain 1 CRU.
‡ The absolute number of CRU that homed to the total primary BM was
determined by inverting the frequencies of homed CRU (£).
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Table 5.2 Determination of the number of intravenously transplanted old
CRU that home to the BM of young irradiated mice
Cell type injected

Fresh Old BM

No. cells (fresh) or fraction
of
1° BM (homed) injected per
mouse

Proportion of negative mice
5 weeks

10 weeks

17 weeks

26 weeks

3

12/15

12/15

11/14

11/14

3

5/14

5/14

8/14

8/14

4

1/14

1/14

2/14

3/14

4

0/8

0/8

0/8

0/8

7,006

7,006

10,019

2X10
6X10
2X10
6X10

1/CRU frequency
(±SEM)

(5,548~8,848) (5,548~8,848) (7,923~12,671)

11,304
(8,932~14,306)

No. CRU injected

428

428

299

265

(±SEM)

(339~541)

(339~541)

(237~379)

(210~336)

0.005

6/6

6/6

6/6

6/6

0.014

10/12

8/9

7/8

4/5

0.042

9/14

8/13

8/13

9/13

0.125

4/10

4/10

4/10

4/10

0.113

0.116

0.115

0.124

Homed Old BM

CRU frequency:
1 per 1° BM Fraction
(±SEM)

(0.085~0.151) (0.086~0.157) (0.085~0.155)

(0.091~0.169)

1/CRU frequency:
No. CRU Recovered per
1° BM

8.8

8.6

8.7

8.1

(±SEM)

(6.6~11.8)

(6.4~11.6)

(6.5~11.8)

(5.9~11)

The experimental design and determinations of the frequencies and absolute
numbers of CRU that were transplanted and recovered after homing is the same
as described in Table 1, except that donor cells were harvested initially from old
(20 to 22 months) mice and young mice (6 to 8 weeks) were used.
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CHAPTER SIX
General Discussion and Conclusions
The primary purpose of the first part of this dissertation study was to
evaluate the general hypothesis that specific gene and their allelic variants
contribute to strain-specific difference in HSC numbers between C57BL/6 (B6)
and DBA/2 (D2) mice. Following a classic forward genetic approach, three
specific aims were derived from this underlying hypothesis: first, linkage analyses
were performed to determine quantitative trait loci (QTL) linked to strain-specific
variation in HSC number and phenotypes were measured in congenic mice to
validate the QTL mapping. Second, the biological processes related to HSC
number regulation were investigated in congenic mouse models, including cell
cycle kinetics, apoptosis and self-renewal. Lastly, by using microarray-based
candidate gene method, a candidate gene was identified that might be involved
in HSC number regulation in mice. The noteworthy findings in this dissertation
project are that 3 QTL on chromosomes 3,5 and 18 were not only mapped but
also confirmed phenotypically in congenic mouse strains, in which the D2 allele
increased whereas the B6 allele decreased HSC number. Surprisingly, in the
context of this dissertation, the chromsome 3 QTL was shown to affect the cell
cycle kinetics, apoptosis, and the self-renewal of HSCs. The D2 allele of the QTL
increased cycling and self-renewal whereas decreased apoptotic rates of HSCs.
Furthermore, a small number of differentially-expressed genes was identified in
chromosome 3 congenic HSCs and the differential expression of one candidate,
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latexin, was found to relate to changes in HSC numbers. The B6 allele was
associated with up-regulated latexin expression and decreased HSC numbers,
whereas the D2 allele was associated with down-regulated latexin expression
and increased HSC numbers. Therefore, my current studies not only prove the
feasibility of forward genetics leading to gene discovery, but also report the
strong evidence of the potential functions of latexin in HSC number regulation.
These findings are important for understanding molecular mechanisms of stem
cell regulation and helpful for developing effective stem cell expansion strategies
that are clinically applied in gene and cell therapy (Morrison et al. 1997;
Sorrentino 2004; Weissman 2000).
The tremendous potential for reconstituting the hematopoietic system of
HSCs has allowed the development of transplantation of HSCs as a clinical
strategy for the treatment of hematological disorders. However, the obstacle for
the successful application of this therapy is the limited number of HSCs available
from primary cell sources (bone marrow, periperal blood or cord blood) (Karlsson
2004; Sauvageau et al. 2004). Great efforts have been made to design protocols
not only to expand HSC populations but also maintain their functions (selfrenewal and multi-lineage differentiation) (Bernstein 2004; Brown and Weissman
2004). Recently, some regulatory molecules, such as WNT-protein family (Wnt,
ß-catenin), Notch family of receptors (Notch1), cell-cycle genes (cyclin D, some
CKIs) and Homeobox genes (especially HoxB4) have been identified that show
promise for harnessing the amplification of HSCs in animal models and even in
clinical settings (Antonchuk et al. 2002; Duncan et al. 2005; Kozar et al. 2004;
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Reya et al. 2003; Stier et al. 2002; Walkley et al. 2005). Our current findings add
an additional potential regulator, latexin, to this list by demonstrating that the
reverse relationship between latexin expression and the HSC pool size.
The underlying mechnisms by which latexin controls HSC pool size are
not yet clear. Latexin is the only known endogenous carboxypeptidase inhibitor
(CPI) in mammals, and recombinant rat latexin has been shown to inhibit
pancreatic carboxypeptidase A1, A2 and A3 (CPAs) (Normant et al. 1995).
Latexin was also found to be widespread in humans, and it specifically inhibits
human CPA4, a member of the A/B subfamilies of mammalian
metallocarboxypeptidases (A/B MCPs), but not other types of MCPs (Liu et al.
2000b; Pallares et al. 2005). Comprising over 220 residues, the latexin protein is
significantly larger than CPIs from plant and parasites (40-70 residues).
Moreover, lack of substrate-interaction site that is located in C-terminus of latexin
protein suggests that the mechanisms by which latexin inhibit CPA differ from
those of non-mammalian CPIs (Reverter et al. 2000). Combining all available
information about latexin and our microarray results, I propose that several
potential regulatory pathways (or mechanisms) by which latexin regulates murine
HSC numbers may exist (Figure 6.1). First, the effects of latexin on HSCs may
reside in its carboxypeptidase A (CPA) inhibitor activity (Normant et al. 1995).
CPA is involved in degradation or maturation of protein or peptide by
enzymatically cleaving C-terminal amino acids of its substrate protein (Vendrell et
al. 2000). Some of these substrates, although yet unknown, may play important
roles in regulating murine HSC number. Therefore, latexin may interfere with the
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normal metabolism of these regulators by inhibiting CPA activity, which in turn
affect HSC numbers. Secondly, the structural existence of potential cGMPdependent protein kinase phosphorylation sites in the latexin molecule indicates
that it might be one of the members in G protein-coupled receptor signaling
pathway and regulate other downstream molecules (Callahan 1999), such as
mitogen-activated protein kinase 8 (Mapk8) and/or Ras, guanyl releasing protein
2 (Rasgrp2), which were found to be differentially expressed in my microarry
studies (Table 4.1). Thirdly, the physical protein structure of latexin demonstrates
two potential Ca2+/calmodulin-dependent protein kinase sites, suggesting it may
also be involved in the calcium-mediated signaling pathway (Callahan 1999).
This hypothesis is strongly supported by the fact that two members of the S100a
family, which bind calcium ions, were diffentially expressed (Table 4.1). Finally,
the similarity of DNA sequence, amino acid sequences, and pysical protein
structure between latexin and the cystatin family of protein and human tumor
suppressor tazarotene-induced gene 1 (TGI1) indicates that other mechanisms
might also exist by which latexin regulates HSC functions (Aagaard et al. 2005;
Pallares et al. 2005). The cystatin family functions as cysteine proteinase and
plays important roles in several molecular functions, including extracellular matrix
degradation, stimulation of mouse fibroblast proliferation as well as inhibition of
osteoclatic bone absorption (Balint et al. 2003; Newman 2002). Moreover, the
findings that each of two topologically equivalent subdomains comprised of
human latexin protein was strongly similar to that of cystatin indicate the
evolutionary conservation between these two proteins. More interestingly, the
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finding that the loss of TGI1 expression contributed to the development of
prostate cancer (Jing et al. 2002; Lotan 2002) and that downregulated TGI1
expression was mediated by methylation of the promoter and CpG island of the
TGI1 gene (Kwong et al. 2005; Youssef et al. 2004; Zhang et al. 2004) provide a
hint that latexin may be involved in hematological malignancy and differential
expression of latexin might be due to the different methylation states in its
regulatoy region of the DNA sequence. Altogether, these potential mechanisms
may synergistically or independently affect HSC number-related biological
processes. Our phenotypic characterization of chromosome 3 congenic mouse
models suggests that latexin expression level probably relates to the cycling,
apoptosis and self-renewal of HSCs. It also probably affects other functions of
HSCs, such as migration and cell growth through regulating genes like tubulin,
alpha1 (Tuba1) and pituitary tumor-transforming1 (pttg1).
In the second part of the current studies, I focused on another important
step that is involved in stem cell transplantation: the homing and engraftment of
HSCs. By using functional assays for progenitor and stem cells, we first reported
the homing efficiencies of young or old donor cells into young or old recipients.
The results indicated that the homing of primitive heamtopoietic cells were not
efficient and were significantly decreased with aging of both the donor and the
recipients. They also illustrated on the other hand that large numbers of HSCs
are needed for transplantation when old donors or recipients involved. In
addition, the proliferation and differentiation capabilities of functional HSCs were
impaired by the homing process itself as well as the age of donors and
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recipients. More importantly, the hematopoietic reconstitution dynamics following
transplantion of bone marrow cells were also affected by the aging process.
These results may provide useful information for clinical settings when the
number of older individuals serving as donors for elderly patients increases.
In conclusion, we may still be many steps away from clinical application of
these findings, but new discoveries concerning regulation of stem cell numbers
and their homing and engraftment capabilities may lead us one step further
toward this goal. My findings regarding latexin and the effects of aging on homing
and engraftment in this dissertation may add new information in this diretion.
However, many detailed studies remain to be done in the future in order to reveal
the underlying mechanisms for both factors. First of all, temporary knockdown of
latexin expression in HSCs througn small RNA interference (SiRNA) technology
will help to further validate latexin as the candidate gene. Secondly, generation of
a knockout mouse model will be a critical step to investigate the in vivo functions
of latexin and the underlying molecular mechanisms. Thirdly, screening of
nucleotide polymorphisms in the regulator regions of latexin DNA sequency will
be important to understand underlying genetic variations responsible for natural
viarions in HSC numbers (Flint and Mott 2001). Fourthly, since we have found
HSC numbers change with age, further investigations will be performed to study
the effects of aging on latexin expression and its relationship to experimentally
induced changes in the population size of HSCs. Most importantly, our final goal
is to use these findings to develop effective HSC expansion strategy that will be
clinically applicable to the treatment of disease. To this end, we will detect the
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expression of latexin in human HSCs and study its effects in hematopoietic
system under the normal, and neoplastic conditions. Finally, we will further
investigate the additive effects of donors and recipients’ aging on homing and
engraftment by setting up transplantion of old bone marrow cells into old
recipients. In addtion, we will analyze and compare gene expression profiles
between young and old HSCs to uncover the underlying mechanisms.
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Figure 6.1 Models of potential latexin-involved biological processes.
According to current available information about latexin and our microarray
results, latexin might be involved in four possible pathways which synergistically
or independently regulate the numbers of HSCs and/or other types of stem cells.
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